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Anti-oestrogens. such as tamoxifen, are widely used in the treatment of breast cancer, although a
significant minority fail to respond. Apart from tumour expression ofOestrogen Receptors (ER).
there are no other good pre-treatment predictors of sensitivity. The management of patients w ould be
facilitated by early prediction of efficacy as current practice requires a trial of several weeks" therapy
In the clinical setting the precise effects of tamoxifen on tumour cell turnover remain unclear, but in
model sy stems a significant anti-proliferative effect has been demonstrated, as well as a possible
induction of apoptosis. Their relative balance, the apoptotic:mitotic ratio, might therefore be a
predictor of drug sensitivity. The use of the Gompertz function, an accurate model of xenograft
growth, could be used to predict subsequent tumour behaviour and thus identify responsive disease
The aim of this study w as therefore to determine the relationship betw een tumour response to
tamoxifen and changes in apoptosis and mitosis, to confirm their chronology and specificity in a
model sy stem, and to assess the possibility of identify ing these changes in fine needle aspirates
(FNAs) rather than biopsy material.
In a cohort of 50 post-menopausal women with ER positive breast cancer treated with tamoxifen the
level of expression of both ER and the cell-survival gene bcl-2 predicted for tumour response. After
three months' treatment there was a significant fall in proliferation in most tumours, but no overall
change in apoptosis. as assessed by morphology. There w as a significant trend for tumour response
to correlate with the change in the apoptotic:mitotic ratio (p < 0.05). To determine more accurately
the timing of these changes, mice bearing xenografts of the ER positive ZR-75-1 and ER negativ e
MDA-MB-231 breast cancer cell lines were treated with tamoxifen. After 2 days, an increase in
apoptosis and the apoptotic.mitotic ratio was seen in the sensitive ZR-75-1 tumours (p < 0.05). and
on day 7 there was also evidence for reduced proliferation (p < 0.05); however clear evidence of
tumour regression only occurred after 14 days. On day 7 there was however a significant correlation
between the apoptotic:mitotic ratio and the difference between the actual and the Gompertz-predicted
tumour volumes (p < 0.02). These changes were not apparent in tamoxifen treated MDA-MB-231
tumours. No changes in bcl-2 expression were seen. Furthermore, although similar changes were
seen in tumour FNAs. statistically they were not as significant, suggesting that they do not offer an
alternative to repeat histological examination of the tumours.
Early changes in the apoptotic:mitotic ratio during tamoxifen treatment of breast cancer may aid m
the prediction of endocrine sensitivity .
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Introduction
Breast Cancer is the commonest cancer to affect women in Scotland (Sharp et al( 1993)). as it is
throughout the developed world. Almost a quarter of all female cancer registrations are for breast
cancer (Sharp et al(1993)). and it is estimated that an American woman has a life-time risk of about
1 in 8 for developing this disease (Feuer et al( 1993)). However it needs to be emphasized that a third
of this risk is after the age of 75 (Henderson. (1990)). and perhaps a more useful statistic is the 1 in
15 risk quoted for Scottish women up to the age of 75 (Sharp et alf 1993)). Breast Cancer thus
presents a major health-care problem, although the overall 5-year survival for women in Scotland
who develop this disease is 64% (Sharp et al( 1993)). Furthermore there is evidence that the
incidence of this disease is increasing, both in Scotland (Sharp et al( 1993)) and elsewhere (Feuer et
al( 1993)). although the mortality appears unchanged. There are two factors that may explain this
rise : increased detection, w hich results in part from national screening programmes, and increased
longevity, since the disease is more prevalent in older women. There is also a steady unexplained
increase in incidence over the past fifty years that may be due to environmental or dietary changes.
There is however world-wide variation in this increase, and indeed for Scotland the 12% increase
seen during the decade 1980-1990 was no more than for all cancer registrations as a whole. Howev er
it needs to be remembered that the incidence of other tumours, such as gastric cancer, is clearly
falling, and furthermore that the nationwide breast cancer screening did not begin until the end of
that decade. Before discussing the aetiology of this disease, which w ill have relevance both to the
rising incidence as well as the impact of therapy; it is important to rev iew some recent data w hich
offer hope in the face of this increasing problem.
For many years the mainstay of treatment for early, and thus potentially curable, breast cancer w as
surgery , sometimes with post-operative radiotherapy . However since the late 1940's there have been
numerable trials conducted throughout the world designed to assess the survival benefit of the use of
post-operative adjuv ant systemic therapy. A recent overview of over 100 trials of chemotherapy ,
hormone therapy and immunotherapy confirmed that the survival ofwomen with early breast cancer
is improv ed by this approach (Early Breast Cancer Trialists Collaborative Group, (1992)). The
benefit of such therapy for patients outwith the minority w ho were entered into these randomised
trials has been confirmed by a retrospective analy sis of cohorts of w omen with breast cancer treated
in British Columbia (Oliv otto et al(1994)), (w hich incidentally also confirmed the increased
incidence of the disease). There was a significant improvement in surviv al for younger women
between 1974 and 1980, w hich corresponded to the introduction of adjuv ant chemotherapy for pre¬
menopausal women with node-positive disease. In contrast there was no difference in survival for
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post-menopausal women in the same period. Between 1980 and 1984 there was a significant
improvement for both groups of women, corresponding to the widespread use of tamoxifen for post¬
menopausal women with node-positive or high-risk node-negative tumours, and the further use of
chemotherapy for pre-menopausal women with high-risk node-negative disease. The authors thus
argue that it is the use of adjuvant sy stemic therapy that has brought about this improv ement; they
chose this third period not to include the large numbers of w omen whose breast cancer had been
diagnosed after the adv ent of nationwide mammographic screening programmes. Similar
retrospectiv e analy ses have also confirmed improved survival due to sy stemic adjuvant therapy in the
U.S. (Chu et al( 1996)) and England and Wales (Beral et al( 1995)).
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Aetiology
It has to be stated that, as with most other cancers, the reason an individual develops breast cancer
remains unknown. As a common disease, it has been extensively studied, and sev eral factors are
known to increase the risk of developing breast cancer. In contrast much less is known about how
w omen might reduce their risk, w hich confirms that some of the fundamental issues involved in the
development of this malignancy remain unclear.
Genetic influences
There is no doubt that for some women at least, there is an increased risk of breast cancer related to
the occurrence of the disease in other members of their family. It is well known that the risk of
dev eloping the disease can be two to five times higher if one or more first or second degree relatives
have been affected (Anderson et al( 1985)). These data alone do not confirm the possibility of a
genetic predisposition, but there is evidence for families in w hich the women are at very high risk of
dev eloping breast cancer (Lynch et al(1984)), for w hom an autosomally dominant gene, inheritable
from either parent, is felt to be the major cause. Worldwide collaboration, based on over 200 such
families that have been identified, has led to the sequencing of tw o genes, mutations in w hich are
thought to be the cause of the majority of familial breast cancer ; BRCA-1 (Miki et al( 1994)) and
BRCA-2 (Wooster et al( 1995)). To date the precise function of either gene remains undetermined,
and there is no evidence that mutations in these genes are significantly involved in the development
of sporadic breast cancer. There is also evidence that acquired genetic mutations may be important
in the aetiology of breast cancer. Women whose breasts have been exposed to ionising (and thus
mutagenic) radiation are at increased risk of breast cancer, irrespective of w hether this w as from
fluoroscopic examination for tuberculosis (Boice et al(1977)). radiotherapy for post-partum mastitis
(Shore et al(1986)). or Japanese women who survived the atomic bombs dropped on Hiroshima and
Nagasaki (Tokunaga et al( 1982)). Another significant risk factor for breast cancer is a previous
diagnosis of certain forms of benign breast disease, most significant amongst which is atypical ductal
hyperplasia, with a 3-5 times increased nsk (Carter et al( 1988): Dupont et al( 1985)). Whether this is
due to a genetic mutation that occurs during or after the benign hyperproliferative stage is unknown,
but the incidence of cyclin D1 abnormalities was noted to be similar for in-situ and invasive
carcinomas (Weinstat-Saslow et al(1995)), whereas they are much less common in benign




Genetics apart, there is also significant geographical variation in the incidence of this disease. The
best publicised is the difference between the developed part of the Western World where the age-
standardised incidence can be as high as 100/ 100.000 w omen, and Asian countries w here it may be
as low as 15/100,000. When women from a low-risk group mov e to a region with a higher
incidence, their own risk increases, even though this may take more than a generation to occur
(Wynder et al( 1986); Ziegler et al( 1993)). Furthermore the incidence is often higher in urban than
rural areas, with some groups, such as Mormons, having a much lower incidence (Adami et
al( 1990)). The reason that living in the Western World itself appears to be a risk factor for breast
cancer is uncertain, but the dietary intake of fat is often considered to be the key factor. How ev er the
strong associations between national dietary fat intake and incidence of breast cancer is not as well
supported by studies in individuals, with inconsistent results being found in case-control studies
(Adami et al( 1990)). Ofmore significance are studies w here a very low fat intake appears to reduce
the incidence of the disease (Lubin et al(1986)). an effect potentially mediated through decreased
lev els of circulating oestradiol (Prentice et al( 1990)).
Hormonal influences
When considering the factors associated with a small, but significant increase in the risk of
developing breast cancer it becomes apparent that apart from familial associations, the majority are
linked to the hormonal milieu within the woman. For example, the use of post-menopausal
exogenous oestrogen, as in H.R.T.. may increase the risk, particularly if administered for 5 or more
years (Colditz et al(1995)). In contrast, early age at first birth may decrease the risk of a subsequent
breast cancer (MacMahon et al(1970)), although re-evaluation of the data suggests that the age of
subsequent births may also alter the risk (Trichopoulos et al( 1983)). Equally prolonged use of the
oral contraceptiv e may increase the risk of dev eloping a cancer (Chilvers et al(1989)), although other
large studies have not confirmed this (Stadel et al( 1985)). However more definite is the decreased
risk associated with an early menopause (Negri et al(1988)). w hich when induced by bilateral
oophorectomy before the age of 40 is associated with only half the chance of subsequently dev eloping
breast cancer (Adami et al( 1990)). In contrast, an early menarche or delayed menopause cause an
increased risk by about 5% per year (Abeloff et al( 1995)). These data all suggest that prolonged
exposure to female sex-hormones, and oestrogen in particular, increase the risk of being diagnosed
with breast cancer, but do not explain the mechanism for this link. Nonetheless, a recent study does
however suggest a possible link between the genetic and non-genetic risk factors for the dev elopment
of breast cancer - it seems that the expression of the BRCA-1 protein, at least in vitro, is under the
control of oestrogen (Guda et al( 1995)).
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The normal breast
Some discussion of the normal breast and its hormonal control will be relevant to the understanding
of the role of oestrogen in the development of breast cancer. The breast, which is fundamentally a
secretory organ, has as its functional unit the lobule. This arises from a terminal duct and is
composed of blind-ended ductules (acini) surrounded by a layer of luminal cells and then a further
layer of myoepithelial cells. All these structures are in turn surrounded by a specialised
mesenchyme, and the w hole is referred to as the terminal duct lobular unit (TDLU). It is from the
luminal epithelial cells of the TDLU that most pre-invasive and invasive breast cancers arise
(Wellings et al( 1975)). During the normal menstrual cycle, the luminal epithelium proliferates, with
the maximum growth rate found during the mid-luteal phase, w hether measured by T1 thymidine
labeling(LI) or mitotic index (MI) (Anderson et al( 1982); Going et al(1988); Potten et al(1988)).
There was no significant v ariation in the degree of proliferation during the menstrual cy cle with the
use of the combined oral contraceptive (Anderson et al( 1982): Potten et al( 1988)). whereas there was
a decrease with increasing age (Potten et al( 1988)). The luteal phase of the menstrual cy cle is
associated with high lev els of both oestrogen and progesterone, whereas the during follicular phase it
is only the oestrogen lev els that rise. Oestrogen exerts its effect on sensitive cells by binding to the
Oestrogen receptor (ER), which in turn interacts with specific DNA regions, the oestrogen-response
elements (ERE) (Green et al( 1988)), which are in the v icinity of target genes whose transcription is
thus modulated. Similarly , progesterone arts via the progesterone receptor (PgR). w hich itself is
expressed under the influence of oestrogen (Horwitz et al( 1975)). However there appears to be a
negative-feedback control of the expression of ER within the normal breast, since the level of ER
falls during the menstrual cycle, particularly in women on the combined oral contraceptive pill.
These data point to a continuum of changes in cell proliferation and gene expression during the
menstrual cycle, which can be considered as being necessary to prepare the breast for pregnancy
should it occur. Hence a woman w ho has more years of regular menstruating without interv ening
pregnancy, such as would occur with earlier menarche. delayed menopause or a Later first pregnancy
(all factors which increase the lifetime risk of developing a breast cancer), w ill have exposed her
luminal epithelial cells to more cell divisions. Since genetic mutations can occur at each mitosis,
prolonged menstruation creates an environment in which there is a higher risk of transforming a
breast epithelial cell into a malignancy.
Breast cancers usually retain some of the phenotype of their originating organ - few are so poorly
differentiated as not to be identified as of breast origin. Concomitant with the retention of some of
the hallmarks of breast epithelial cells is the expression of oestrogen receptors. Tumours presenting
in post-menopausal women are more commonly ER-positive, probably due to increased lev els of the
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protein in cells that express ER (Gaskell et al( 1992b)) (rather than an increased number of cells
expressing ER). This is consistent with the observations in the normal breast, since post-menopausal
women have much lower levels of circulating oestrogens and progesterone, and thus there is less
stimulus to drive the negative-feedback loop that seems to be apparent in the luteal phase of the
menstrual cycle. The expression of oestrogen receptors affords a mechanism w here circulating, or
locally synthesised oestrogen, can stimulate the proliferation of a breast cancer Hence it is possible
that prolonged exposure to oestrogens. w hich is associated w ith an increased risk of breast cancer,
could stimulate the growth of a clinically silent tumour, and thus increase the chance of detection.
Since most studies of risk factors for breast cancer do not assess the life-time risk for the women
under study, but rather correlate the incidence in a cohort with various factors, it is possible that any
apparent increased risk is not due to increased initiation of cancers, but earlier detection of
oestrogen-sensitive malignant lesions stimulated by for example exogenous oestrogen in H.R.T. One
would therefore anticipate that oestrogen receptors would more often be found in the breast cancers
detected in w omen with a hormonally-related increased risk for the disease ; and positive associations
between H.R.T. use and both higher ER concentration in the tumour (Lower et al(1996)) and lower
grade tumours (which are in turn associated with ER positivity(Fisher et al( 1981); Fisher et
al( 1980))) have been reported (Harding et al( 1995)). However, one might also expect that tumours
presenting in younger, pre-menopausal w omen were more commonly hormone-sensitive, but in fact
the opposite is the case. Thus the mechanism for the relationship between oestrogens and the
increased risk of breast cancer remains unclear.
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Hormonal Treatment of breast cancer
With the hormonal milieu clearly being of importance in the risk, and possible promotion, of breast
cancer, it is natural that attempts should be made to alter that milieu to try and control the growth of
an established breast cancer. The partially successful attempt by Bealson of controlling the disease
with oophorectomy (Beatson. (1896)) in fact constitutes the first report of systemic therapy for any
cancer. A subsequent report confirmed responses for this form of hormone therapy in about one third
of a group of pre-menopausal w omen (Boyd. (1900)). a figure consistent with current experience of
hormone therapy in similar patients with unknown tumour ER concentration.
During the 1950's. there was clinical interest in the use of oral anti-oestrogens to control advanced
breast cancer, in order to reduce the side-effects associated with the alternatives of surgical (or
radiotherapeutic) oophorectomy and surgical adrenalectomy. Clomiphene was found to be effective,
but too toxic for prolonged use (Herbst et al( 1964)). I.C.I, had developed the anti-oestrogen l-(p-
dimethylaminoethoxyphenyi)-1.2-rra/75-diethy 1-but-l-ene. (ICI 46.474 or Tamoxifen) for use as a
possible oral contraceptive (Wiseman. (1994)). It was therefore also tested in metastatic breast
cancer, and found to be effectiv e and well-tolerated (Cole et al( 1971)). In parallel, sev eral studies
were also undertaken which confirmed its efficacy in the DMBA-induced rat mammary carcinoma,
the only hormone-dependent animal tumour model available at that time (Jordan. (1974); Nicholson
et al( 1975)).
Pre-operative therapy for non-metastatic breast cancer
Follow ing the demonstration that a significant proportion of cases of adv anced breast cancer
responded to tamoxifen, further studies were conducted to test the possibility that post-surgical
adjuvant administration of tamoxifen might improv e surv iv al, which has indeed been confirmed bv
the most recent meta-analysis (Early Breast Cancer Tnalists Collaborative Group. (1992)). Whilst
the drug continues to be a mainstay of endocrine therapy for breast cancer, including adv anced
disease (Jaiyesimi et al( 1995)). in all situations in which it is employed, treatment failures occur.
When used in the adjuvant setting for early. potentially curativ e, disease this is only apparent at
relapse, at which point cure is no longer a realistic possibility. However there has been increasing
use of primary sy stemic therapy for non-metastatic breast cancer, w here chemotherapy and/or
endocrine therapy is administered first, before definitive loco-regional treatment. Most studies report
the use of chemotherapy. and therefore this will be considered first to illustrate the potential of this
indication for drug therapy.
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Pre-operative chemotherapy
Pre-operative or "neo-adjuvant" systemic therapy has been used for locally advanced breast cancer for
at least two decades. The rationale for its use was the concept that effective cyto-reduction would
render the primary cancer more amenable to surgery, and improve the otherwise rather poor long-
term survival ofwomen w ith this type of disease. The impact of sy stemic treatment on local control is
significant, but it rarely translates into improved survival. An EORTC study found that the
combination of CMF and hormones (ovarian irradiation and prednisolone for premenopausal women
or tamoxifen for post-menopausal) administered after radiotherapy gave a significantly better local
control rate but no significant survival advantage (Rubens et al( 1989)). A similar benefit in local
control for the use of combined hormone and chemotherapy was been noted in a retrospective
analy sis (Perez et al( 1994)).
There have been many studies involving different schedules and drugs, but it has been much easier to
improve response rates than survival; and as has been found in metastatic disease, as well as
laboratory models (DeVita, Jr. (1993)). a higher response rate does not always translate into
improved survival. However there are clinical data to suggest that the pathological response may be
clinically important; those patients whose tumours that hav e gone into a pathological complete
remission have a better survival (Bonadonna et al(1993): Feldman et al(1986)), and for all patients
the principal determinant of a worse long-term prognosis is the number of ipsi-lateral axillary nocks
that are found to contain metastases at the time of surgery (Altia-Sobol et aft 1993); Gardin et
al(1995); Grohn et aft 1984)).
With this experience of primary sy stemic therapy in locally adv anced disease, and the data from
laboratory models demonstrating an apparent proliferative stimulus to other sites of disease upon
remov al of the primary tumour (Holmgren et aft 1995)). (w hich can be prevented by prior therapy
with cy lophosphamide or ovarian ablation (Fisher et al(T989))), there has been increasing interest in
the use of chemotherapy before surgery in patients with operable breast cancer (Epstein, (1996)).
This has the twin adv antages of increasing the potential for breast conserv ation (Pow les et aft 1995)),
as well the theoretical possibility of an improvement in surviv al. Howev er this latter aim has y et to
be realised, and although two randomised trials have reported a benefit (Mauriac et aft 1991); Scholl
et al(1994)), in one case this was lost with further follow-up (Scholl et aft 1995)), and in other 10% of
those relapsing in the control arm had had no adjuv ant therapy (Mauriac et aft 1991)). Thus any
survival adv antage for pre-operativ e therapy over conv entional post-operative adjuv ant treatment is
likely to be small. Furthermore several studies have confirmed that despite a response in the primary
tumour conferring a survival advantage (Bonadonna et al( 1993); Jacquillat et al(1990); Scholl et
al(1995); Williams et al(1988)). the more profound influence on the subsequent clinical course is
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again the number of ipsi-lateral involved axillary nodes (Cameron et al( 1997). Frye et al( 1995);
Jacquillat et al(1990)).
Prc-operative hormone therapy
In contrast there are few published data on the use of hormone therapy for locally advanced disease
although a study from Nottingham (Robertson et al( 1994)) which compared primary tamoxifen and
radiotherapy ( with cross-over on progression) found no difference in survival between these two
modalities. Similarly a randomised studs conducted by the E.C.O.G. found that there was not only no
detriment, but possibly an advantage, in treating elderly patients with tamoxifen first, and
withholding chemotherapy (in the form of CMF) for tumours progressing on tamoxifen (Tay lor. IV
et alt 1986)). However neither of these studies restricted the use of tamoxifen to ER positive tumours,
and as such they are not a fair representation of the current practice in many centres. In early, or
operable breast cancer, there are similarly few reports of primary endocrine therapy , w ith most of the
available data coming from elderly women w here therapeutic minimalism is usually the goal (Allan
et alt 1985)) - w hich may no longer be justified (Di xon. (1992)). It is clear however that excellent
results can be obtained - a 5-year survival rate of ov er 90% w as reported in one study for those
women who had had a clinical complete response to tamoxifen (Horobin et al( 1991)). However a
poorer response was associated with a worse survival, although in another study. a measure of ER
was a better predictor of medium-term surviv al than was the clinical response after either 3 or 6
months' therapy (Gaskell et al(1992a)). With women under the age of 70. there is less experience of
hormone therapy. particularly in patients w ith operable breast cancer. The largest series is from the
Edinburgh Breast Unit (Anderson et al( 1991)). where pre-operativ e hormone therapy was initially
offered to all women with large primary breast cancer. However after no responses were observed m
tumours with an ER concentration of less than 20 fmol/mg cytosolic protein, pre-operativ e hormone
therapy was confined to patients with ER positive tumours (.Anderson et al( 1989)). The long-term
follow -up of these women has been recently published, and the 10 y ear actuarial surviv al is no
different for those women whose tumours responded to pre-operative chemotherapy or hormone
therapy (Cameron et al( 1997)). This was not howev er a randomised study , so no firm conclusions
can be drawn, but it suggests that effective hormone therapy would appear not to be detrimental in
comparison with doxorubicin-based chemotherapy.
Response rates to tamoxifen v ary between published series, depending on the stage of disease and
ty pes of tumours treated. It is univ ersally accepted howev er that the presence ofOestrogen Receptors
is associated with a 60 - 70% response rate to tamoxifen (Allan et al( 1985); Allegra et al( 1980):
Brooks et al(1980); Osborne et al(1980); Williams et al( 1987)). Howev er cut-off v alues for positivity
can vary between 5 & 20 fmoL'mg cytosolic protein ; the latter having clinical meaning as no
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significant responses were seen in tumours with values below that level after three months pre¬
operative hormone therapy (Anderson et al( 1989)). Although a lack of Oestrogen receptors predicts
for tamoxifen insensitivity (Anderson et al( 1989); Robertson et al( 1994)). there are data to suggest
that up to 10% of ER negative/poor tumours may sometimes respond to tamoxifen (Allegra et
al( 1980): Williams et al( 1987)) or indeed other hormone therapies (Dao et al( 1980)). Further
refinement of the prediction of response to hormone therapy has been attempted by the additional
measurement of progesterone receptor (PgR) concentration. Undoubtedly the response rate is higher
for tumours that express both ER and PgR. with rates of 66 - 83% reported (Brooks et al(1980); Dao
et al(1980); Osborne et al( 1980)). However a policv of only giving hormone therapy to ER and PgR
positive tumours would still fail to induce a response in 20% of patients" tumours, and would also
exclude the 30 - 60% of ER positive/PgR negative tumours w ho would have responded to such
treatment (Brooks et al(1980); Dao et al(1980); Osborne et al( 1980)). PS2. another oestrogen-
inducible protein has also been considered for its utility as an indicator of oestrogen-sensitivity
(Soubeyran et al( 1996a)). but as with PgR. there are a significant minority of tumours expressing
both ER and pS2 that do not respond.
There are data to suggest that the concentration of ER can help predict for endocrine-sensitivity,
with response rates being significantly better in tumours with higher levels of ER (Gaskell et
al( 1992a). Osborne et al( 1980)) ; however limiting the use of hormone therapy to those patients
w hose tumours hav e a high lev el of ER (such as > 100 fmol/mg) would not only exclude a significant
proportion of patients with responsive tumours, but could exclude the patients with the best long-
term prognosis as there are data suggesting that the prognosis for women w hose tumours have a
particularly high ER value may be worse than those with a lower, but still positive value (Sancho-
Garnier et al( 1995); Thorpe et al( 1993)). Finally a high proliferative fraction may predict for a
poorer response despite ER-positiv ity (Nicholson et al(1991)). and there is one study suggesting that
bcl-2 expression might be a more specific marker than ER of a hormone-sensitiv e tumour (Gee et
al( 1994)).
In conclusion therefore, pre-operative therapy with tamoxifen is in routine clinical use. although
largely for elderly women. There are however data to suggest that its use could be extended to other
patients, but accurate predictors of response would greatly benefit this approach. Long-term surviv al
is associated with a complete pathological response to therapy. be it in the primary tumour or the
axillary nodes. Residual disease in the breast possibly reflects resistant disease, whereas persistent
axillary nodal inv olv ement may not only reflect resistance but also an increased risk of sy stemic
disease which is itself potentially resistant. However current knowledge does not seem to be able to
predict tamoxifen response with a sensitivity of more than 80%.
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Failure of tamoxifen therapy
Clinically tamoxifen is administered for considerable lengths of time, and laboratory studies confirm
its long-term efficacy (Osborne et al( 1987)). However the undoubted benefit of adjuv ant tamoxifen
continues to be marred by the continual relapse of patients whilst still taking the drug Thus one can
consider that there are likely to be two populations of patients, as in the metastatic setting : those
whose tumours progress despite tamoxifen, and those in whom an initial response gives way to
secondary resistance. Further laboratory and clinical work has been conducted toward determining
the precise mechanism of action of the drug as well as identify ing phenotypes that are primarily
resistant Confirmation that the existence of both primary and secondary tamoxifen resistance is not
confined to patients w ith ov ert metastatic disease comes from studies of tamoxifen administered to
patients with non-metastatic breast cancer. Furthermore unsuccessful tamoxifen therapy not only
exposes a woman to the toxicity of the drug, which includes the rare but serious problem of
endometrial carcinoma (Barakat. (1995)). but might be prejudicial to her ov erall therapy Some
patients may receive tamoxifen in addition to cytotoxics, so it could be argued that lnefficacy is less
significant than when used as monotherapy. However there certainly are at least in vitro data
demonstrating antagonistic interactions between tamoxifen and commonly used cytotoxics, including
5-fluorouracil. and possibly cylophosphamide (Osborne, i 1994)). In contrast there is a suggestion
that tamoxifen might have a sy nergistic action with doxorubicin (Osborne et al( 1989)). although an
antagonistic interaction has also been reported (Hug et ah 1985)). There are other reasons to be
concerned about the concomitant administration of cytotoxics and tamoxifen, which has not been
demonstrated to be adv antageous as compared with sequential administration. Firstly. as will be
discussed subsequently (see page 36). tamoxifen appears to reduce the proliferativ e index of tumours,
irrespectiv e of their ER status (Clarke et al( 1993)). and (untreated) tumours with higher proliferativ e
fractions are more sensitive to chemotherapy (Remv ikos et al( 1993)). Furthermore there are data,
generated from the clinical tumours studied in this thesis, that tamoxifen administration can result in
increased p-glycoprotein expression, particularly in non-responders (Keen et al( 1994)). However the
clinical results are mixed ; a large retrospective rev iew of patients with metastatic disease found that
prior hormone insensitiv ity prejudiced survival when cytotoxics were subsequently administered
(Swenerton et al(1979)). whereas another reported no detrimental effect (Gregory et al( 1993)). A
randomised cross-ov er study in locally adv anced disease and metastatic disease, which did not select
therapy on the basis of ER status, found a trend tow ards 3 better outcome if patients w ere given
tamoxifen first, as compared with those giv en initial CNfF chemotherapy (Taylor. IV et al( 1986)).
Finally the Edinburgh Breast Unit's experience in early breast cancer is that the response rate to
doxorubicin-based chemotherapy was possibly worse in those patients given prior hormone therapv.
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with only 14/22 (64%) responding as opposed to the 24'28 (86%) given primary chemotherapy
(Cameron et al( 1997)). and their survival appeared worse (p = 0.1. unpublished data)
In summary therefore, earlier and more accurate prediction of tamoxifen sensitivity or resistance
could be of immediate clinical benefit
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Aims of this study
Tamoxifen has an important role in the treatment of breast cancer However it is not universally
efficacious, and a failure to respond to tamoxifen might even be counter-productiv e in some tumours.
The aims of this study were therefore to :
i. examine biological changes in clinical breast cancer occurring during tamoxifen
therapy.
ii. correlate these changes with tumour response.
iii. confirm the timing of these changes in a model system.
iv. confirm the specificity of these changes to tumour response in the model system.
In order to facilitate the translation of these findings to clinical practice, the methodologies chosen
had to be reproducible when applied to clinical specimens. Hence techniques such as flow cytometry
and immunohistochcmistrv were chosen in preference to in-situ RNA detection or electrophoretic
gels.
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Potential markers for tamoxifen response
Predicting exactly which tumours will respond to tamoxifen is. has alreadv been stated, difficult A
lack of expression of oestrogen receptors identifies tumours with only a low probability of response,
but it is less clear as to what is the best method of predicting which ER positive tumours will
respond to hormone therapy. The markers considered, including pS2 and PgR. have already been
discussed and there is a need to identify other indicators of potential resistance to tamoxifen for ER
positive tumours. Such markers need not just be static, but could be dy namic, w here the evidence of
resistance to therapy is reflected in the changes in tumour biology that occur with therapy. Potential
biological characteristics of breast cancers w ill therefore be considered and the current know ledge of
their interaction with tamoxifen discussed.
Oestrogen Receptors
Given that ER positiv ity is consistently the best predictor of hormone sensitivity in breast cancer, it is
possible that any changes in expression that occur w ith therapy might improve upon the utility of this
protein for identification of tamoxifen resistance.
Expression of the Oestrogen receptor appears to be under a negative feedback control, with inhibition
of the mRNA for the ER occurring upon exposure to oestrogen (Wiseman. (1994)). Anti-oestrogens
such as 4-hy dro.xytamo.xifen could block this effect. One might therefore expect that effective anti-
oestrogen therapy would be associated with increased expression. However if hormone therapy is
effective, then it could selectively reduce the proportion of breast cancer cells that arc ER positive,
leav ing a greater proportion of the tumour as ER negativ e, and thus a repeat measurement of ER
might result in a lower lev el of expression. Ineffectiv e therapy would therefore be expected to result
in no change, but the direction of change in responding tumours remains unclear. The data from
clinical studies are mixed - with some reports of a decreased lev el of expression after endocrine
therapy (Allegra et al( 1980); Lumsden et al( 1997); Taylor et al( 1982)). and others finding no overall
change (Hawkins et al( 1990); Hull et al( 1983)). The negativ e study reported by Hawkins et al
(Hawkins et al( 1990)). did note that the ER concentration fell after treatment in three patients treated
with tamoxifen, but not with other forms of prc-opcrative endocrine therapy. and suggested that some
of the discrepancy in the clinical studies could be due to the know n interference of bound tamoxifen
with the DCC assay (Hull et al( 1983)). and concluded that a change in ER was not the mechanism of
action of endocrine therapy for breast cancer Consistent with this was the small rise in ER
concentration seen in the benign uterus during therapy with the LHRH agonist zoladex (Lumsden et
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al( 1997)). a trend also observed when this agent is used in the prc-operative treatment of breast
cancer (Hawkins ct al( 1990)).
Proliferation
Given the relationship between oestrogens and both the incidence of breast cancer and the biology :f
the normal breast epithelium, it is important to develop further the link between these hormones ar.d
the behaviour of both the normal and malignant breast. Oestrogen exerts its effects at the cellular
level by binding towards the C-terminal end of a nuclear protein, the oestrogen receptor, w hich then
dimerises (Kumar et al( 1988)) and interacts with a specific DNA sequence, the ERE (Green et
al( 1988)). Subsequent upon this binding, transcriptional activation of oestrogen-induced genes is
mediated by two regions ; AF-1. which appears to be constitutively functional, and is located in the
N-terminal region, and AF-2 which is in the hormone-binding domain and depends on ligand
binding for its functionality (Parker. (1994)). Oestrogen-stimulated proliferation, which usually
requires other mitogens like insulin or Insulin-like Growth Factor-1 (IGF-1). acts early in Git in
contrast progestogens stimulate and both anti-oestrogens and anti-progesterones inhibit cell
proliferation later in Gi (Sutherland et alt 1992)). Shortly after exposure to a growth stimulant, there
is evidence of increased expression in breast cancer cells of various genes, including c-fos and then c-
myc (Sutherland et al( 1994)). Induction of Cyclin D1 also occurs in early Gl. but this is transient,
and levels fall as the cell progresses through the cell cycle (Sutherland et al( 1994)). Cyclin D1
appears to be rate-limiting for the transition from Gl to S phase (Musgrove et al( 1994)). and can te
inhibited by cyclin-dependent kinase inhibitors such as p21A AF"1 Cip~' (Harper et al( 1993): Xiong et
al( 199.3)). Further ev idence of the potential importance of cy clin D1 in breast cancer comes from a
recent study w hich reported that the incidence of ov er-expression rose from 18% of atypical ductal
hyperplasia (ADH) (a benign proliferative lesion with only a five-fold increased risk for breast
cancer) to over 75% in ductal carcinoma-in-situ or frank invasive carcinoma (Weinstat-Saslow et
al( 1995)). Studies using imnuinohistochenustry hav e found however that only one-third of breast
cancers over-express the gene product (Bartkov a et al( 1994). Gillett et al( 1994)). The observ ation
that those clinical breast cancers that ov erexpress cy clin D1 are more likely to be ER-positiv e
(Buckley et al( 1993): Fantl et al( 1990)) is consistent with its involvement in oestrogen-stimulated
growth Furthermore over-expression or gene amplification of cy clin D- may predict for a w orse
outcome (Schuuring et al( 1992)). particularly w hen associated with high lev els of the retinoblastoma
protein (pRB) or the epidermal growth factor (EGFR) (Mcintosh et al( 1995)); this may be because
increased cy clin D1 expression appears to enhance amplification of other genes, at least in an
experimental situation (Zhou et al( 1996)).
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There are many potential surrogate markers of increased proliferation within a breast cancer.
During the S-phase of the cell cycle. DNA is synthesised. Thus measuring the uptake of DNA-
precursors permits an assessment of the proliferative fraction of breast cancer cells The standard
method has been to measure the proportion of cells that became radioactive following the
administration of 'H-thymidine. expressing the result as the Labeling index (LI) (Meyer et al( 1988)).
However this method requires the use of radioisotopes, is not practical in patients or fixed tissue, and
has thus been largely superseded by other techniques. A non-radio-isotope v ariation of this method
using bromo-deoxy-undine (BrdU) is av ailable (Lloveras et al( 1990)). but is also limited by the
requirement for the cells to be v iable. Techniques that rely on active DNA sy nthesis are impossible
in fixed cells, but alternativ e methods are becoming av ailable Estimation of the S-phase fraction by
flow cy tometry (for details see the methods section) permits measurement of the proportions of cells
in the v arious phases of the cell cy cle, as identified by their DNA content: thus cells in G0 or G: are
distinguishable from those in S-phase and those in G;or M However discrimination between resting
G0 and actively proliferating Gi cells is not possible by this methodology alone, nor can the technique
separate pre-mitotic G; cells from those in mitosis. Furthermore the actual proportion of cells acuvely
proliferating cannot be estimated because of the inability to identify G- cells, and has to be estimated
by multiplying the S-phase fraction by 3 (Meyer et al(1986); Sahin et al( 1991); Wintzer et al( 1991)).
Whilst good results can be obtained from disaggregated cells grown in flasks or obtained from
tumours by Fine Needle Aspiration, when used on paraffin-embedded material the method is less
reliable (Hedley. (1989)).
For solid tumours which are often fixed and processed into paraffin-w ax blocks it has been necessary
to assess other markers of proliferation. The classic measure is the mitotic index. Cells that are in
mitosis are easily identified as having absent nuclear membrane (i.e. the cells have passed prophase),
"clear hairy extensions of nuclear material" (i.e. chromosomal condensation), w hich are either
clotted (early metaphase). in a plane (metaphase/anaphase) or separated (telophase) (Jannink et
al(1996)). Indeed the total number of mitotic figures in 10-high power fields is one of the three
cardinal features used to assess the grade of a clinical breast cancer (Bloom et al( 1957); Elston.
(1984)). and the mitotic index has been shown to be assessable with reproducibility (Clayton. (1991);
v an Diest et al(1992)). Alternatively , by using antibodies, immunohistocherrustry allows the
identification of cells that express antigens associated with proliferation. A number of proliferation-
associated antigens are known - including Ki-67. which is expressed throughout G. S & G;/M
(Gerdes et al( 1984)). PCNA (Mathews et al( 1984)) which accumulates in S-phase (Ogata et
al( 1987)) and Ki-Sl (Kreipe et al( 1993)) which is topo-isomerase I (Boege et al( 1995)). That these
are all measures of proliferation is confirmed by the correlations between PCNA and thymidine-
labelling (Battersby et al( 1990)). DNA-flow cytometry (Garcia et al(T989)) and Ki-67 (Dawson et
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al( 1990): Gasparini et al( 1994a)) : between S-phase fraction and Ki-Sl (Camplejohn et al( 1993)).
Ki-67 (Dawson et al(1990): Gasparini et al(1994a); Kcshgegian et al( 1995)) and inconsistently
PCNA (Dawson et al(1990); Gasparini et al( 1994a): Keshgegian et al(1995)); but poor correlations
w ere found betw een S-phase fraction and BrdU labelling (Lloveras et al( 1994)). How ever, there are
data to suggest that both PCNA and Ki-Sl staining ma> \ary with different concentrations of
antibody, whereas the MIB-1 antibody for Ki-67 (w hich is associated with several other proliferative
markers (Keshgegian et al( 1995)) including the mitotic index (Weidner et al( 1994))) is more robust
and is not expressed in non-proliferating cells (McCormick et al( 1993)).
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c-erb-B2
In the same manner that oestrogen can drive benign and malignant breast cell proliferation via the
oestrogen receptor, there are other families of growth factors and their receptors that appear to play
important roles in the biology of breast cancer. One of the most frequently implicated receptors are
members of the class I receptor tyrosine kinase family, which includes c-erb-B2 or HER-2/neu
(Coussens ct al( 1985)). In \ftro studies suggest that whilst the expression of c-erb-B2 is inhibited by
oestrogen (Dati et al( 1990)). is upregulated by tamoxifen (Antoniotti et al( 1992)) in cell lines
(including ZR-75-1) that are sensitive to tamoxifen's anti-proliferative effect In contrast tamoxifen
had no effect on growth or c-erb-B2 expression in an insensitive cell line. MDA-MB-231. The true
relationship between growth regulation and c-erb-B2 expression is however more complex as not all
compounds that are growth-inhibitory are associated with altered c-erb-B2 expression. Using the
T47-D and ZR-75-1 ER-positive cell lines, it has been shown that in addition to the previously
observed effects of oestrogen 3nd tamoxifen on expression c-erb-B2. progesterone increased
expression whilst inhibiting growth, whereas prolactin had a similar ant [-proliferative effect without
any observed change in expression at either the message or protein levels (Taverna et al( 1994)). A
direct link between the two receptor pathways, ER and c-erb-B2 was recently confirmed, which goes
some way to clarifying their relationship in clinical breast cancer. In a study employing MCF-7 ER-
positive breast cancer cells, some of w hich had been transfected with the gene encoding for c-erb-B2.
it was clearly demonstrated that the c-erb-B2-transfected cells were no longer dependent on oestrogen
for growth, and were insensitive to tamoxifen's growth inhibitory effects, when grown both in cell
culture and nude mice (Pietras et al(1995)). This change in tamoxifen-sensitivity came about without
any alteration in the intra-cellular tamoxifen concentration, and could be reversed by the addition of
a monoclonal antibody to the c-erb-B2 protein. rhuMAb HER-2. The interaction between the tw o
receptor pathways was confirmed by the increased phosphorylation and ERE binding of the ER upon
growth stimulation in the transfected cells by heregulin. a peptide growth factor that binds to the c-
erb-B2 receptor (Carravvy et al( 1994)). That this implicates a true post-receptor oestrogen-dependent
pathw ay was confirmed by the increased PgR expression observ ed, confirming that the c-erb-B2
receptor can induce changes in genes that are under the normal control of oestrogen. Furthermore
prolonged exposure to heregulin resulted in a significant decrease in the level of both ER and PgR
expressed, which could thus itself give rise to a hormone-insensitive cell.
In clinical breast cancer. c-ert>B2 was first recognised to be of importance as a prognostic factor
Gene amplification resulting in ov er-expression occurs in up to a third of breast cancers (Barnes.
(1989); Slamon et al(T987)). and is associated with a poor prognosis in lymph-node positive tumours
(Borg et al( 1991); Schonbom et al(1994); Slamon et al(1987); Tetu et al( 1994)) although the
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association is less-well defined in lymph-node negative tumours (Borg et al( 1991); Gaspanni et
al( 1993): Gullick et al( 1991)). Several studies suggest that over-expression correlates with other
poor prognostic features, such as high proliferation as measured by S-phase fraction (Borg et
al( 1991)) or Ki-67 (Sirvent et al(l994)). tumour grade (Schonborn et al( 1994): Sirvent et al( 1994))
and the absence of steroid receptors (Borg et al( 1991): Sirxent et al(1994)) ; although other studies
do not always find such associations (Lonn et al(1994)). Some of these discrepancies may be due to
methodological discrepancies such as different fixatives (Penault-LLorca et al( 1994)). or antibodies
(Press et al( 1994)). The data relating c-erb-B2 ovcrexpression or gene amplification (w hich appear to
not be synonymous (Barnes. (1993))) with the absence of steroid receptors highlights an important
relation between these two classes of receptors, which is further confirmed clinically by report of
upregulation in tamoxifen-treated clinical cancers (Johnston et al(1993)). consistent with in vitro
data. This effect, which on first thought appears counter-intuitive to the anti-proliferative effect of
tamoxifen, could therefore be an explanation for the observation, that at least in some series, c-erb-
B2 positive breast cancers are hormone-insensitive, even when expressing ER (Allred et al( 1992):
Guslerton et al( 1992)). although not all authors confirm these findings (Archer et al(1995); Barnes.
(1993)). Indeed, there is a study suggesting that c-erb-B2 positive tumours might actually do worse
when given tamoxifen, as compared to controls, the majority of w hom were in control arms of
adjuvant trials and thus received no post-surgical systemic therapy (Borg et al(1994)). Furthermore
an association has been reported in ER-positive breast cancer between c-erb-B2 expression and
proliferation (Borg et al( 1991)).
Thus although studies suggest that the relationship betw een c-erb-B2 and oestrogen is such that the
c-erbB2- pathw ay is. upon stimulation, capable of bypassing the dependency of the ER upon its
natural ligand oestrogen, the data on the effect of tamoxifen on c-erb-B2 expression suggest that it
could be a candidate marker for early detectable changes with tamoxifen treatment. As with most
oncogenes, there are several ways in which levels of expression can be detected, but as stated above
the intention was to define a marker of tamo.xifen-response that was available both in tissue and flow-
cytometry Therefore, as for proliferation, the most suitable is immunohistochemical detection with a
monoclonal antibody. because the same methodology can be transferred to FNAs analysed by flow
cytometry simply by employing flouroscein-tagged secondary antibodies (Stal et al( 1994)).
Furthermore, although detection of amplified mRNA lex els has been reported using the flow
cytometry (Li et al( 1994)). the discrepancies sometimes reported for c-erb-B2. both in \itro (Taverna
et al( 1994)) and in vivo (Barnes. (1993)). between levels ofmRNA and protein suggested that
changes in protein expression would be more relev ant as it is the receptor itself that is involved in the
cellular changes associated with c-erb-B2.
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Apoptosis & cell-death
Growth depends on the relative balance between cell production and cell loss (Schwartzman et
al( 1993)). Cell death was traditionally considered to be a pathological process, caused by a hostile
environment, resulting in necrosis (reviewed in (Wyllie. (1981))) It can occur in response to several
insults, including ischaemia (Borgers et al( 1987)). and metabolic poisons (Trump et al( 1984)). and is
associated w ith distinctive changes ; initial swelling of the cvroplasm with only minor changes in the
nucleus. Subsequently there is organelle and plasma membrane disruption, and the intracellular
contents spill into the extra-cellular space (Trump et al( 1982)). Proteolytic digestion of histones
results in exposure of the DNA w hich is then cleaved into fragments of varying sizes (Duvall et
al( 1986)). This process is typically seen in contiguous cells, and may be associated with hemorrhage
and or an inflammatory response
Howev er there is another, more controlled form by which a cell can die. This programmed or
physiological cell death has been increasingly realised to play a major role in tissue homeostasis, and
is prevalent in many tumours It occurs rapidly , and in contrast to necrosis, usually affects scattered
cells ("Bellamy et al( 1995)). Its morphology was first described in 1907 (Collin. (1906)) but it was not
until 1972 that v arious reports of these observations w ere recognised to be examples of the same
process, which was given the name of apoptosis (Kerr et al( 1972)), from the Greek word for leav es
falling off trees. Morphologically, apoptotic cells are quite distinct from necrotic ones, and this is
discussed in the review referred to above (Wyllie. (1981)). Apoptosis usually affects single or small
numbers of cells in an asynchronous fashion. Under the light microscope the first visible feature of
this process is cytoplasmic condensation, which is apparently associated with loss of intracellular
fluid (Lockshin et al( 1981)) There is a loss of intercellular contact, and the cell is also released from
the basement membrane. Intermediate filaments condense around the nucleus (Wy llie. (1987)), and
the cell is isolated from its neighbours. This process can be very rapid, occurring in a few nunutes
(Tenniswood et al( 1992)). The next stage, which remains visible for perhaps a few hours, consists of
chromatin condensation which results in nuclear blebbing (Cohen. (1993)). w hich occurs
concomitantly with activation of an endogenous Ca;" dependent endonuclease w hich cleaves the
DNA often into lengths that give rise to the typical appearance of the "DNA ladder" on agarose gel
electrophoresis (Arends et al( 1990)). Morphologically the typical apoptotic cell has sev eral
membrane-bound dense py knotic nuclear fragments known as apoptotic bodies, which are then
usually phagocytosed either by macrophages or adjacent cells (Wyllie. (1993)). Perhaps because
DNA fragmentation into the classic "ladder" is so easily detected, it has been proposed as the
"hallmark" of apoptosis (Compton. (1992)). However DNA ladders cannot alone distinguish
between apoptosis and necrosis, since they have been seen following hepatic necrosis induced by
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paracetamol (Ray et al( 1993)). and necrosis of murine mastocytoma cells caused by DEAE-Dextran
(Collins et al( 1992)). Furthermore there are reports of apoptosis. detected morphologically, that are
not associated with DNA laddering (Cohen et al( 1992); Thompson. (1991)). It is therefore the
morphological appearance of an apoptotic cell that remains its " hallmark" (Wyllie. A.H.. personal
communication).
Much of the understanding of apoptosis has come from work in lymphoid cell systems. which may
not be immediately relevant to epithelial tissues such as the breast. Some of the triggers that induce
apoptosis are beginning to be understood, and include APOl. oxfas, (Itoh ct al( 1991)). TNF and
other members of the same family (Fehsel et al( 1991): Kyprianou et al( 199 la)). There is also
evidence for a third pathway invoking ceramide and perhaps Protein Kinase C as an inhibitor
(discussed in (Schwartzman et al(1993))). Downstream the final common pathway appears to involve
cysteine proteases of the Interleukin-lb converting enzyme (ICE.) family, whose actions include
cleavage of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP) (Nicholson et al(1995)).
Various regulatory genes have been identified, including c-mvc. bcl-2 and other members of the same
family, and p53 ; some will be discussed in more detail. The importance of c-myc is that it is
associated w ith increased proliferative stimulus to the cell, but if there are insufficient growth factors,
also increased apoptosis (Evan et al( 1992)). In contrast. Ha-ras transfection induced a similar
proliferative drive but without the increased propensity to undergo apoptosis (Arends et al( 1993))
Other interventions that cause cell-cy cle block, such as topo-isomerase II inhibition or thymidine-
induced S-phase arrest, also induce apoptosis and thus appear to mimic the effect of serum starv ation
(Bertrand et al( 1991); Fanidi et al( 1992)). These and other data suggest that at least one group of
cells that are primed for apoptosis are those in a high turnov er state (Wyilie. (1993)). an observ ation
that will have relev ance when examining the evidence for apoptosis in breast epithelial cells. There
is no doubt that p53 plays a major role in the induction of apoptosis in many cell sy stems ; this is
discussed elsew here (vide infra). However apoptosis can occur without p53 being involv ed, and in a
classic pair of studies it was show n that in lymphoid cells p53 is necessary for etoposide (a potent
topo-isomerase II inhibitor) and y -ray induced apoptosis. but not for that consequent upon
glucocorticoid exposure (Clarke et al( 1993)). Furthermore there is evidence that androgen ablation
can induce p53-independent apoptosis in prostatic glandular cells (Berges et al( 1993)). and in human
prostate cancer xenografts (Kyprianou et al( 1990)) in w hich it appears to be associated with
increased TGF B, expression.
Apoptosis occurs in the normal breast epithelium (Ferguson et al( 1981)). and the frequence with
which it is seen varies throughout the menstrual cycle, with a peak occurring only a few day s after
that of proliferation (Anderson et al( 1982)). Having proliferated during pregnancy, mammarv tissue
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in the rodent then involutes at the time ofweaning, w ith induction of apoptosis in the glandular
epithelial cells resulting in the loss of 75- 85% of the cells (Battersby et al( 1988); Walker et
al( 1989)). Control of these processes is through a complex set of hormonal interactions, although it
is not possible to determine which specific hormone is responsible. It is perhaps therefore not
unexpected that ovarian ablation can cause apoptosis in breast tumours (Warri et al( 1993)).
The gold standard measure of apoptosis is the characteristic apoptotic cell - with its contracted
eosinophilic cytoplasm, condensed chromatin with or without nuclear blebbing. occurring in a single
cell asynchronously with other cells in the vicinity that may be undergoing the same process
(Bellamy et al( 1995)). However identification of such cells in a tissue section is time-consuming,
and potentially subject to inter-observ er variation. Furthermore the low incidence of apoptosis in
breast cancers (Lipponen et al( 1994)) heightens the possibility that there could be sigmficant intra-
tumour variation, depending on the section examined, unless a large number of cells w ere to be
examined. Because of these limitations other techniques hav e been investigated in the hope that they
might be more sensitive and less subject to v ariation. For cell line experiments, many workers hav e
separated extracted DNA on an agarose gel. citing the characteristic DNA ladder as proof of
apoplosis. When the total number of cells are know n, quantification of the laddered DNA permits
comparison of the apoptotic frequency betw een experiments However for clinical breast tumours,
only a proportion of the extracted DNA will hav e come from the invasive cancer cells, with unknown
proportions also being contributed by stroma, benign ducts. D.C.I.S. and infiltrating leucocytes.
Indeed in a study of hormone depletion in rodent tumours, in which the presence of apoptotic cells
had been confirmed, the proportion of the DNA that was fragmented was too small to be visualised
by this technique (Wijsman et al( 1996)). Thus without a detailed analysis of the relativ e cellularity of
the specimens, comparisons are almost impossible.
However the occurrence of DNA fragmentation can be used immunohistochemically to identify cells
that contain DNA strand breaks. There are essentially two different techniques in use. w hich onlv
vary in the enzyme used to identify free DNA ends. In Situ Nick Translation was first used in
cultured cells (Fehsel et al( 1991); Kishimoto et al(1990)). and subsequently adapted for cell
suspensions and tissue sections (Gold et al( 1993)). The pnnciple of the method is that DNA
polymerase will extend free 3' ends of DNA. If the cells are incubated with DNA polymerase and
dUTP labeled with either fluorescein or digoxigenin (which is then further incubated with
fluorescein-labeled anti-digoxigenin antibodies), any free DNA ends will be labelled with these
marked nucleotides, which will be visible under a fluorescent microscope. The alternativ e method
uses the enzyme terminal deoxy-transferase (Gav rieli et al( 1992)). and similarly labeled dUTP
nucleotides. Both these techniques have the adv antage that they can be used on either cell
24
suspensions or tissue sections, and that both positive and negative controls can be performed (by
respectively pre-incubating with DNAase or omitting the basic enzyme). However they are essentially
indirect techniques for measuring DNA damage, and as discussed above, and in a recent review
(Darzynkiewicz et al( 1992)). cannot be relied upon as the onl> form of identification of an apoptotic
cell. Necrotic cells may also stain w ith these techniques, although the actual intensity of the stain
may help distinguish between necrotic and apoptotic nuclei. Studies w hich have compared TUNEL
and ISEL have shown that whereas the former was more sensitive for the early stages of apoptosis.
earlier identification of necrotic cells occurred with the latter (Gold et al( 1994)). Furthermore, in a
small study in clinical breast cancer, the two techniques were noted not to be synonymous (Azam et
al( 1994)). with TUNEL being the more sensitive technique for detecting morphologically obvious
apoptotic cells. Advocates of the use of these techniques in the identification of apoptotic cells also
cite another beneficial argument, namely that they can detect cells at an earlier stage of apoptosis
(Gavrieli et al( 1992); Umansky. (1982)) and thus potentially increase the sensitivity of detection.
However in one study of breast cancers, there were also cells that w ere clearly apoptotic by
morphological criteria that were not identified by the TUNEL method (Dowsett et al( 1995)).
Problems using the TUNEL assay to distinguish between apoptosis and necrosis have also been
reported in other systems (Grasl-Kraupp et al(1995). Wijsman et al(1996».
For cell suspensions there are other methods of identifying apoptotic cells. Firstly, apoptotic cells
often hat e reduced DNA staining with various fluorochromes. giving rise to the characteristic sub-
G1 peak using a flow cytometer (Darzy nkiewicz et al(1992)). It remains unclear whether this is due
to reduced DNA accessibility to the fluorochrome. or reduced DNA content - although the latter
explanation is more likely, since different fluorochromes give rise to the same sub-Gl peak, and
studies on DNA in fixed and unfixed apoptotic cells suggest that a considerable proportion of the
DNA in apoptotic cells is of low molecular weight, and dissociates from cells whose membranes ha\ e
become more permeable secondary to the fixation process (Arends et al( 1990)). The disadvantage of
relying on a sub-Gl peak to identify apoptotic cells in needle aspirates from xenografts grown in
nude mice, is that any cells of a mouse origin (such as leucocytes, vascular endothelial cells and
stroma) will have a reduced DNA content as compared with the human-derived tumour cells, and
will thus themselves also form a sub-Gl peak ! (See figure 1). Furthermore any other DNA
fragments from necrotic cells could blur the pre-Gl region of the DNA histogram, rendering
measurement of changes in sub-Gl peaks difficult, unless they are of considerable size.
A potentially more useful technique relies on the fact that unfixed apoptotic cells retain integrity of
their plasma membranes, unlike necrotic cells (Lennon et al( 1991». However such dye-exclusion
assays will only be able to also differentiate between live and apoptotic cells by using a second dye
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that assesses viability such as Hoechst 33342 (Pollack et al( 1991)). which requires excitation by a
laser at a different frequency from many that are w idely available. A further refinement of the
method is to pre-incubate with trypsin and DNAase 1 in order to completely disrupt the necrotic and
late apoptotic cells which cannot exclude these enzy mes (Darzvnkiewicz et al( 1984); Potmesil et
al( 1983)). Finally there is ev idence that apoptotic cells have a different flow cytometric appearance
as assessed by their forward (a measure of size) and side (a measure of granularity) scatter
characteristics, when examined in conjunction with their DNA-binding to propidium iodide and
Hoechst 33342 (Gold et al( 1993)). Apoptotic cells are smaller, with lower forward scatter, and
marginally more granular with higher side scatter. However a more recent study suggests that this
change in side scatter is only temporary. and indeed w as also seen in cells undergoing necrosis
(Lizard et al(1995)). Indeed this same report commented upon the fact that apoptotic cells were
unable to exclude Propidium Iodide (PI) at an earlier time point than had been previously realised,
calling into question the use of these assay s as a discriminant between apoptosis and necrosis The
same approach has been confirmed to discriminate necrotic from apoptotic cells only at an early stage
(Bry son et al( 1994)).
Most of the flow cyiometric studies have used cells in culture, although at least one group has
confirmed that the TUNEL end-labeling techniques do work in tumour FNAs. but there was no data
on the ability to exclude necrotic cells (Gorczyca et al( 1994)). In fact the proportion of apoptotic
cells identified (1 - 51%) is far more than ev er reported for morphological assessments, suggesting
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Figure 1 Flow cytometric analysis of DNA content (measured as red fluoroescence) of a FNA
taken from a ZR-75-1 breast cancer xenograft grown in a nude mouse, with a sub-
Gi peak containing cells derived from the host animal.
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Bcl-2
Given the marked propensity of lymphoid cells to undergo apoptosis. it is perhaps of little surprise
that the first gene to be associated with negative regulation of apoptosis was discovered to be
overexpressed as a consequence of the t( 14; 18) translocation w hich appears to be pathogenic in the
majority of cases of follicular lymphoma (Clears et al( 1985)). Named bcl-2. it w as found to be w idely
expressed in mans tissues and some tumours, including both benign and malignant breast (Nathan et
al( 1993)). The importance of this novel oncogene was not appreciated until it was demonstrated that
it could inhibit the apoptosis which occurs upon serum-deprivation (Hockenberv et al( 1990)). It is
expressed in hormonally-sensitive glandular epithelial cells (Oltavi et al( 1993)). often only in stem-
cell and proliferation zones (Hockenbery et al( 1991)). perhaps thus preserv ing the progenitor cells
There is considerable evidence for the apparent universality of the role that bcl-2 plays in inhibiting
apoptosis. such as that induced by glucocorticoids and cytotoxics (Miyashita et al( 1992)). The exact
mechanism by w hich bcl-2 inhibits apoptosis remains unclear, but it appears to act down-stream of
the initiation of apoplosis (Yin et al(1995)), and upstream of the activation of the I.C.E. cascade
(Shimizu et al(1996)), possibly via the modulation of intranuclear Ca~~ (Marin et al( 1996)).
Furthermore it has been reported to dimerise with another protein, bax. with which it has extensiv e
homology (Oltavi et al( 1993)). Ov ere.xpression of bax. w hich is capable of homo-dimerisation.
accelerated apoptosis. whereas expression of bcl-2 resulted in hetero-dimerisation and reduced
apoptosis. More recently it has been reported that bax is expressed in large amounts in the normal
breast, to a lesser extent in MCF-7 and T47-D malignant breast cell lines (but not some others), and
hardly at all in a small series of tumours (Bargou et al(1995)). Further members of the bcl-2 family
have been identified including bak (Chittenden et al( 1995); Kiefer et al( 1995)). bad (Yang et
al( 1995)) and two forms of bcl-.x ; a long, apoptosis-inhibiting form bcl-Xj., and its inhibitor, the short
bcl-.x, form (Boise et al( 1993)).
However in breast cancer the role of bcl-2 is less clear. It is expressed in the majority of the breast
cancers studied and is positively associated with ER status (Johnston et al( 1994); Krajevvski et
al( 1995); Lipponen et al( 1995); v an Slooten et al( 1996)). It has even been suggested that bcl-2
expression was a better predictor of hormone-sensitivity than ER (Gee et al( 1994)). and its
expression was inv ersely related to both EGFR and c-erb-B2. putative markers of hormone
insensitivity. Other studies hav e reported inv erse correlations with poor prognostic features such as
tumour grade, increased p53 expression, and c-erb-B2 over-expression (Hurlimann et al( 1995);
Joensuu et al( 1994); Lipponen et al(1995); Sierra et al( 1995); v an Slooten et al( 1996)) as well as
increased proliferation as detected by either Ki-67 staining (van Slooten et aft 1996)) or the S-phase
fraction (Lipponen et aft 1995); Steck et aft 19%)). Bcl-2 positive tumours are more often well
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differentiated, with low proliferation, and intact post-ER pathways, as evidenced by the expression of
pS2 and cathepsin D (Hurliniann et al( 1995)).
However the relationship between apoptosis and bcl-2 has not been fully elucidated in clinical breast
cancer. Tw o reports of the inv erse association of bcl-2 and apoptosis in breast cancers hav e used the
indirect immunohislochemical methods ofTUNEL (Sierra et al( 1995)) or ISEL (Sierra et al( 1996 ) ;
hence as discussed abov e, it is possible that the incidence of apoptosis was ov erestimated in tumours
with significant necrosis. Furthermore the majority of grade III carcinomas did not express bcl-2. and
high grade tumours are more likely to contain necrotic regions (Clayton. (1991)). Thus the observed
inverse relationship betw een apoptosis and bcl-2 could in part be explained by the presence of
necrosis in bcl-2 negative grade III tumours. There is a small study in 41 breast cancers that
reported, particularly in tumours with a low mitotic rate, an inverse association between apoptosis. as
measured by morphology , and bcl-2 expression (Chan et al( 1993)). Finally another small study
estimated the proportion of bcl-2 positiv e and apoptotic cells by flow cytometry. and again found
evidence suggesting an inverse relationship (Steck et al(1996)). However apart from the potential
problems of distinguishing between necrotic and apoptotic cells with the TUNEL technique, this
study has the additional problem of potentially including non-malignant cells, some ofw hich are
known to express bcl-2 (Nathan et al( 1993)). Hence the available data strongly suggest that bcl-2
expression is associated with reduced apoptosis. but is often based upon an indirect methodology. and
analysis has not been restricted to ER positive (or bcl-2 positive) tumours.
Several studies have noted that bcl-2 expression is associated with a better surviv al for patients with
early breast cancer (Hurlimann et al( 1995); Joensuu et al(1994)).A large retrospective study reported
that bcl-2 predicted for the "efficacy" of post-surgical adjuv ant therapy (Gasparini et al( 1995a)):
howev er adjuv ant therapy is administered to patients w ithout any know ledge of their residual tumour
burden. Thus a surviv al adv antage for one group could be due to any combination of sev eral reasons:
more patients cured by surgery alone, more patients with slower grow ing tumours, or more patients
whose disease is sensitive to the applied therapy. Thus to note a surviv al advantage for those given
tamoxifen in the adjuv ant setting could be because the tumours were more sensitive to tamoxifen -
and the association between ER positivity and bcl-2 expression, as well as the data correlating
response to tamoxifen and bcl-2 expression, both support the hypothesis that bcl-2 expression in the
primary tumour of a patient giv en tamoxifen is likely to predict better surviv al.
The conclusions that can be draw n from the data in clinical breast cancer are that bcl-2 would appear
to be associated with better differentiated tumours ; low grade. ER and PgR positivity. yet there is
also the suggestion that bcl-2 inhibits apoptosis within these same tumours. However in cell sy stems.
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highly proliferative eclls. such as those overcxprcssing c-m>c. are also more prone to undergo
apoptosis. There are data to suggest that this may be the case in breast cancer (Lipponen et alt 1994n
: although in that study both the mitotic and apoptotic indices w ere expressed per mm" of epithelium
(corresponding to 5 x 400 high-power fields), a methodology that ignores variation in ccllularity
between different tumours. The same association has been reported in bladder and gastric carcinomas
(Koshida et alt 1997): Lipponen et al(1994))and lymphomas (Czader et alt 1996)). suggesting that the
in v itro observ ations may relate to the clinical setting. Hence it may be that bcl-2 is a marker of a
particular breast cancer phenotype - low proliferation (and hence less apoptosis). low grade and
more hormone sensitiv ity - and the expression of bcl-2 in normal breast epithelial cells w ould suggest
that the persistent expression of bcl-2 is due to better differentiation. Consistent with this hypothesis
is the data from breast cell lines where bcl-2 expression appears to be under oestrogen control
(Teixeira et al( 1995)). although this can be inhibited by tamoxifen (Wang et al( 1995)). However a
small clinical study would dispute this, finding that bcl-2 expression increased in 11 ER-positiv e
tumours given tamoxifen before surgery (Johnston et al( 1994)). The majority of these tumours were
apparently negativ e for bcl-2 despite being ER positiv e. a finding that is not in keeping with other
reported series, and in the absence of any data on response to tamoxifen, one cannot be sure whether




The oncogene p53 is a nuclear protein that has specific target DNA sequences, for which it acts as a
transcriptional regulator (Tarunina et al( 1993). Vogelstein et al( 1992)). Mutations in this gene are
amongst the most common genetic alteration observed in human malignancies (Hollstein et
al( 1991)). It appears to act as a "guardian to the genome", serving the very important function of
inducing apoptosis in response to DNA damage (Lane. (1993)). such as that caused by ionising
radiation or cytotoxics (Clarke et al( 1993)). The cellular response to damaged DNA includes a rise
in p53 levels, which in some cells causes Gi arrest (Kastan et al( 1992)). and in others apoptosis
(Yonish-Rouach et al(1991)). predominantly in the G phase of the cell cy cle (Ryan et al( 1993)).
Mutant p53 appears to disable this cellular self-destruct pathway (Wang et al(1993)). which may thus
render a cell less sensitive to cytotoxic therapy Down-stream genes involved in p53-regulated events
include mdm2 (Juven et al( 1993)). p2fAAF1 (El-Diery et al( 1993)). bcl-2 and bax (Miyashita et
al( 1994); Selvakumaran et al( 1994)). It has however recently been demonstrated that in response to
the same stimulus p53 is capable of causing both growth arrest and apoptosis (Liebermann et
al( 1995)). This suggests that the outcome of p53 actu ation depends on other factors, including those
which alter the propensity to undergo apoptosis. Consistent with this is the observation that for p53
to induce bax it requires the cell to be capable of undergoing apoptosis (Zhan et al(1994)). However
as has been previously commented upon, apoptosis can occur independent of p53 activation.
Evidence that this can occur in the same setting as p53-induced apoptosis comes from a studs
involving a cell line immortalized by c-myc and a temperature-sensitise p53 mutant (Sakamuro et
al( 1995)). With functioning p53. the cells underwent apoptosis, which was accompanied by Gi -
arrest and increased expression of bax. In contrast, ssith the mutant p53, serum deprivation could still
induce apoptosis. but without ex idence of these other changes, although bcl-2 could suppress
apoptosis ssith either form of p53.
The importance of p53 expression in clinical breast cancers remains under debate. Several studies
have set out to determine the relationship betxveen prognosis and ox erexpression. as detected
immunohistochemicallv. Many of them have been reviewed recently (Mansour et al(1994)). with the
conclusion that the majority of reports do find the presence of detectable p53 protein is a marker of
poor outcome, particularly in node-negative breast cancer. Furthermore many studies report
associations xvith other poor prognostic features ; high tumour grade (Cattoretti et al( 1988b);
Fnedrichs et al( 1993); Home et al( 1996)). lack of oestrogen receptors (Fnedrichs et al( 1993); Home
et al(1996); Thompson et al( 1990)). increased proliferation (Cattoretti et al( 1988b)) However the
studies are not unanimous. One possible explanation is the use of different antibodies used for
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immunohistochemistry ; indeed 40% of the tumours in a recent study gave inconsistent staining w ith
four different antibodies each ofwhich is in common use (Home et al( 1996)). There are fewer data
relating p53 status with response to therapy. A small stud} of 17 patients treated with hormone
therapy upon relapse reported that none of the 6 p53 positive patients responded (Home et al( 1996)) :
the ER status of these patients was not reported and the majority of p53 positive tumours are ER
negative (Archer et al( 1995)) However, other studies ha\e reported no relationship between p53
expression and hormone insensitivity (.Archer et al( 1995 >). A large stud} sequenced the p53 gene in
over 300 breast cancers and reported an association between p53 mutations and lack of response to
adjuvant therapy (Bergh et al( 1995)). However there is no absolute measure available for response to
adjuvant therapy. Early disease progression and/or death may reflect lack of sensitivity to the applied
therapy but equally could be a reflection of a more aggressive underlying biology In contrast,
patients remaining disease-free need not have benefitted from the adjuvant therapy, but rather have
disease that is already cured or be more inherently indolent. Thus although the data are consistent
with the notion that p53 mutations conferred resistance to both tamoxifen and perhaps CMF
chemotherapy, it is equally possible that p53 mutations are associated with a poorer prognosis
independent of the drug sensitivity of the disease. Consistent with this is the observation that p53
expression is associated with the presence of lymph node metastases (Vojtesek et al( 1995)), the latter
being consistently reported as the strongest prognostic indicator in early breast cancer (Bonadonna et
al( 1995); Bonadonna et al( 1985); Botti et al( 1995); Fisher et al( 1983); Nemoto et al( 1980);
Schottenfeld et al(1976): Valagussa et al( 1978)). Thus of greater interest is a small study of neo¬
adjuvant anthracy cline-based chemotherapy in w hich it w as reported that the presence of a particular
p53 mutation conferred primary resistance to the chemotherapy (Aas et al( 1996)). There are
however no similar data available for tamoxifen.
p21wafucipi
p21y Aj : is an inhibitor of the Gi cyclin-dependent kinases inv olved in the Gi-S transition (Dulic et
al(1994); Gu et al(1993)), including cyclin D1 (Harper et al( 1993)). Although p21WAF1 has been
implicated in p53-mediated growth arrest (El-Diery et al( 1993)). it has a role to play in cellular
differentiation that is unconnected with p53 expression. There is also evidence to suggest that
p21WAF1 may be implicated in p53-independent apoptosis. Overexpression of bcl-2 in the MCF-10
breast cell line resulted not only in reduced apoptosis. but also reduced p2 lw AF1 expression
(Upadhyay et al( 1995)). In contrast in MCF-7 cells, ov erexpression of p21W AF' caused giant cell
formation and apoptosis (Sheikh et al( 1995)). Furthermore tamoxifen induced growth arrest of both
MCF-7 and T-47D cells is associated with increased expression of p21 * AF1 (Maas et al( 1995)). and




The family of type p transforming growth factors. TGFpi. TGF(K TGFpj have been shown to be
potent inhibitors of proliferation of most types of cells that hav e been studied (Alexandrow et
al( 1995)). although TGFp, has been the best studied member of the group. Cells are sensitiv e to this
anti-proliferative effect in both early and late Gi. and certain cyclins and cyclin dependent kinases
are their possible targets (Alexandrow et al( 1995)and references therein). Furthermore TGF p can
induce apoptosis in some cell systems, including uterine epithelial cells (Rotello et al(T991)). the
prostate (Martikainen et al( 1990)) and hepatocytes (Oberhammer et al( 1992)). With respect to breast
tissue. TGF p expression occurs in the mammary gland (Robinson et al( 1991); Wakefield et
al( 1992)). and is growth inhibitory to normal human mammary epithelium (Hosobuchi et al( 1989).
Valverius et al(1989)). Malignant breast cancer cell lines however show a v aried response to TGFp .
although growth inhibition occurs in the majority (AJexandrovv et al( 1995)). The data howev er on
xenografts is scarce, and includes a report that no effect was seen when MDA-MB-231 tumours
were treated with TGFpi (Zugmaier et al( 1991)). Furthermore the TGFps have profound effects on
the stroma, largely stabilising the matrix (Alexandrow et al(1995)).
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Angiogenesis
The limit of nutrient diffusion is around 1 mm, and thus for 3 tumour to grow beyond that size a
separate blood supply is required (Folkman. (1990)). The development of these new vascular
channels is termed angiogenesis. and it would seem that the process is driven by the tumour, with the
host vasculature developing endothelial buds in response to growth factors secreted by the tumours
These buds eventually coalesce into a complete blood supph for the tumour. The importance of this
angiogenesis has recently been elegantly confirmed by xenograft studies, w here the volume of
metastases w as show n to increase significantly (as a consequence of reduced apoptosis) w hen the
primary tumour w as removed, an effect that could inhibited by an anti-angiogenic factor (Holmgren
et al(1995)). This would suggest that dormancy of tumour metastases is the consequence of impaired
or inhibited angiogenesis (Folkman. (1995)). and there are data to suggest that one such anti-
angiogenic factor, angiostatin. is produced by the primary tumour (O'Reilly et al( 1994)). A large
number of factors that both stimulate and inhibit angiogenesis have been reported, but amongst the
inhibitory factors is tamoxifen (Gagliardi et al( 1993)). There have been more than a dozen studies
that have determined the prognostic relevance of the degree of angiogenesis in a patient's breast
cancer (Gasparini et al( 1995b)). and although their conclusions are varied, the majority report a
survival detriment for women whose tumours have a high vascular density. There are
methodological variations between the studies, both in the antibodies used to identify the vessels
(usually either anti-factor VIII or anti-CD31). as well as the counting techniques. One of the more
important studies found that in a group of over 250 patients w ith node-negativ e breast cancer, w ho
had not received any adjuv ant therapy. a high vascular density was independently associated with a
worse outcome (Gasparini et al( 1994b)).The exact relationship between v ascular density and poor
surv iv al remains undefined but the lack of any correlation with either mitotic/proliferativ e indices
(Vartanian et al(1994)). and other poor prognostic markers such as p53. hormone receptor status.
(Fox et al( 1994): Gasparini et al( 1994b)). suggests it is an independent factor rather than a marker of
other poor-risk biological features.
Commercially, the available anti-endothelial cell antibodies are murine anti-human antibodies (to
von Willebrand's factor VIII. CD-31 and CD-34). Thus none of these would be suitable for testing in
a mouse tumour xenograft. We however had available a sample of a non-commercial antibody . MEC
13.3, which is a monoclonal rat anti-murine endothelial cell antibody (Vecchi et al( 1994)). and
works only on frozen tissue.
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In vitro and in vivo effects of tamoxifen on breast cancer
The rationale and clinical experience of tamoxifen therapy in breast cancer have ahead) been
discussed, and although the pharmacokinetics and pharmacodynamics have been well studied, thee
are not very relev ant to this thesis. Howev er one aspect does need to be mentioned, and that is that
the major metabolite 4-hydroxytamoxifen is an active anti-oestrogen in its own right (Jordan et
al( 1977)). with a much higher binding affinity for the ER than its parent drug (Wakeiing et
alf 1980)). Extensive laboratory studies with tamoxifen have determined much about the mode of
action, and cell-cycle effects both in vitro and in model tumour sy stems. However the precise
mechanism of action in patients is only partially understood, and in particular it remains unclear as
to why some tumours manifest de novo resistance to the drug, despite having the hallmarks of
hormone-sensitivity.
Experimental data
The initial model for tamoxifen's anti-oestrogenic action was as a competitiv e inhibitor of the ER by
occupying the ligand-binding domain (Horwitz et al(1980)) This has been updated in the light of
recent know ledge, particularly in v iew of the differing sensitiv ities of the tw o transcriptional
activ ating regions. AF-1 & AF-2 (Parker. (1994)) ; it is proposed that the effect of tamoxifen
binding to the ER is to not to prevent DNA-binding. but only to inhibit AF-2. whereas the activity of
AF-1 remains unaffected. Thus tamoxifen (and its metabolites) can act as either an antagonist or
agonist depending on the AF region of the receptor that is responsible for the particular oestrogen-
induced effect. This therefore accords with the data suggesting tamoxifen can act as an agonist
particularly on the uterus (Wolf et al( 1995)). There are however data to suggest that tamoxifen may
have other mechanisms of action (reviewed in (Colletta et al( 1994); Wolf et al(1995))). Protein
kinase C (PKC) inhibition has been suggested as another mediator of tamoxifen's action (Wiseman.
(1994)), which could be important since PKC plays a key role in the transduction of membrane
signals (Nishizuka. (1988)). and the PKC inhibitor H7 can induce apoptosis in lymphoid cells
(Traganos et al( 1993)). However any putative inhibition of PKC is unlikely to be the mechanism of
tamoxifen's anti-proliferative actions, as PKC activators completely inhibit MCF-7 cell growth
(Issandou et al( 1990)). as does tamoxifen (Tominaga et alt 1993)). Tamoxifen can also act as an anti¬
oxidant and alter cell membrane fluidity (discussed in (Vecchietti et al( 1980); Vogelzang. (1984):
Wiseman. (1994))).
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The anti-proliferative activ ity of tamoxifen has been well-documented. It w as first demonstrated in
vitro for the hormone-sensitive human breast cancer deriv ed cell line. MCF-7; an effect that could be
rev ersed by the addition of oestrogen (Lippman et al( 1975)). Tamoxifen treated cells show ev idence
of G| arrest (Osborne et al( 1983); Sutherland et al( 1983a)). with an accompanying fall in the
proportions of cells in S & G;/M (Brunner et al( 1989); Butler et al( 1988); Danova et al( 1993);
Sutherland et al( 1987)). Further characterisation of the mechanism of the Gi -block induced by 1CI
164.384 and tamoxifen in MCF-7 cells suggests that rapid down-regulation of cyclin D1 may be
crucial, since it occurred before any changes in entry to S-phase were detectable (Watts et al( 1994)).
Similar data have been reported for the pure anti-oestrogen ICI 164.384 administered to T-47D
breast cancer cells (Musgrove et al(1993)). MCF-7 cells which had been xenografted into athymic
mice also demonstrate growth inhibition by tamoxifen (Osborne et al( 1985)). an effect w hich could
be overcome by oestradiol (lino et al( 1991)). Therefore despite the initial suggestions that tamoxifen
could be tumoricidal in vitro (Lippman et al( 1975)). it was generally held that tamoxifen was a
tumourostatic agent.
Data from in vivo experiments are less consistent, with some reports of decreased proliferation (Kute
et al(1985); Osborne et al(1985)). and others finding evidence of increased cell loss or cytotoxicity
(Brunner et al( 1989)). One study has indeed found evidence of both mechanisms in MCF-7
xenografts (Sarkaria et al( 1993)). However, as discussed above, cell loss occurs by two distinctive
mechanisms, necrosis and apoptosis. Although apoptosis may be induced following oestrogen
deprivation (Kyprianou et al( 1991b); Szende et al( 1989); Szende et al( 1990); Warri et al(1993)). it is
not a consistent finding, and a recent study reported no changes in apoptosis in ZR-75-1 xenografts
following oestrogen-withdrawal (Kristensen et al( 1995b)). Furthermore increased apoptosis has
been observed with the tamoxifen analogue, toremifene (Warri et al( 1993)). and with tamoxifen in
vitro (Frankfurt. (1995). Perry et al(1995a)). However caution needs to be exercised in interpreting
these reports, particularly those in which high concentrations of tamoxifen (as opposed to the more
activ e metabolite 4-hydroxytamo.xifen) have been employed in vitro : one study reported that
tamoxifen could equally induce apoptosis in the ER-negative cell line MDA-MB-231 (Perry et
aft 1995a)), which was not found to occur with lower concentrations (Bardon et aft 1987)), and may
thus be a non-specific cytotoxicity (Sutherland et aft 1983b)). perhaps mediated via TGFli. rather than
the ER (Perry et aft 1995b)). Interestingly, there are two reports that tamoxifen does not cause
apoptosis in xenografts (Kristensen et aft 1995b); Szende et aft 1990)). but in both the mean apoptotic
rate is higher with tamoxifen, although it is not statistically significantly so. In contrast, there are
some data to suggest that tamoxifen can induce necrotic cell-death in xenografts (Haran et aft 1994))
as a consequence of inhibiting angiogenesis (Gagliardi et al(1993)); but equally hypoxia has been
reported to induce cell death that was termed apoptotic (Yao et aft 1995)). although the techniques
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employed (DNA ladder & TUNEL-staining) cannot alone distinguish the relative contributions of
necrosis and apoptosis to the observed cell death. In conclusion therefore, tamoxifen may cause
apoptosis in breast tumours, although the data are not completely consistent, particularly with regard
to the ER-specificity of the process
Given the known anti-proliferative effects of the TGF-[3s (reviewed in (Alexandrow et al( 1995):
Wakefield et al( 1992))). they are possible effectors of tamoxifen's actions, and hav e been thus
studied. Their expression is under hormonal control, being inhibited by oestrogens (Dickson et
al( 1986)) and stimulated by tamoxifen (Knabbe et al( 1987)). although not in ER negative cell lines
Howev er the net effect of the combination of oestrogens and anti-oestrogens appears to be critically
dependent on the experimental conditions (Wakefield et al( 1992)). There is evidence that tamoxifen
can increase TGF p; activity in association with, and indeed before the onset of. apoptosis (Chen et
al( 1996): Perry et al( 1995b)). Perry's study employed 10pM tamoxifen (Perry et al( 1995b)) and
confirmed the effect on G, block, but reported that the induction of apoptosis occurred in both ER
positive and ER negative cell lines. However no increase in apoptosis was seen upon oestrogen
withdrawal, which conflicts with prev ious reports (Szende et al( 1989); Szende et al( 1990); Warn et
al( 1993)). including Kyprianou's work which documented a rise in TGF (3 in ER positive MCF-7
xenografts as they regressed consequent upon oophorectomy (Kyprianou et al( 1991b)). Perry's study
raises the possibility of tamoxifen hav ing an effect upon TGF (3 levels independent of the oestrogen
receptor, and consistent w ith this is the repon that it can induce TGF p secretion from human foetal
fibroblasts (Colletta et al( 1990)).
Clinical data
In clinical breast cancers there have been few reports of the biological effect of tamoxifen therapy,
and only one that sought to identify changes that parallel or even predate tumour response (Keen et
al( 1997)). There are data to suggest that tamoxifen can reduce proliferation (as assessed by Ki-67)
irrespectiv e of the ER status of the tumour (Clarke et al( 1993)). A more recent study reported no
effect on ER-negative tumours but a 30% reduction in proliferation in ER-positive tumours, although
this was not statistically significant even at the 10% level (Dowsett et al( 1995)).The investigation
howev er suffered from the defect that only indirect comparisons could be made as the control v alues
were obtained from untreated tumours in age-matched patients. Apoptosis was also assessed in the
same tamoxifen treated tumours by the ISEL method (Wijsman et al( 1993)). and the apoptotic index
of most tumours was found to be below an arbitrary 1% threshold. A trend (p = 0.08) towards more
apoptosis in treated ER-positiv e tumours was howev er reported, with a significantly less apoptosis in
ER-positive tumours as compared to ER-negativ e tumours, that paralleled a similar difference in
proliferation. Furthermore the proliferatiomapoptosis ratio was significantly less only in the ER-
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positi\ c treated tumours However these studies examined tumours after 6 - 65 and 5 - 35 da> s'
treatment respectively, and thus could not comment on the relationship between am changes and
tumour response. In contrast, the studv of Keen et al (Keen et al( 1997)) reported significant
associations between tumour response after 3 months" tamoxifen, and falls in proliferation (as
assessed by Ki-Sl) and bcl-2 expression (which might thus reflect an increase in propensity to
apoptosis). It is on this same set of tumours that the current study w ill assess changes in mitosis and
apoptosis. .An obvious candidate for examination of the effect of tamoxifen would be the product of
any gene know n to be under oestrogenic control. The Oestrogen and Progesterone receptors as well
as the protein pS2 could thus all be potential markers of true endocrine-sensitivity, but the few
studies reported find no consistent relationship between changes in expression and response. A fall
in the level of ER has been reported, with no significant change in either pS2 or PgR (Johnston et
al( 1995)). but no response data were available In contrast, another study reported decreases in both
ER and PgR. and a significant rise in pS2 but no change in c-erb-B2 (Soubeyran et al( 1996b))
However none of the observed changes correlated with response to 5 months" tamoxifen therapy.
As discussed earlier (page 33). the TGFp familv are potential mediators of certain tamoxifen effects.
However the data from clinical studies do not confirm changes in their levels of expression to be
strongly associated with tamoxifen sensitivity Butta (Butta et al( 1992)) demonstrated an increase in
extra-cellular TGF(f (but not TGFp; orTGFpff following three months' therapy with tamoxifen.
This effect was however noted to occur in both ER negative and ER positive tumours, and no
association with tumour response was reported. In contrast. MacCallum reported that the same
duration of therapy, in w omen with ER positive tumours, was not associated with any consistent
change in mRNA levels of any of the three members, but that there was a significant increase in
TGFP; levels in responding tumours (MacCallum et al( 1996)). Finally in advanced disease there is a
report that TGFPi can be cleaved to a smaller 5GkDa protein w hose expression is associated with
tamoxifen resistance (Baillie et al( 1996)). consistent with reports that the over-expression of TGFp,
can induce oestrogen-independence in MCF-7 xenografts (Arteaga et al( 1993)). Hence this familv of
proteins was not considered further in this study.
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Assessment of response
In considering the efficacy of an anti-cancer therapy. one has to define the purpose of that treatment
In the long term, the patients interest is usually best served by cure of the disease, but for many
patients that is an unachievable goal. The assessment of a therapeutic strategy cannot always aw ait
the long-term survival of patients, and in the arena of palliative treatments, other short-term gains
such as improv ement of tumour-related symptoms are sought Therefore tumour regression often
becomes an end-point in itself, and the precise measurement of this can be difficult. Primary breast
cancer affords the possibility of a more direct tumour volume measurement than is often possible for
later stage disease, but still has the problem that within the malignant tumour there are benign
structures such as stroma, infiltrating ly mphocytes, blood vessels and fat. Furthermore clinical
tumour measurements are prone to error (Warr et al( 1984)). and not just because of the thickness of
skin and sub-cutaneous tissue Radiological measurements of primary breast cancers offer an
alternativ e method of sequential tumour volume measurements. Mammography can be helpful, but
is uncomfortable for the patient, and does not identify a distinct tumour volume in all cases. An
alternative is ultrasound, which is painless and does not require the same expertise as
mammography. This technique, although it has been shown to be more accurate than clinical
measurements (Forouhi et al( 1994)). still tends to ov erestimate as compared with the true
pathological v olume (Nishimura et al( 1988)). How ev er any clinical measure of tumour v olume is
static, and does not take into account the biological mechanisms of tumour response.
It is clear that tumour growth or regression is a consequence of the balance betw een cell proliferation
and cell death (Schvvartzman et al( 1993)) and any alteration in this balance will change the growth
curve of the tumour. It remains unclear however what are the relative contributions of apoptosis and
necrosis to the overall cell loss. Furthermore in assessing tumour response (or otherwise) to therapy,
no account is taken of w hat cellular changes occur : the most widely accepted sy stem for defining
response, that proposed by the UICC. defines a response as a fall of at least 50% in the product of two
orthogonal diameters of a tumour, with a complete response occurring w hen no clinically detected
tumour remains (Hayvvard et al(1977); Miller et al( 1981)). Howev er if one considers the possibilitv
of tumours w ith different proliferation rates, it is immediately apparent that the same clinical
response can occur as a result of different biological responses in the tumour. Assume, for example,
that the av erage cell cycle length is 24 hours, and the lifespan of a morphologically apoptotic cell be
6 hours (consistent with (Berges et al( 1993))). Consider then two tumours with the same
apoptoticimitotic ratio; Tumour A. is a slow growing tumour with a proliferative fraction of 1% and
an incidence of apoptotic cells of 0.125%. In one day . 1% of the cells divide, and 0.5% of the cells
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die by apoptosis. Hence the growth rate is 0.5% per day. giving a doubling time of 139 days. In
contrast tumour B. w hich has a higher proliferative fraction of 10%. and an apoptotic cell incidence
of 1.25° o will grow at 5% a day. and double its volume in 15 days. Thus to induce a 50% reduction
in tumour volume over any given time period, the increase in cell loss rate has to be much higher in
the slower growing tumour. Hence an anti-proliferative drug that reduces proliferation by 75% will
induce a response in the fast tumour in 28 days, but not until 284 days in the slow tumour, assuming
no resistance dev elops ov er the 9 months of therapy 1 Conv ersely, for a pure cytotoxic (i.e. a drug
with no anti-proliferativ e effect) to induce a response by three months (i.e. 90 days), the increase in
cell kill for the fast tumour needs only to be 116%. whereas in the slow tumour it is more than twice
as great at 255%. However at the same time, the potential tumour growth saved by the drug
administration is much greater in the faster tumour w ith over a hundred-fold reduction from an
untreated volume (assuming no decelerating growth) in contrast to the 70% reduction for the slower
tumour (see figure 2. noting the log-scale) ! Recalling that most cytotoxics are more effective in
faster proliferating tumours, one can immediately see that a more powerful drug is required to
demonstrate the same efficacy (by UICC criteria) in a slower-growing tumour.
Thus for a sensitiv e analysis of how a tumour responds to tamoxifen, it would be beneficial to know
its growth rate, w hich is usually not possible. An alternativ e then is to change the definition of
response to a continuous variable, being the percentage volume reduction. This does not avoid all
pitfalls, but permits lesser degrees of response to be considered.
Xenografted tumours do however afford the possibility of observing the pattern of growth before
therapy starts, as well as the continued growth in the untreated animals. Deducing future potential
growth can then be done by fitting a curv e to the initial v olumes and extrapolating, with the tumour
response then defined no longer as a reduction from the v olume at the initiation of treatment (which
will be called the relativ e volume), but from the potential untreated volume (see figure 2 ). noting
that both tumours hav e the same v olume before and after treatment). This concept, of using predicted
growth as the basis on w hich to assess treatment efficacy has been proposed ("Norton et al( 1976)). but
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It remains therefore to consider the methodology for fitting growth curs es to the xenograft volume
data. There is a large bods of svork on fitting different grossth curs es to experimental tumour
grossth. but no better model than that originally described by Gompertz (Gompertz. (1825)) has been
found to describe the decelerating grossth that is clearly seen sshen malignant cells are grown in
spheroids (Marusic et al( 1994a): Marusic et al( 1993)) or as xenografts (Durbin et al( 1967); Laird.
(1965); Laird. (1964); Marusic et al(1994b); Simpson-Herren et al(1970); Spang-Thomsen et
al(1980)) particularly ss hen the data span a sside range of s olumes (Steel. (1977)). Mathematically
this describes exponential grossth. but the grossth rate decays exponentially ssith time (and thus
volume) such that there is a finite maximum solume. to sshich the grossth curs e is asymptotic (see
figure 3). This is expressed as :
sshere V(t) is the tumour s olume at time t. V0 the s olume at time t = 0 . and a and p are parameters
describing the initial grossth rate (a/p) and the rate of decas from exponential grossth (P). The
theoretical maximum volume, sshen t = oc , is equal to VoCCL'3. It has been noted that this theoretical
maximum s olume appears to be roughly constant for a given species (Brunton et al( 1978)). The
acceptance of this model has been further increased since it has been found to describe clinical
tumour grossth ofmyeloma. (Sullivan et al(1972)) breast cancers (Norton. (1988)) and lung
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metastases from testicular tumours (Demicheli. (1980)). However it should be noted that other
workers have found that exponential growth (Brown et al( 1984)). logistic models (Spratt et al( 1993))
or intermittent Gompertzian growth (Speer et al( 1984)) have also fitted clinical data well, and that in
many cases the Gompertz curve has been fitted to very few data points, which could equally fit
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Figure 3 Exponential and Gompertz growth curves
For the prediction of xenograft tumour volumes the Gompertz model w ill be used, but w ith one small
modification ; since the initial tumour volume (V0) is unknown, a third variable (x) is required,
being the time difference from when the v olume was 1 to when it was first clinically apparent, thus
eliminating the unknown V0:
V(t) =em
Having defined the equation to which the tumour volumes must fit. the next issue is to choose the
methodology, as this is not a linear function. In the literature cited above, two options have been
used. The most definitive comparison of different growth models as applied to tumour spheroids
noted that not only was the Gompertz function as good as any other, but also that this was best done
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by using the method of least squares fitted to the logarithms of the tumour volumes rather than the
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where Vj are the actual measured volumes.
In order to do this complicated mathematical routines are required, and advantage was therefore
taken of a general modelling package available to run on micro-computers under DOS. called
.ADAPT (D'Argenio et al( 1990)) which allows the actual function (i.e. equation III) to be user-
specified.
However it should be noted that there is an alternative methodology, as used in one study fitting
Gompertz function to individual xenograft tumour data (Spang-Thomsen et al( 1980)). That is if the
natural logarithm is twice taken on both sides of equation I. one has :
lnf— - ln(V)l = lnf—1 - fit












as e"7*5 is the same as V®. Thus by using a known or estimated value for V*,. fitting the Gompertz
curve becomes a simple linear problem, and this can be achieved by performing linear regression of
log [VJVi] on the time t. The disadv antage of this method is that it does require an accurate
estimate of the maximum volume, or alternatively a two-step minimization procedure : firstly to
estimate the maximum volume for that individual tumour and then to use linear regression to obtain
values for a and p. Computationally this can be done using the Microsoft programme Excel, bv
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minimising the deviation of equation IV from linearity as defined by the coefficient for the
correlation between the values of In[ln[Vao/Vj| and ti, the time points when the measurements
were made But if the tumour volume data suggests an unexpectedly high or low maximum volume
as a consequence perhaps of errors in a small number of measurements, the resulting curve may be
unreliable or even not definable. The approach using the non-linear equation III does not suffer from
this potential problem, as all three parameters a. p and x are estimated concurrently, and has





To use a series of 50 pairs of tumour tissue taken before and after three months' tamoxifen therapy
from patients w ith histologically proven ER-positive invasive breast cancer. The level of expression
of bcl-2 (a cell survival gene and thus a potential surrogate marker for apoptosis). had been
previously determined in these tumours, and both the absolute level and tamoxifen-induced change in
expression have been reported to correlate with clinical response to tamoxifen therapy (Keen et
al( 1997)). Further sections from the same tumour blocks were cut. and after routine H & E staining,
examined for mitosis and apoptosis. The apoptotic and mitotic indices were then compared with the
expression (and changes in expression) of bcl-2 in order to ascertain w hether the previously noted
changes in this surrogate marker did indeed reflect appropriate changes in biological processes
Furthermore the changes in apoptotic and mitotic indices were analysed, in conjunction with the
changes in bcl-2 and ER_ in order to determine the effect of tamoxifen upon tumour biology.
Model xenograft study
To determine the chronology of the tamoxifen-induced changes in apoptosis & mitosis and their
relative timing as compared with tumour response in a model system, comprising xenografts of the
hormone-dependent (ZR-75-1) and hormone-independent (MDA-MB-231) breast cancer cell lines
The advantage of a model system w as that precise growth and regression curves could be obtained
and correlated with any observed changes in cell death or proliferation. Multiple invasive techniques
could be employed and control groups of untreated and tamoxifen-insensitive tumours used for
comparison. Given that this model sy stem permitted more precise estimation of the timing of any
changes, it also afforded the opportunity to examine changes in other markers that might reflect the
biological changes consequent upon anti-oestrogen therapy. Finally the use of FNA samples was
assessed in parallel to determine w hether that technique held any promise for enabling early in vivo




These comprised tissue taken before and after tamoxifen therapy from 50 elderly women, attending
the Edinburgh Breast Unit, to whom the drug had been administered for three months prior to
definitive loco-regional surgery. The women are usually over 70 years old, and have a primary breast
cancer of at least 3cm in maximum diameter, and in w hom there were no obv ious metastases by
routine staging tests. Many hav e operable disease - for others it is locally inoperable because of fixed
axillary nodes (N; disease) or skin or muscle involv ement (T4 disease). The purpose of pre-operative
tamoxifen therapy is to attempt surgical dovvnstaging. and to establish in vivo tamoxifen sensitivity.
Thus pre-operative tamoxifen therapy is only offered if the tumour ER concentration is at least 20
fmol/mg cytosolic protein. ER measurement and histological confirmation of invasive breast cancer
are established on a pre-treatment tumour biopsy. from which additional material is usually made
available for research. .After 3 months' tamoxifen therapy , prov ided there has been no tumour
progression, the patients are then offered the option of electing to continue with tamoxifen alone, to
undergo definitive loco-regional surgery. or if they are uncertain of their own preferences, to enter a
trial which randomises them between these two options. Ov er a period of 2 years. 50 patients
underwent pre-operativ e biopsy. 3 months' tamoxifen and subsequent loco-regional surgery , and thus
from whom tissue was available both before and after tamoxifen treatment. During the tamoxifen
therapy, the patients' tumours were monitored clinically and by ultrasound at four weekly intervals.
Tumour respone to tamoxifen was calculated as the percentage change in v olume over the three
months' therapy. At surgery tumour tissue was snap frozen in liquid N;, subsequently thawed, fixed
in formalin for at least 24 hours and mounted in paraffin-wax blocks, from w hich serial sections w ere
cut.
Xenografts
The oestrogen-sensitiv e ZR-75-1 breast cancer cell line, and the oestrogen-insensitive MDA-MB-231
breast cancer cell line, were maintained by sequential passage in female nude athymic mice
(Hsd01a:ICRF-nu). purchased from Harlan (UK). BICESTER. Oxon. At each passage a 1 mm
fragment of tumour w as inserted subcutaneously in each flank of the animal w hen the mice w ere 8 -
12 weeks old ; on the same day a slow-release oestrogen pellet (0.72 mg. released over 60 day s
supplied by Innovative Research of America. Ohio. U.S.A. ) was inserted subcutaneously in the
midline. All mice were maintained on a standard diet (Harlan (U.K.)). and water ad libitum.
Bidintensional tumour diameters were recorded, and tumour volumes were calculated as
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Volume = 7T/6 . D d~. where D was the larger of the two diameters
Once the average of the tumour volumes reached about 0.25 cnrl the animals were randomly
assigned to either a treatment group in whom a slow-release tamoxifen pellet (2.5 mg over 60 days.
Innovative Research of America) was inserted sub-cutaneously adjacent to the oestrogen pellet: or a
control group in whom no further pellet inserted. There were no treatment-related animal deaths.
Fine Needle Aspirates (FNAs). were performed using a sterile 5ml Plastipak syringe and a 23G Yale
Microlance needle, with a minimum of 10 passes made through the tumour, whilst the arumal was
restrained manually. 2 ml of standard freezing mixture (10% DMSO and 90% foetal calf serum) was
then aspirated in to the syringe The contents were snap frozen in liquid N;. and transferred to -80(IC
for storage. If the animal was to only have one of two tumours excised the FNA was performed after
the administration of the anaesthetic, in order to minimise the time interval between FNA and
tumour excision.
For animals bearing single tumours, fine-needle aspiration w as performed immidiately prior to the
animal being killed by cerv ical dislocation, following which the tumour was excised. Animals
bearing tw o tumours were anaesthetised using hypnorm and hypnovel. and the tumour subjected to a
FNA before excision (the surgical wound being closed with MICHEL clips). The remaining tumour
was excised at the later time-point in the same manner as for animals bearing one xenograft. Excised
tumours were immediately snap frozen in liquid N2. and then transferred to -8()"C for storage.
Response to treatment
Tw o measures of response w ere considered. The first, termed "relative volume" w as the ratio of the
volume on treatment to that at the start of treatment. The second called "response", w as the
proportional reduction from the predicted volume at the same time point, using an extrapolated
gompertz growth curve fitted to that tumour's pre-treatment volumes. Thus a response of 0 implies
the treated volume was identical to the predicted volume, whereas a response of 1 occurred when the
treated tumour volume was 0. A negative response implied that the treated volume was larger than
that predicted by the growth curve. This particular definition was chosen such that the values would
be similarly interpreted as for the clinical tumour response, although the latter was based on the
actual pre-treatnient volume rather than a predicted untreated v olume.
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Study 1 : animals bearing either ZR-75-1 or MDA-MB-231 tumours
ZR-75-1 tumours were used from three passages, numbers 25.28 and 29. as illustrated in table 1. In
the first passage. 25 animals were established with ZR-75-1 tumours in both flanks, and all animals
were administered tamoxifen after the day 0 tumours had been excised. One tumour in every animal
w as left to grow until day 28 ; 5 animals had one tumour removed on each of days 0.2.7.14. and 21:
How ever on day 28. one of the tumours could not be palpated, giving rise to a total of 49 tumours
from that experiment. Subsequently, from passage 28. 7 animals were established with xenografts.
(3 were single and 4 double takes). In one animal both tumours regressed before day 0, and are thus
not included in the results. None of these animals were given tamoxifen ; 3 tumours were removed
on day 0. leaving 6 to be removed on day 28. Finally (passage 29) 10 animals were established with
two tumours each, and a further 16 with single tumours. The protocol for tumour removal in passage
29 was more complicated, in order to have roughly equal numbers of rumours at the v arious time-
points. Amongst the untreated animals, the one animal bearing tw o tumours had one each removed
on day 0 & 28. whereas the two animals with single tumours both had them remov ed on day 28. In
the remaining 23 animals allocated to the treatment group. 3 mice with double tumours had one
remov ed on day 0 and another on day 28. The remaining mice had tumours removed on either days
2 & 14. or day s 7 & 21. apart from six mice bearing single tumours of w hich 3 each were removed
on days 14 & 21.
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days of tamoxifen 0 2 7 14 21 28 day 28 control













Treated 12 12 11 11 27
Control 11 10
4 4 indicates 4 tumours removed at each of the two time points, all from mice
bearing two tumours
3 indicates 3 tumours removed at one time point from mice bearing single tumours.
Table 1 Details of timing of tumour removal for ZR-75-1 xenografts
MDA-MB-231 tumours from passages 2 & 7 were also established in a similar manner, as shown in
table 2. At passage 2. there were 6 mice bearing two tumours allocated to the treatment group, with
three tumours removed as day 0 controls, and three having their first tumour removed on day 14. The
intention had been to remove all six remaining tumours until day 28. but tw o mice w ere sacrificed
prematurely because of tumour ulceration. Four ""single take " mice were allocated to the treatment
group and had their tumours removed on day 7. and 6 mice w ith "single takes" left untreated ; four
had their tumours removed on day 28. and the other tw o on day 0. In the subsequent experiment,
passage 7. there were 13 "double takes" and 17 "single takes". However because of faster growth in
this experiment than the previous one, the experiment had to be terminated on day 21. 3 mice
bearing one tumour and one mouse bearing two tumours w ere left untreated, and all four of these
control tumours were removed on day 21. A further 5 mice had their only tumour removed on day 0.
In the treatment group, one mouse bearing two tumours had one tumour removed on day 0, with the
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other on day 21.6 treated tumours were removed on both day 2 and day 7 - three from mice w ith
single tumours, and three from mice with double tumours, whose second tumour was removed on day
21. On day 14 three tumours from "double take" mice and two from "single take" mice were
removed but one animals in this group had to be sacrificed prematurely because of tumour
ulceration, leaving only two tumours to be removed on day 21. Finally 3 "single take" and 2 "double
take" mice had their tumours treated until day 21 w hen all were removed.
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Treated 6 10 8 16 4
Control 11 5 4
3 indicates 3 tumours removed at one time point from mice bearing single tumours.
3 3 indicates 3 tumours remov ed at each of the tvvo time points, all from mice
bearing two tumours.
2 RIP indicated 2 mice bearing double tumours, with the first one remov ed but the
animal sacrificed before the time when the second tumour was due to be excised.
Table 2 Details of timing of tumour removal for MDA-MB-231 xenografts
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Study 2a : mice bearing synchronous ZR-75-1 and MDA-MB-231 tumours
Animals had a 1 mm fragment of ZR-75-1 tumours (passage 36) implanted in their left flank, and a
1 mm fragment of MDA-MB-231 (passage 9) implanted in their right flank. Of the 48 animals, both
tumours took in 24 animals, only ZR-75-1 tumours grew in 12 animals, and only MDA-MB-231
tumours grew in a further 12. The animals with two tumours were managed as follows : 4 were used
as day 0 controls with all tumours being removed on day (). 10 each were either administered
tamoxifen or left untreated 5 animals having both tumours removed on day 2. and the remaining 5
having both tumours removed on day 7.
Excised tumours
days of tamoxifen 0 2 7
treated 5 5
control 4 5 5
numbers indicate the number ofmice killed at each time point: each mouse bearing one ZR-75-1
tumour and one MDA-MB-231 tumour.
Table 3 Details of animals bearing synchronous MDA-MB-231 & ZR-75-1 xenografts
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Study 2b : mice bearing single tumours subjected to sequential Fine needle aspiration
The remaining 12 animals bearing single tumours of each type (ZR-75-1 or MDA-MB-231) w ere
evenly split between treatment and control groups, and had FNAs performed on days 0.2.5.7.9.12.14.
and 21. with the tumours excised on day 21: although one mouse bearing a MDA-MB-231 tumour
died on day 5.
days of tamoxifen 0 2 5 7 9 12 14 21
treated
ZR-75-1 6 6 6 6 6 6 6 6
MDA-MB-231 6 6 5 5 5 5 5 5
control
ZR-75-1 6 6 6 6 6 6 6 6
MDA-MB-231 6 6 6 6 6 6 6 6
numbers indicate the number of mice whose tumours v\ ere subjected to an FNA.
Table 4 Details of animals bearing synchronous MDA-MB-231 & ZR-75-1 xenografts




Microwave Dilution Incubation Supplier
primary
bcl-2 yes 1:100 4°C. 16 hours DAKO,
c-erbB-2 no 1:40 20°C. 1 hour NOVOCASTRA.
MIB-1 yes 1:50 20°C. 1 hour IMMUNOTECH S.A.
p53 (D07) yes 1:30 20°C, 1 hour NOVOCASTRA.






1:100 20°C. 1/2 hour DAKO.
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(0.72 mg. released over 60 days)
slow -release tamoxifen pellet





23G Yale Microlance needle
HARLAN (UK).
HARLAN (UK).
INNOVATIVE RESE ARCH OF AMERICA.




BECTON DICKINSON UK LTD
BECTON DICKINSON UK LTD.
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Addresses of commercial suppliers :
Becton Dickinson UK Ltd.. Between Towns Road. Cowley. OXFORD. U.K.
Boehringer Mannheim GmbH. Mannheim. GERMANY
CALTAG Laboratories. 436 Rozzi Place. South San Francisco. CALIFORNIA 94080. USA
DAKO Limited. 16 manor Courtyard. Hughenden Avenue. HIGH WYCOMBE. Bucks. UK
DIFCO Laboratories. Detroit. MICHIGAN. USA
FISONS Scientific Equipment Limited. Bishop Meadow Road. LOUGHBOROUGH. Leics. UK
FLUKA Chemicals. The Old Brickyard. New Road. GILLINGHAM. Dorset. UK
GIBCO Life Technologies Limited 3 Fountain Drive. Inchtnnan Business Park. PAISLEY. UK
Harlan (UK). BICESTER. Oxon. U.K.
Immunotech S.A.. 130 Avenue de lattre de Tassigny. 13276. MARSEILLE. FRANCE.
International Market Supply. Congleton. Cheshire. U.K.
Innovative Research of America. Ohio. U.S.A.
Jensen Animal Health. Grove. Oxon. U.K.
NBS Biologicals. New Brunswick Scientific (UK) Limited Edison House. 163 Dixons Hill Road.
North Mymms. HATFIELD. UK.
Novocastra Laboratories Limited 24 Claremont Place. NEWCASTLE-UPON-TYNE. UK.
Roche Products Ltd.. P.O. Box 8. WELWYN GARDEN CITY. HERTS. U.K.




A portion of each tumour was fixed for at least 24 hours in paraformaldehyde and then routinely
processed into paraffin blocks. The blocks were numbered as follows ; all the ZR-75-1 tumours from
studs 1 were randomly allocated a sequential number from 1 The MDA-MB-231 tumours from
passages 2 & 7 were randomly allocated a sequential number from 200. Finally the ZR-75-1 and
MDA-MB-231 tumours from the combined experiment (passages 36 & 9 respectively) were
randomly allocated a number from 100. 3 gm sections were cut and mounted onto glass slides, and
routine Haematoxylin and Eosin staining was performed. For those tumours with sufficient tissue, the
remainder of the sample was kept in liquid N;. for subsequent use. including the cutting of 5 gm
thick frozen sections on a cryostat. which were then stored at -80(,C.
The routine H & E staining afforded the opportunity to confirm that the sections contained tumour,
which was important for the xenografts. All tumours from w hich data are presented contained
tumour - however the two control ZR-75-1 tumours from passage 28 which had very poor growth,
and were therefore excluded, did in fact contain only scattered tumour cells, and therefore their
exclusion also appears justified on histological grounds.
Apoptosis & Mitosis
Given the difficulties of defining an optimum method for apoptotic assessment, it was felt
appropriate to rely only on the classical morphological measures. These were to be assessed by one
observer (DAC). after instruction by an expenenced pathologist. Dr. T.J.Anderson. A proportion of
the sections assessed for apoptosis from both the clinical cases and the mouse xenografts w ere
counted by both observ ers in order to provide a measure of reproducibility for the method.
The microscopy of the xenograft sections was performed on sections stained with routine
Haematoxylin and Eosin. The observer was blinded to the treatment status of the animal, and to the
day on which it was removed. It was not possible to be blinded to the cell line used, as ZR-75-1 and
MDA-MB-231 tumours were morphologically distinct, with the former having more obvious patterns
of differentiation including islands of tumour surrounded by stromalA ascular channels In order to
assess the apoptotic (and mitotic) indices. 10 random high-power (x400) fields were examined using
the HOME microscope (Brugal et al(1992)) by one observer (DAC). This computer-linked
microscope records which cells are marked, permitting later confirmation by the second observ er
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(TJA). Any Held that abutted onto or contained an area of necrosis was not used, because on the
peripheries there were sometimes cells whose nuclear morphology suggested apoptosis but without
the classic contracted eosinophilic cytoplasm. In order to avoid confusion and possible bias it was
felt appropriate to ignore these fields (as in (Arends et al(1994))). For some tumours the section was
to small to identify 10 distinct fields, and in these cases all the tumour cells in one section were
examined For the second experiment, which involved animals bearing both ZR-75-1 and MDA-
MB-231 tumours, most tumours were smaller than in the previous experiment, and thus only 8 fields
were used to standardise the number of fields examined betw een different tumour tvpes removed at
different times.
Apoptotic cells were identified by their morphometric appearance (Cohen. (1993)) (see figure 4). and
mitotic figures were defined as by Baak (Jannink et al( 1996)). using the convention that two parallel
chromosome clots are counted as separate mitoses (Jannink et al( 1996)) (see figure 5) The total
number of cells in the 10 high pow er fields was estimated by counting the number within a
representative region of each field of view (usually about one third), w hose area (A) was then
measured by the HOME microscope (Brugal et al( 1992)). Multiplying the number (N) counted in
this region by the ratio of the total area of the section (Ao) to the area of the smaller region gave an
approximation to the total number of cells for that field ( = A x A0 / N ): the whole section was
counted when the tumour was too small to be div ided into 10 fields. The apoptotic and mitotic
indices ( AI and MI respectiv ely ) were defined as the ratio of the number of apoptotic cells (or
mitotic figures) to the total number of tumour cells. The apoptotic:mitotic ratio was the ratio of the
total counts for each section (with the exception of those tumours where no mitoses were seen in the
10 random high power fields, w hen the ratio w as underestimated as being equal to the apoptotic
count for the 10 fields; this situation only arose in a single, regressing, control ZR-75-1 tumour,
which had been remov ed on day 28. and in 34/61 treated ZR-75-1 tumours, remov ed on days 7 - 28).
For the clinical breast cancers, the HOME microscope was used, but in order to permit a comparison
between tissue taken from different tumours both before and after treatment, a minimum of 5 high-
power fields was examined, until at least 1 000 malignant cells had been viewed ; ev en so there were
five post-treatment tumours for which there insufficient tissue av ailable to examine more than 1 000
malignant cells. The same criteria for apoptotic and necrotic cells were employed as for the
xenografts. The apoptotic : mitotic ratio was also defined as for the xenografts, and in the absence of
any mitotic figures being noted in the fields examined, the ratio was underestimated to be equal to
the number of apoptotic figures counted.
59
yi . |\\v v ► > % v
M **>• i _ ^ * /,J » ^ 4
/ * 11 4. ' * 4 A % j I *
A- * Vi *»* •»'
*>«:v* , - \i»u / **% »4 ' .( # #4 * .
Figure 4 Photomicrograph of a ZR-75-1 xenograft with an apoptotic cell seen at the centre of
the plate, with a horseshoe-shaped nucleus. Further typical apoptotic cells are to be
seen superiorly and towards the bottom and top left comers (H & E staining, x 400
magnification)
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Figure 5 Photomicrograph of a clinical breast cancer with a mitotic cell in telophase seen at
the centre of the plate. Further typical mitotic Figures are to be seen in the top left
and bottom right corners (H & E staining, x 400 magnification)
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Necrosis
ZR-75-1 tumours from the first experiment (study 1) were assessed to determine the proportion of
each tumour that was necrotic. Necrotic tissue was identified under light microscopy by the presence
of cells that were morphologically necrotic (Borgers et al( 1987); Trump et al(1982); Trump et
al(1984). Wyllie, (1981)). with or without adjacent hemorrhage (see figure 6). The HOME software
w as employed to calculate the total area of necrosis and the total area of tumour in the section
(excluding areas of pure stroma). The proportion of each tumour that w as necrotic was defined as the
ratio of the area of necrotic tissue to the total area of the tumour within the section.
A similar study could not be consistently conducted on the MDA-MB-231 tumours. This was because
they tended to have large central necrotic cores, and on bisection and subsequent fixation of the
tumour, the volume (and thus cross-sectional area) of the necrotic core w as variably reduced.
Figure 6 Photomicrograph of a ZR-75-1 xenograft, with an "L"-shaped region of necrosis
visible in the centre of the plate, A further, smaller region is seen towards the bottom




Semi-quantitative detection of antigen expression in tissue is best performed using
immunohistochemistry. Its main advantage over the more quantitative methods (such as Western
blotting) is that the site of expression can be visualised and thus an observ er can restrict the
assessment to subgroups of cells - w hich in most cases is to malignant cells. The methodology used
for immunohistochemical staining with antibodies is based on the original description (Sternberger.
(1974)). but with some later refinements (Cattoretti et al( 1988a); Hsu et al( 1981); Shi et al(1991)».
All staining runs included a section known to be positiv e (usually a routine formalm-fixed breast
tumour, except for the bcl-2 runs, w hen a section of normal tonsil was employed), as well as a section
known to be negative. In each run there were 20 - 24 sections, which always included sections from
all time-points, and both treated and untreated tumours. Furthermore all slides had at least two
sections, so that one could be used as a negative control by simply omitting the primary antibody
Any run in w hich the positive control did not stain or the negative control did stain was rejected
For paraffin-embedded material, the tissue was first de-waxed by sequentially placing the sections
(usually mounted on lysine-coated slides) in xylene, pure alcohol. 95% alcohol. 70% alcohol and
water, each for about 5 minutes. Endogenous peroxidase activity was blocked by a 15 minute
incubation at room temperature with 30% Hydrogen peroxide. For some antigens (see page 54). a
retriev al technique was necessary, performed by microwaving (Shi et al(1991)). The sections were
immersed in 500 ml of 0.01M Citnc Acid pH 6.0 (achiev ed by addition of 1 M NaOH) and
microwaved for 3 periods of 5 minutes each in a standard 750 W domestic microwave with turntable
(additional hot distilled water was added after each 5 minute period if the sections had become
uncovered). The sections were subsequently left to stand in the hot citric acid for a further 20
minutes, and transferred to TBS for 5 minutes. Non-specific antibody binding was reduced by
incubation for 20 minutes in 20 % foetal calf serum diluted in TBS (20% FCS). Primary antibody
solution (50 - 100 pi) (see page 54 for dilutions) was placed ov er the sections, with the negativ e
control sections being left covered by 20% FCS. and incubated either at room temperature for 1 hour
or overnight at 4"C (see page 54). The sections were then washed x 2 with TBS for 5 minutes,
followed by an hour's incubation with a secondary, biotiny lated rabbit anti-mouse, antibody. After
further washing x 2 with TBS. the sections were incubated for 20 minutes in ABC complex ( 3 pi of
av idin and 3 ul of biotinylated peroxidase in 1ml of TBS (Cattoretti et al( 1988a))), rinsed in TBS.
and covered with 100 pi of DAB (lmg/'ml) containing 1 % Hydrogen Peroxide for 2 - 5 minutes
(the actual length of time w as determined by the rate ofbackground staining appearing in the control
sections). Normally sections from xenografts required less exposure than clinical specimens because
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they were more prone to non-specific background staining by DAB. particularly after microwaving.
The sections were then immediately rinsed in running w ater, counterstained with Haematoxylin for
20 seconds, dehydrated, cleared and mounted with DPX mountant before covering with a cover slip
for viewing.
The sections were then "scored" by Mewing 10 random high-power fields under a ZEISS microscope,
excluding necrotic regions. The total number of malignant epithelial cells within each field was
counted as well as the number of cells that w ere clearh stained brown with the D.AB : and the ratio
of these two counts calculated. Examples of stained sections are shown in figures 7 and 8. Figure 7
illustrates the results of immunohistochemistry for bcl-2 m a clinical breast cancer, with in this
particular example virtually all the tumour cells are positive, and this tumour would have been given
a bcl-2 score of 3. In contrast, figure 8 demonstrates the pattern typically seen with MIB-1
expression in the xenografts, where the staining was not homogenous across the section. Regions in
which positive cells were to be found more frequently were often, but not exclusively, located towards
the periphery of the tumour as is the case for the tumour show n.
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Figure 7 Photomicrograph of a clinical breast cancer stained for bci-2 expression to which a
bcl-2 score of 3 w as given (x 100 magnification).
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Figure 8 Photomicrograph of a ZR-75-1 xenograft stained for MIB-1 expression, illustrating
the variation in staining across the section, maximal at the periphery (the




Assessment of the xenograft microvasculature w as performed on 5 urn thick frozen sections, with a
directly fluorescein-conjugated secondary antibody. (This was despite attempts to use paraffin-
embedded sections and antigen retrieval by microwaving or pre-treatment with tiypsin or proteases).
Thus there w as no requirement for rehydration (or dehydration), blocking of peroxidase or antigen
retrieval techniques. The sections were therefore brought up to room temperature from the -80°C
freezer in which they had been stored, incubated with 20% FCS 80% PBS for 20 minutes, covered
with the MEC 13.3 antibody for 30 minutes (diluted 1 in 2 with 20% FCS), washed in 2 rinses of
PBS. and then incubated with the secondary antibody. fluorescein-conjugated goat anti-rat. A
counter-stain for the nuclei was provided by a further 5 minute incubation in 50 ml PBS containing
100 pi of propidium iodide. The sections were then viewed under a ZEISS fluorescent microscope ;
an example of a ZR-75-1 xenograft section is show n in figure 9,
The methodology employ ed for assessment of the micro-vascular density was to measure the
proportion of the area of each section that expressed the v ascular antigen, a murine equiv alent of CD-
3 l(Vecchi et al(1994)). Therefore a representative region of each section corresponding
approximately to a single low-power ( x 10) field was view ed. The total area of the field of view was
calculated using the H O M E, software, not including areas that did not containing tumour or were
frankly necrotic (as assessed under 584 - 607 nm w hich permitted visualisation of the nuclei by-
fluorescence of the PI). Then the marked region was viewed under high power ( x 40). at 515 - 545
nm (permitting the fluorescein to be visible), and all areas of vasculature marked, and their total area
calculated. Defining areas of pure v asculature sometimes required the frequency to be changed (by
changing filters) to ensure that the area did not include tumour tissue. Thus the area of vasculature
was measured, not the area of tumour encompassed by vessels. The v ascular density was the ratio of
the positive area to the total area viewed.
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Figure 9 Digitally captured image of fluoroescein-stained vaculature in a ZR-75-1
xenograft. The vessels in stroma surrounding the tumour are to be seen towards
the bottom of the section. One particularly clear intratumoral vessel can be seen in
the upper right corner. (X 200 magnification)
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Flow-cytonietry
DNA cell cycle analysis of FN As
For DNA content analysis, the method employed was originally described by Vindelas (Vindelas et
al( 1982)). Five standard solutions were required :
Citrate Buffer 85.5g sucrose and 11.76g trisodium citrate are dissolved in
800ml distilled FTO. 50 ml DMSO are added, the pH
adjusted to 7.6 and distilled H:0 added up to a solume of 1 litre.
Stock solution 2 g trisodium citrate. 121 mg Tris. 1044 g spermine
tetrachloride and 2 ml Nonidet P40 are dissolved in distilled
water to 2 litre, with the pH adjusted to 7.6.
Working solutions (all can be stored frozen and brought to room temperature before use) :
Solution A 15 mg trypsin in 500ml stock solution. pH adjusted to 7.6.
Solution B 250 mg trypsin inhibitor and 50 mg RN.Aase A in 500 ml
stock solution.
Solution C 208 mg propidium iodide and 500 mg spermine tetrachloride
in 500 ml stock solution.
.After thawing, the FNA was centnfuged at 500 g for 5 minutes; washed in PBS. and resuspcnded in
100 pi citrate buffer Solution A (225 pi) was then added to the buffer/cell mixture (100 pi), and the
mixture gently ins erted and incubated at room temperature for 10 minutes. Solution B (170 pi) w as
added, gently mixed and incubated at room temperature for 10 minutes. Finally solution C (175 pi)
is added, the mixture inserted and incubated on ice for 10 minutes. Analysis of the preparation was
performed on a B.D. FACScan. using the red (584 - 607 nm) channel. The region to be counted was
gated on area versus svidth in order to eliminate cell doublets that could otherwise be inadsertentis















Figure 10 DNA histogram from an FNA taken from an untreated ZR-75-1 xenograft, with DN'A
content measured as red fluoroescence
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Cell-death assay (FACS-TUNEL)
•After thawing, an aliquot of the FNA was suspended in 2 ml of 1% paraformaldehyde for 10 minutes
at room temperature This mixture was then centrifuged at 500g for 4 minutes, the supernatant
discarded and the pellet re-suspended in 70% ethanol at room temperature. .After a further 10
minutes this was re-centrifuged. washed \2 in TBS. re-centrifuged. and the cell pellet re-suspended
in 40 (il of 20% 5\TdT buffer diluted in distilled water and allowed to stand for 10 minutes at room
temperature. The suspension was centrifuged for 4 minutes at 500g. and the pellet incubated for 2
hours at 37^C in 25 pi reaction mixture (100 pi ofwhich contains 20 pi 5xTdT buffer. 78 pi
distilled water. 1 pi dUTP/fluorescein and 1 pi TdT (=15 units)). Finally the cells were washed twice
in TBS. re-suspended in 1ml TBS and left to stand for 15 minutes at room temperature.
Flow cytometric analysis was performed on a B.D. FACScan. exciting at 488nm using an argon
laser. Forw ard and Side scatter, and green fluorescence (515 - 545 nm) were collected on a log scale,
and analysed using LYSYS-II software running on a HP-3000 computer. Populations were identified
on a scatter-plot of green fluorescence against side scatter (see figure 11). The apoptotic population
was taken as the identifiable group of cells with high green fluorescence and intermediate side
scatter. Necrotic cells, which were not counted as apoptotic. were identified as ha\ing low side
scatter and intermediate green fluorescence. DNA histograms were performed on the samples that
had been stained with PI. and analy sed using the "cellfit" software, under red fluorescence (584 - 608
- nm).
A further refinement of this method, applied to some of the FNAs with sufficient residual material,
w as to try and remove the necrotic and late-stage apoptotic cells by pre-treatment with enzymes that
can be excluded by viable and early-stage apoptotic cells. This is achieved, after thawing, but before
exposure to paraformaldehyde, by incubating the cells with 0.25% trypsin and 100 gg/ml DNAase 1




FL-1 - green fluorescence
Figure 11 Fluoro-TUNEL assay of a FNA from a ZR-75-1 xenograft. Apoptotic cells are
shown in red, having high DNA-fragmentation (high FL-1 fluorescence) and high
side-scatter. Cells with low side-scatter and high DNA-fragmentation are shown
in blue, and represent a mixture of late apoptotic cells, necrotic cells and
individual apoptotic bodies. As such they are not included in the overall
percentage of apoptotic cells.
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In order to confirm that cells identified as apoptotic b> this technique would have at least included
those similarly classified as apoptotic by morphological criteria, a fluorescent microscope (ZEISS.
Germany) was used. Firstly after staining by the above procedure, cells from both MDA-MB-231
and ZR-75-1 FNAs were analysed on a BD FACStar cell sorter. The populations considered to be
apoptotic and necrotic by the above criteria were gated out They were then smeared onto a lysine-
coated slide, and examined for green fluorescence using a fluorescent microscope Apoptotic cells (as
defined by their chromatin morphology) were seen in the high green, intermediate side scatter group,
but not even cell showed clear chromatin condensation . which is not unexpected since DNA
fragmentation occurs before chromatin condensation (Schwartzman et al(1993)). In contrast no
morphologically apoptotic cells were seen in the low side scatter, intermediate green fluorescence
group of cells. For a further test, sev eral sections of ZR-75-1 tumours mounted on lysine-coated
slides, were prepared with the same reagents. The sections were then examined under the same
fluorescent microscope. Again, nuclei that were clearly apoptotic were identified, although there
were also confluent areas of fluorescent cells that were probably necrotic, together with scattered cells
that did not have blebbed chromatin that could have represented cells at an earlier stage of apoptosis.
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Growth modelling
This was performed using a suite of programmes written in FORTRAN 77. called ADAPT. The user
specifies the function (equation 111 on page 43). as well as the data points, which consist of the time
and log (volume). .All estimations were run from the same starting values ofa = 0.5. ft = 0.05 and t
= 10. No formal tests of stability were conducted, as the Gompcrv function is continuous, as are all
its derivatives, but informal tests showed that the modelling was robust with respect to the actual
starting values.
A minimum of three recorded untreated volumes are required to fit a Compert/ growth curve, and
this was not always the case, particularly for the tumours from the second study (as due to unforeseen
circumstances, tumour v olumes were only measured three and one weeks before starting therapy, as
well as on the day treatment was begun). Therefore certain tumours could not have indiv idual
growth curves fitted, and as discussed on page 173. for some experiments averaged growth curves
were used. However, since the v olumes were log-normally distributed, and the function in equation
III is based on the log of the volumes, it w as the av erage of the log of the v olumes that was used. If
the tumour was too small on day -21 for an accurate measurement, omitting this v alue from the
average would increase the v alue on day -21. w hich w ould then underestimate the curvature of the
average growth curve, possibly thus overestimating the subsequent growth. In order to avoid this, the
smallest possible volume measurement (0.002 enf. corresponding to a diameter of just under 0 15
cm. the smallest diameter recorded for any tumour) w as given to tumours which had been too small
to be measured, but in which a measurement was av ailable at the next time point, confirming that
tumour was present.
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Data and statistical analysis
Tests for normality of data were conducted (combining data from different passages) for each




loge(% apoptotic cells by FACS)
loge(xenograft volumes)
% vasculature
% cells in S-phase by FACS
% cells in Gi by FACS
% cells in G;/M by FACS
For these variables therefore parametric tests could be employed, and correlations performed using
the Pearson's correlation coefficient. For the remaining variables, non-parametric tests (usually
Mann-Whitney or non-parametric trend analyses) and the Spearman's rank correlation were used.
student-t tests and non-parametric trend analyses (after (Cuzick, (1985)))
Excel for Windows version 5.0 Microsoft Corporation, Redmond. WA, U.S.A.
Mann-Whitney, Spearman & Pearson rank & Normality tests
Minitab release 5.1.1 Minitab Inc., State College. PA. U.S.A.
Growth curve predictions
ADAPT II Biomedical Simulations Resource,
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A major part of this study consists of histological examination of sections. The
histological and immunohistochemical techniques employed are standard and apart
therefore from the routine inclusion of positive and negative controls require no further
validations However the assessment of the sections is subject to potential observer
error, and confirmation therefore that the scoring of the sections is consistent and
accurate is required. This section therefore details the assessments made to ensure the
reproducibility of the methods employed for counting the total number of malignant
cells examined and the counting of the apoptotic cells in both xenografts and clinical
tumours, and finally the mitotic figure counts for the clinical tumours.
1.1. Cell counting
In order to facilitate counting of the total number of cells in a section, a representative
proportion of each high-power field w as counted and the total number of cells in that
field estimated by multiplying the relative areas of the region counted and the total
field. In order to ensure that this estimated total was accurate, the real total number of
tumour cells in a random sample of 21 high-power fields was counted including both
treated and untreated tumours, as well as ZR-75-1 and MDA-MB-231 xenografts
Figure 1.1 shows the correlation, which is highly significant (r, = 0.821. p < 0.001).
and confirms that the use of an estimated total is sufficiently accurate. Similar
relationships were found w hen restricting the comparison to either just ZR-75-1
xenografts ( r, = 0.793. p < 0.01) or MDA-MB-231 xenografts (r, = 0.799. p < 0.01).
and for treated (r, = 0.837. p < 0.01) and untreated xenografts separately (r, = 0.785. p
< 0.01). The identification of a correlation does not necessarily confirm the visual
impression that the tw o methods of counting are equivalent, and this can be
determined by calculation of the closeness of the tw o methods of scoring, known as the
repeatability. For all sections, this is equal to 85 cells, and there is only one tumour
w here the difference in absolute values between the two methods exceeds this value
When considering the subgroups, there is one treated tumour, one untreated tumour,
and one MDA-MB-231 tumour, but no ZR-75-1 tumour whose difference between the
two methods of counting exceeds the respective repeatability. Thus overall there is


















Figure 1.1 Comparison of estimated and actual high-pow er field cell counts for xenografts
1.2 Apoptosis and Mitosis
Any scoring sy stem that is based on cellular appearance will be necessarily in part
subjective For immunohistochemistry. the criterion of positivity is simply the
recognition that a cell or (in the case ofMIB-1) its nucleus is a different colour from
the others. However for the identification of apoptotic and mitotic figures, w hich were
determined by their morphology. there is the possibility that the criteria employed by
one observ er may be different from those of another observer. Therefore a number of
sections were re-examined, both by my self and also by an experienced pathologist. Dr.
T J Anderson, in order to confirm that the scoring was reproducible. The criteria for
identify ing mitotic figures is well documented and in routine clinical use, therefore
comparison w as only made for the clinical tumours to ensure equivalence of the tw o
observ ers' scoring. However the morphological appearance of apoptotic cells is less
widely applied, and does not form a part of any routine clinical assessment, and
therefore the scores obtained in both clinical and xenograft tumours were compared.








Since every patient had two pathological specimens, the tumours examined for
ratification of their apoptotic and mitotic indices were a selection of pairs ; for this
comparison tumours were chosen such that they were representative of low. moderate
and high apoptotic indices. The raw data are given in table 1.1. and show an excellent
correlation between the two scorers. It can be seen that two scores are identical in the
majority of cases, and w hen dissimilar, either observ er can count the higher number
The equivalence of the two scores is underlined by the fact that no mitotic score and
only one apoptotic score exceeds the "repeatability".
Apoptoses Mitoses
tumour DAC TJA DAC TJA
BC49 pre 12 14 2 3
BC169 post 11 11 1 1
BJC79 pre 4 3 2 3
BJC82 post 1 I 0 0
BJC78 pre 3 3 1 1
BJC86 post 2 2 0 0
BJC48 pre 2 2 0 0
BJC26 post 4 6 1 0
BJC77 pre 7 6 4 4
BJC84 post 2 2 1 1
BJC74 pre 7 7 0 0
93/3196 post 14 13 6 6
BJC45 pre 4 4 0 0
BJC49 post 3 2 0 0
BJC89 pre 9 5 3 2





Repeatability 3 1 tumour 1 0 tumour
Correlations r, = 0.948 p< 0.0001 q = 0.959 p < 0.0001
Table 1.1 Raw scores for counting apoptotic and mitotic figures in clinical breast
cancers by two observers.
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A further assessment of one observer's consistency (DAC) was performed by re¬
counting previously assessed sections, after an interval of some 6 months. Again, the
data confirm that the criteria applied consistently, particularly for mitotic figures (see
table 12 ). .Although on the majority of occasions the apoptotic scores are not identical
for the two counts, there is no trend with time as the higher score can occur on either
occasion. There is an excellent correlation for both apoptotic and mitotic scores, and in
neither case does the difference between the two scores exceed the "repeatability".
Apoptosis Mitosis
tumour first count second count first count second count
BC74 6 3 ( 1/2 area) 0 0
BJC49 3 2 0 0
BJC56 6 4 2 1
BJC64 8 8 0 0
BJC80 3 2 0 0
BJC81 20 22 2 2
BJC83 4 3 0 0
BJC84 2 3 1 1
BJC85 2 1 0 0





Repeatability 2.5 0 tumour 1 0 tumour
Correlations r, = 0.972 p< 0.001 r, = 0.954 p< 0.001
Table 1.2 Raw scores for counting apoptotic and mitotic figures in clinical breast
cancers by one observers on different occasions.
1.2.2. Xenografts
Sections from 13 ZR-75-1 tumours were double-counted for apoptotic cells. They were
chosen at random, but ensuring that there were representativ es of both treated and
untreated tumours, as well as tumours from each time point. Five fields were counted
for each tumour, except for two which were too small for 5 fields and were thus
examined in toto and considered as one field. The data were analysed for all 57
individual fields separately, as well as for the thirteen tumours. Two tumours (DAC022
& DAC079) had little tumour material left, and thus instead of 5 fields, the w hole
section was examined. Table 1.3 gives the raw data, and confirms that there is excellent
correlation between the apoptotic cell counts for the tw o observers. As with the clinical
tumours, there is no consistent bias for one observ er to count more cells than the other.
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and the equivalence of the two counts is confirmed by the observ ation that in only one
















for tumours for all fields separately
Repeatability 5 ; 1 tumour exceeds 2 ; 1 exceeds
Correlation r, =0.985 ; p < 0.001 r, = 0.976 ; p< 0.0001
Table 1.2 Raw scores for counting apoptotic figures in xenografted tumours by
two observers.
1.3 Discussion
Histological methodologies were employed to determine the mitotic and apoptotic
indices. They are subject to potential inter-observer variation because the observ er is
identify ing cells as apoptotic or mitotic on the basis of differing morphologies. The
criteria used to identify mitotic figures are those used in routine histology, and hav e
been previously show n to be reproducible betw een a large number of different observ ers
(van Diest et al( 1992)). For the clinical tumours, inter and intra-observ er variation was
assessed, and for both comparisons a statistically significant correlation was found.
Thus the reproducibility of the technique is confirmed. For the xenografts therefore, no
further such studies were conducted
The assessment of apoptosis is howev er more controv ersial, and has been less well
studied. The criteria used to identify- apoptotic cells are well described (Bellamy et
al( 1995)). but there has only been one study published to date that has assessed their
reproducibility in breast cancer (Vandeschepop et al( 1996)). This study elected to count
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apoptotic cells in the most poorly differentiated regions of the tumour, in contrast to the
present study in w hich fields were chosen at random w ithin the tumour section
Furthermore, as necrosis is associated with higher grade tumours (Clayton. (1991)).
there is the possibility that regions of necrosis might thus be included in the counts
Nevertheless, this study did report good intra- and inter-observer variability, but found
that the highest power (xlOOO) gave the most consistent results A comparative study in
bladder carcinoma has been published (Lipponen et al( 1994)). also with good intra- and
inter-observer correlation. The issue of reproducibility was therefore considered in
some detail in the present study. For the xenografts there was an excellent correlation
between two observers, both for individual fields and when assessing the incidence
throughout a tumour. Similarly for the clinical tumours, the intra- and inter-observer
variation was low.
The two other measures that were based on histology were the measurement of necrosis
and vasculature. The former simply required the area of necrotic tissue to be measured
and compared with the area of the total section. The HOME softw are (Brugal et
al(1992)) used to calculate the area is the result of a long collaboration between the
industry and pathologists throughout the European Union ( Dr. Gray, personal
communication), and it was felt unnecessary to rev alidate it. The identification of
regions of necrosis w as not considered to be potentially difficult The measurement of
the v asculature portion of the tumour is more subjective. However each section had an
internal positive control, namely the vessels visible in the stroma at the periphery of the
tumour, and they were alw ays examined before study ing the rest of the section.
Furthermore there was another way to corroborate some of the v ascular channels
identified, since when examining the section under a different fluorescent filter so that
the propidium iodide stained nuclei w ould be visible, it could then be seen that in many
cases the apparent channels, seen as spaces betw een the PI stained tumour nuclei,
coincided with the v essels identified by the fluorescent antibody. However no formal
studies of the reproducibility of the measurements were conducted.
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2. Clinical Tumours
This section reports the data obtained by histological (and in the case of ER.
biochemical) evaluation of tumour material taken before and after three months'
tamoxifen therapy in 50 elderly women with non-metastatic breast cancer, whose
tumour response was assessed by four-w eekly ultrasound measurements.
2.1 Response
Response was defined as the ratio of the onginal tumour volume to that measured after
three months' therapy. The ultrasound rather than pathological volume was used in
order to hav e a consistent definition over the duration of treatment. Table 2.1 confirms
that the majority of the tumours responded to tamoxifen, with 19 (38%) of patients
having more than a 50% volume regression, and in a further 29 (32%) there was
definite regression but to less than 50% ov er the three months. Only 2 (4%) of tumours
progressed and the remainder had stable disease.
Non-responders Responders
progressed









(> 50% v olume
decrease)
2 (4%) 13 (26%) 16 (32%) 19 (38%)
Table 2.1 Pattern of response in 50 tumours after three months' tamoxifen therapy.
2.2 Oestrogen Receptor concentration
All tumours were ER positive ( > 20 fmol/mg cytosolic protein), since that was an
inclusion criterion for the study. The v alues of ER before and after three months'
tamoxifen therapy are given in table 2.2 and figure 2.2.1. where it can be seen that there
is a clear fall in ER v alue with therapy (p < 0.000001). with a higher v alue being seen
after therapy in only two tumours (of w hom one had a minor response and the other
progressed).
minimum median mean maximum
pre-treatment (n=49) 29 262 348 1496
post-treatment (n=38) 0 60 64 168




Figure 2.2.1 ER concentration before and after 3 months'
tamoxifen therapy in clinical breast cancer
Figure 2.2.2 confirms that the pre-treatment, (although not the post-treatment) ER concentration is
strongly correlated with response ( r = 0.595. p < 0.0001). The change in ER also correlates with
response as a continuous variable, as shown in figure 2.2.3. with the larger falls occurring in those
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Bcl-2 expression was scored on a semi-quantitative basis. The results for all the
tumours are summarised in table 2.3. and confirm that the majority (88%) of tumours
express bcl-2 before therapy, but the proportion falls to 74% after therapy, with the
biggest reduction occurring in the proportion of tumours expressing bcl-2 in more than
75% of the malignant cells. The difference in expression after treatment is statistically
significant (p = 0.006). Figure 2.3.1 illustrates the pattern of change in expression,





5 - 25 % cells
2
25 - 75 % cells
3
> 75% cells
pre-treatment 6 (12%) 18 (36%) 12 (24%) 14 (28%)
post-treatment 13 (26%) 17 (34%) 11 (22%) 8(16%)










changg in bcl-2 expression
Figure 2-3.1. Change in bcl-2 expression with three months' tamoxifen therapy
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There is a significant relation between initial bcl-2 expression and ER. with the tumours
w ith the highest bcl-2 expression (i.e. a score of 3) having higher values of ER (VV =
465. p = 0.01) (figure 2.3.2), as well as between initial bcl-2 expression and response,
with higher expression occurring in tumours with a better response (see figure 2.3.3). (
z = 2.04, p < 0.05). There are however no significant relationships between the post-















Figure 2.3.2 Pre-treatment bcl-2 expression and ER concentration
in clinical breast cancers
88
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Figure 2.3J Pre-treatment bci-2 index and tumour response after 3 months tamoxifen therapy
Furthermore there is a correlation between the change in bcl-2 expression and response,
with the more significant reductions in expression being associated with better
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Morphologically apoptotic cells were infrequent in the clinical breast cancers. The
mean number of tumour cells examined was 1687. with a range of 1000 - 4100 in the
pre-treatment biopsies and 584 - 3848 (with 5 tumours having < 1000 cells) in the post-
treatment sections. The apoptotic indices before and after treatment are shown in table
2.4.. and there is no significant difference between them.
minimum mean ± s.e. maximum
pre-treatment 0% 0.45% ± 0.04 1.5%
post-treatment 0% 0.37% ±0.04 1.6%
Table 2.4. Apoptotic indices before and after three months' tamoxifen therapy.
There was a statistically significant correlation betw een the apoptotic index and the
expression of bcl-2, as shown in figure 2.4.. with the tumours expressing high levels of
bcl-2 ha\ing fewer apoptotic cells ( z = -2.1. p < 0.05). When considering the pre- and
post-treatment tumours separately, this relationship only held true for the former group
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For the changes in apoptosis. there were no correlations with response, or ER
concentration. However, figure 2.4.3 shows the significant correlation between the
change in apoptosis and the change in bcl-2 expression (z = -2.66. p < 0.01). which



















change in bcl-2 staining index














Change in bcl-2 staining index
Figure 2.4.4. Change in bd-2 staining index and initial apoptotic index
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2.5. Mitosis
Mitotic figures were less frequent than apoptotic cells, but nevertheless there was a clear
decrease in mitotic activity after 3 months' therapy (W = 2850. p = 0.025). as shown in
table 2.5 and figure 2.5.1.
minimum mean ± s.e. maximum
pre-treatment 0% 0.18% ±0.03 1.1%
post-treatment 0% 0.10% ± 0.02 0.6%
Table 2.5.1 Mitotic indices before and after three months' tamoxifen therapy.
Although the ER concentration is not associated before treatment with the mitotic
index, it is significantly correlated with the mitotic index after three months" tamoxifen
(r =0.34. p < 0.02); the higher the initial ER. the higher the residual mitotic index after
three months' tamoxifen, as shown in figure 2.5.2. Furthermore there are no
correlations between the post-treatment ER concentration and the mitotic index before























Furthermore, although the pre- and post- treatment mitotic indices did not correlate
with response as a continuous variable, there w ere significantly more non-responders
with a 0 mitotic index after treatment (p < 0 03. Fisher's exact test), as shown in table
2.5.2. although there are no differences in the pre-treatment mitotic indices of
responders and non-responders. There were also no differences in the change in mitosis
with treatment between responding and non-responding tumours.
post Mitotic index = 0 post Mitotic index > 0
Responders 10 25
Non-responders 10 5
Table 2.5.2. Post-treatment mitotic index and response
too 1000 10000
pre-treatment ER concentration (fmol mg)
Figure 2.5.2 Pre-treatment ER concentration and post-treament Mitotic index
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That this is not just the result of arbitrarily picking a zero mitotic index as the cut-off. is
indicated by the observation that the post-treatment mitotic indices are in general low er
in the non-responders (W = 289. p < 0.05). as shown in figure 2.5.3. Furthermore,
although there are no differences in the apoptotic indices between the two groups of
tumours with a zero post-treatment mitotic index, figure 2.5.4 shows that overall the
apoptotic index is higher after treatment in the tumours w hich still hav e detectable
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Figure 2.5.4 Apoptotic and Mitotic indices after three months' tamoxifen
There is in fact a more general positive relationship between the apoptotic and mitotic
indices, which is true for tumours both before (r = 0.375. p < 0.01) and after three (r =
0.380, p < 0.01) months' tamoxifen. This is illustrated in figures 2.5.5 and 2.5.6.
where, if it is assumed that the mitotic rate is the independent variable, it can be seen
that the nature of the relationship is changed by the therapy, with the steeper line
occurring in the tumours after therapy. In contrast if the apoptotic index is considered
to be the independent variable (which is less biologically likely as without proliferation
there would be no tumour cells to undergo apoptosis), then the regression lines are
almost identical before and after treatment (data not shown).
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Figure 2.5.5 Correlation between Apoptotic and Mitotic indices before tamoxifen treatment




Figure 2.5.6. Correlation between Apoptotic and Mitotic indices after tamoxifen therapy (with
Recession line forced through the origin)
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Apoptotic: Mitotic ratio
Since tumour growth is a reflection of both cell division and death, one w ay of
combining the histological assessments of apoptosis and mitosis is the ratio of the
number of apoptotic cells : number ofmitotic cells. In those tumours in w hich no
mitotic figures were seen, the ratio is underestimated as being equal to the total number
of apoptotic figures seen. (This situation arose in 13 pre-treatment samples and 20
post-treatment cases.) As table 2.6. suggests, there is no significant difference between
the values before and after treatment, which is also true w hen considering the sub¬
groups of tumours which have responded or not.
minimum mean ± s.e. maximum
pre-treatment 0.333 3.5 ± 0.4 14
responders 0.3 2.5 ±0.5 14
non-responders 1.5 3.0 ±0.8 8
post-treatment 0.6 3.5 ±0.4 11
responders 0.6 3.0 ±0.4 11
non-responders 1.0 2.2 ±0.8 10
Table 2.6. Apoptotic:Mitotic ratio before and after three months' tamoxifen
therapy.
For correlations with other data, it is the normally distributed log-transformed
apoptotic:mitotic ratio that is considered. There are no significant correlations between
the apoptotic:mitotic ratio and any of the previously presented data (apart from the
synchronous apoptotic or mitotic ratios). For the change in the (log of) the
apoptotic:mitotic ratio, there is however a trend towards significance with the response
(r = 0.314. p < 0.05), as shown in figure 2.6.1.
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response
Figure 2.6.1 Change in Apoptotie: .Mitotic ratio and response to three months' tamoxifen therapy
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2.7. Discussion
The data (figure 2.2.2) confirm that the level of ER predicts for the degree of response
to tamoxifen as has been previously shown (Brooks et al(1980); Gaskell et al(1992a);
Osborne et al( 1980)). Most prev ious studies that have observed this relation have
included significant numbers of ER-negative tumours (Allan et al(1985): Nicholson et
al( 1991)). which have a low response rate to primary tamoxifen therapy (Anderson et
al( 1989)). The relationship between the degree of ER positivity and the response to
primary tamoxifen has also been noted before (Gaskell et al( 1992a); Osborne et
al(1980)). although not with both parameters as continuous variables. The overall
response rate seen at three months, namely 70%. compares favourably with other
studies (Allan et al(1985)). although a non-standard definition of response was used.
However the formal UICC criteria include a repeat assessment of response a month
later, and that would not have been possible as the patients proceeded to definitive loco-
regional surgery at three months.
The change in ER with treatment, as shown in figure 2.2.1 and table 2.2 is also
consistent with previous literature (Allegra et al(1980); Lumsden et al(1997); Taylor et
al(1982)). The observation in figure 2.2.3 that the degree of response and the fall in ER
are positively correlated has not been previously reported, but is consistent with
effective anti-oestrogenic therapy , but also the possibility that those tumours that
manifested a greater response had less tumour in w hich to measure the residual ER.
This latter possibility should however be at least in part overcome by the use of an ER
corrected for the weight of available cytosolic protein, and the data therefore suggest
that effective tamoxifen therapy might be a more potent inhibitor of ER expression than
ineffective therapy. However as a means to predict tamoxifen sensitivity, the change in
ER is not sufficiently specific.
The positive association between bcl-2 positivity and ER seen in figure 2.3.2 has been
previously recognised (Gee et al(l994); Johnston et al(1994); Krajewski et al(1995)).
Furthermore a relationship between bcl-2 expression and response to tamoxifen therapy,
as suggested by figure 2.3.3 has also been previously reported (Gee et al( 1994)).
However in that study a significant positiv e correlation was found when tumours were
classified as either positive or negativ e for both markers. A correlation was also
reported for degrees of positiv ity . but the statistics were inv alid (using the X test with
small numbers). Performing more appropriate tests, such as a non-parametric trend
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test, the result remains significant, but only because of 12 progressing ER and bcl-2
negative tumours : there is no relationship for the remaining 28 ER-positive tumours
There are thus no previous data reporting a significant relationship between bcl-2
expression and response in ER-positive tumours, but it is none-the-less to be expected
as bcl-2 is induced by oestrogen (Teixeira et al( 1995)). and the data indeed suggest that
it may be a marker for a hormone-sensitive tumour (as opposed to one that merely
reflects the oestrogen receptor).
Furthermore, consistent with this relation between bcl-2 and hormone-sensitivity, is the
fall in expression seen over the three month period, as tamoxifen can inhibit its
oestrogen-induced expression in vitro (Wang et al( 1995)). However there has been only
one previous studs comparing bcl-2 levels before and after tamoxifen therapy, in which
a significant increase was reported in 11 tumours of unknown ER and tamoxifen-
sensitivity (Johnston et al(1994)). However in the current studs 18% (9/50) of the
tumours showed increased expression after three months' tamoxifen therapy (see figure
2.3 .1). but 5 of these did not respond (p = 0.1. Fisher's exact test). Hence the
previously reported results (Johnston et al( 1994)) would not be inconsistent with a
majority of the tumours being tamoxifen insensitive. The correlation betw een the degree
of fall in bcl-2 expression and the degree of response at three months (see figure 2.3.4)
suggests that effective anti-oestrogen therapy inhibits the expression of bcl-2 in ER-
positive tumours.
The lev el of apoptosis detected is broadly similar to the only other published study
w hich also failed to show any overall change with tamoxifen treatment (Dow sett et
al( 1995)). Another study of apoptosis in breast cancer has reported the higher rate of
around 1% (Vandeschepop et al( 1996)); but this w as not confined to ER-positiv e
tumours, and may have included ER-negative tumours. As grade correlates with
proliferation (Haerslev et al( 1996); Pierga et al( 1996)). which in turn correlates with
apoptosis (Lipponen et al(1994)), the inclusion of ER negative tumours could result in a
higher ov erall rate of apoptosis. The inverse correlation between apoptosis and the
lev el of bcl-2 expression (see figure 2.4.1) is not unexpected, as bcl-2 has an important
role in inhibiting apoptosis (Hockenbery et al( 1990)). and has been noted previously
(Sierra et al( 1995)). using an indirect method which, because it was based on the
detection of fragmented DNA, may also detect necrotic cells (Gold et al( 1994)), and
necrosis is associated with high-grade tumours (Clayton. (1991)) and ER negativ e
tumours (Fisher et al( 1981)) which are themselv es less likely to express bcl-2 (Lipponen
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et al( 1995); Sierra et al( 1995)). There are two previous reports on the relationship
between bcl-2 expression and apoptosis as assessed morphologically. One (Chan et
al( 1993)) observed the inverse association between bcl-2 and apoptosis (as in the
present study), particularly in tumours with a low proliferative rate, but it has not been
formally published, partly due to problems with inter-observer discrepancies (A Hanby.
personal communication). The other (Lipponen et al( 1995)). although finding a weak
trend reported in contrast highly significant negative correlations between bcl-2
expression and markers of proliferation. What is not immediately apparent is the reason
that the relationship between apoptosis and bcl-2. apparent before therapy (figure 2.4.2)
is not maintained after three months' tamoxifen, and this will be discussed further (vide
infra).
The lack of any significant correlations between the change in apoptosis. and response
or ER level are perhaps not surprising, given that overall there was no change in the
level of programmed cell death after three months' tamoxifen. However there w as a
relationship with the change in bcl-2 expression (figure 2.4.3). w hich might be
anticipated as the latter inhibits apoptosis in many cell sy stems. The relationship is not
as strong as that between the initial level of apoptosis and change in bcl-2. suggesting
that factors other than the level of bcl-2 expression are also important in determining
the rate at which tumour cells undergo apoptosis after three months' tamoxifen. The
relation betw een change in bcl-2 expression and initial apoptotic index may be due to
the relation between the apoptotic index and bcl-2. which itself is related to response,
and thus (as in figure 2.3.4) to the change in bcl-2 expression.
The loss of a linear relationship between bcl-2 expression and apoptotic index with
therapy could be due to variations in the degree of true endoenne-sensitivity. for which
the best available indicator is the tumour response. When this is considered, it is found
that the tumours with a fall in bcl-2 expression which responded have a rise in the
apoptotic index that is significantly higher than the non-responders (W = 52. p =0.07
for change in AI and W = 48. p < 0.04 for % change) (and see figure 2.7.1). Similarly,
w hen considering only the responding tumours, then those whose bcl-2 expression falls
have a significantly higher rise in the apoptotic index (W = 447. p < 0.025 for change
in AI and W = 442.5. p < 0.05 for % change) as compared with those whose bcl-2 rises
or remains unchanged. Thus effective tamoxifen therapy is associated both with a fall
in bcl-2 expression and a rise in apoptosis. although whether one causes the other
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remains unclear. In contrast there were no differences in the degree of reduction in














Figure 2.7.1. Percentage change in apoptotic index for tumours with a fall in bd-2 expression
after three months' tamoxifen
The reported mitotic index is consistent with other reports for clinical breast cancer.
There are none w hich record the data in the same manner as this studs . but a larger
studs of over 300 tumours recorded an as erage of 0.47 mitosis per high-power field
(Clayton. (1991)) (corresponding to an index of around 0.2%, slightly lower than w hat
svas noted in this studs ); another smaller studs noted that bcl-2 positise tumours in
particular had a mitotic index of less than 0.6% (Chan et al( 1993)). The fall in mitotic
index with treatment is also consistent ssith previous studies (Clarke et al(1993);
Johnston et al( 1994)) (although both studies used Ki-67 labelling rather than mitotic
index). It is of interest that although there is no relation before treatment betsseen the
ER concentration of the tumour and its proliferative fraction, after three months'
tamoxifen it svould seem that the tumours with higher ER salues has e more
proliferation.
The observation that there svere significantly more non-responding tumours with a zero
post-treatment mitotic index would seem at first to be at odds ssith data that
demonstrate tamoxifen's anti-proliferatis e effects, and remains incompletely explained
as there were no significant differences in apoptosis betsseen the responding and non-
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responding tumours in the sub-group of tumours with no detectable mitoses after
treatment. Howev er there were significantly more apoptoses in the tumours with
detectable mitoses after treatment, and mindful of the fact that most (13/15) of the
tumours classified as non-responders were static, one has a majority (8/13) of static
tumours w ith no proliferation (and thus less apcptosis) after tamoxifen therapy. Thus
they may be non-responders simply because they have minimal mitotic and apoptotic
activity, and thus any change in volume over a three month period is too small to be
reliably detected.
These data also confirm that there is a positive relation between the proportion of cells
in mitosis and undergoing apoptosis, both before and after three months' tamoxifen
therapy (figures 2.5.5 & 2.5.6). This has been previously reported for breast cancers
(Lipponen et al( 1994)). low grade Non-Hodgkin's lymphomas (Czader et al( 1996)) and
bladder tumours (Lipponen et al( 1994)). and although the methodologies used were
slightly different the relative incidences are comparable. However figure 2.5.6 suggests
that nature of this relationship is altered by the treatment, w hich has not previously
been noted.
What then is the relation between these two effects of tamoxifen - reduction in bcl-2
expression (and in some cases a concomitant increase in apoptosis) and its anti¬
proliferative action ? The ratio of apoptosis to mitosis has been applied in studies of
xenografts (Arends et al( 1994)). As can be seen in table 2.6., the ratio does not change
after three months" tamoxifen therapy , and did not correlate with changes in other
markers, apart from a trend towards significance with tumour response, shown in figure
2 6.1. For many tumours there was only a small change in the ratio, but the subsequent
clinical behaviour of these tumours remains unknown, and experience with other
patients managed similarly, but who declined surgery at three months, reveals that some
of those whose tumours have responded may subsequently progress, w hereas others
will undergo further regression on continued exposure to tamoxifen (unpublished
observations). Hence it could be conjectured that the tumours which manifested a fall
in the ratio at three months might have subsequently remained static or progressed if
they had not undergone surgery. Consistent with this are the "outliers" in the series ;
the tumours with the largest increases are all responders. and the two progressing
tumours both had a fall in the ratio, although in one case it was indefinable as no
apoptotic or mitotic figures were seen in the post-treatment specimen.
106
An alternative method to study the relation between the observed effects of tamoxifen
on both bcl-2 and proliferation is to look at sub-groups of tumours, although in this
small study such analy ses must be interpreted with caution. It is interesting therefore to
note that the effect of tamoxifen on the apoptotic indices of the tumours with a low
initial apoptotic:mitotic ratio is significantly different (y_2 = 6.77. p < 0.01) as compared
w ith those w ith higher initial values, with a more of the tumours with an initially low
apoptotic:mitotic ratio manifesting a rise in apoptosis three months' later, whilst no





initial ln(A/M) 4 > 20% = t > 20% 4 > 20% = t > 20%
<0.5 3 1 8 9 1 2
>0.5 21 8 8 20 1 6
Table 2.7.1. Effect of three months' tamoxifen therapy on the apoptotic and
mitotic indices according to their initial relative levels.
Further examination of the data shows that there are significant differences in the pre-
and post-treatment apoptotic and mitotic indices for these two groups (see table 2.7.2.)
The differences betw een the mitotic indices for the tw o groups of tumours are
significant (see table 2.7.2) ( W = 459. p < 0.001 & W = 413. p < 0.02 for the pre- and
post- values respectively ). In contrast the difference between the apoptotic indices is not
significant although there is a possible trend towards it being higher pre-treatment in
the group with the higher ratio (W = 223. p = 0.06). Thus the division into two groups
of tumours according to their initial apoptotic:mitotic ratio appears to reflect the
differences in their initial mitotic rates, yet the contrasting effects of three months'
tamoxifen are more apparent on the lev el of apoptosis.
initial ln(A/M)
Median Apoptotic index Median Mitotic index
pre- post- pre- post-
< 0.5 (n = 12) 0.0030 0.0026 0.0025 0.0012
> 0.5 (n = 37) 0.0040 0.0027 0.0007 0.002
Table 2.7.2. Median apoptotic and mitotic indices for tumours classified by their
initial apoptotic:mitotic ratio.
When considering the bcl-2 scores for these two groups of tumours, there were no
differences in the absolute values or the change in bcl-2 scores. However there is a
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significant difference in the response to tamoxifen (W = 409. p < 0.02). as shown in
table 2.7.3.
initial ln(A/M) Median response non-res|)onder^
< 0.5 70% 2/12 (17%) (both static)
>0.5 32% 13/37 (35%)
Table 2.7.3. Response for tumours classified by their initial apoptotic:mitotic ratio.
This suggests that there may be two distinct phenotypes of tumours - those w ith a low
initial apoptotic:mitotic ratio, in which tamoxifen appears to induce apoptosis. and a
measurable tumour regression, and a larger group of tumours with a higher ratio (due in
large part to a lower proliferation rate) which are much less likely to respond with
either an increase in apoptosis or tumour regression. However in contrast, the anti¬
proliferative effect of tamoxifen is indistinguishable between these tw o groups,
consistent with previous reports of a reduction in proliferative fraction (as measured by
MIB-1) irrespective of the level of ER (Clarke et al( 1993)). The reasons for this
distinction remain unclear, but the association between a zero post-treatment mitotic
index and lack of response, (as shown in figure 2.5.3 and table 2.5.2) is relevant, as
19/20 of such tumours are in the high apoptotic:mitotic ratio group (a highly significant
difference - p < 0.02. Fisher's exact test), and their response is not different from the
other 18 tumours in the same group. A tumour with minimal proliferative activity after
three months" exposure to tamoxifen will have less apoptosis (as the relationship
between these two processes seems fundamental), and is therefore likely to be static.
This was the case for the majority of non-responders in this series. There is however no
certain evidence that these differences in response are due to different levels of
apoptosis after three months' therapy.
Thus the data presented here confirm prev ious observ ations, but do not answer the
question of w hether or not bcl-2 expression inhibits apoptosis or is merely co-expressed
in a cell with a low apoptotic rate for other reasons. In fav our of the former argument is
the observation that the change in bcl-2 expression is inversely related to the change in
apoptosis - with a decrease in the former being associated with a fall in bcl-2 level. On
the other hand, there is considerable evidence to suggest the latter explanation. There
are reports of strong inv erse relationships betw een bcl-2 expression and markers of high
proliferation (Binder et al( 1995); Lipponen et al( 1995)) as well as the observed
relationship between the apoptotic and mitotic indices, which are strongly related in
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both treated and untreated tumours (see figure 2.5.5 & 2.5.6). Hence we have a putative
phenotype of a high ER. high bcl-2. low mitotic (and thus low apoptotic) tumour, w hich
is more sensitive to tamoxifen. One might therefore imagine that as effective tamoxifen
treatment reduces the level of bcl-2 expression, there would be a concomitant increase
in the level of apoptosis. Howev er the inv erse relation between bcl-2 expression and
apoptosis is not as apparent after three months' tamoxifen therapy, and therefore it may
be that changes in apoptosis and bcl-2 expression are both reflections of an anti-
oestrogenic effect of tamoxifen, but are not directly linked.
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ZR-75-1 Xenografts
ZR-75-1 human breast cancer xenografts were, as explained in the methods, derived
from three separate passages ( Nos. 25, 28 & 29). There were minor differences in the
results for the tumours from these different passages, but none that alter the ov erall
conclusions ; therefore all the results hav e been combined to simplify the data
presented. This section will report data on groups of tumours removed at the different
time points and treatment status. Results and the correlation with tumour growth for
individual tumours will be covered subsequently in section 7.
3.1. Growth
The combined growth data are shown in figure 3.1.1. Prior to the insertion of the
tamoxifen pellets there w as no difference in the growth of the tumours allocated to the
control and treatment groups. However although the control tumours continued to grow
throughout the experiment, those tumours treated with tamoxifen regress, with a highly
statistically significant difference in tumour v olume occurring at day 14 and beyond ( p
< 10~* or less). However it should be noted that 4 of the untreated tumours that were
excised on day 28 actually regressed between days 21 & 28. and their growth curves are
shown separately in figure 3.1.1.
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Figure 3.1.1. Growth of control and tamoxifen treated ZR-75-1 xenografts
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3.2. Apoptosis & Mitosis
Apoptotic cells were infrequent in the ZR-75-1 xenografts, and as figure 3.2.1
illustrates, the incidence of apoptosis was higher in the tamoxifen treated xenografts on
days 2 and 7. The values are statistically significantly different on day 2 both from the
values in the day 0 untreated tumours (W=98. p = 0.04). and those in the day 28
controls (W = 177. p = 0.01). Furthermore there was a trend for the day 7 values to be
higher than those in the day 28 controls (W = 166. p < 0.07). Combining the day 2 and
7 results together gives a significant difference as compared with the day 0 controls, and
even more so when the day 0 and day 28 control values are combined ( W = 359. p =
0.005). Thereafter the rate appears to fall, such that there are no differences between the
values in the treated tumours on days 14-28 and either group of untreated tumours.
Furthermore there were no differences in the apoptotic indices between the two groups
of untreated tumours irrespective ofw hether or not they were regressing on day 28.
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Figure 3J.1 Apoptotic index in tamoxifen treated and control ZR-75-1 xenografts
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Mitotic figures were less frequent than apoptotic figures, and the trends with time in the
treated and untreated tumours are shown in figure 3.2.2. where it can be seen that the
treated tumours have fewer mitotic figures than the day 0 untreated tumours, with
statistically significant differences on days 7 (W = 168. p < 0.03). 21 (W = 174. p =
0.002) and 28 (W = 322. p < 0.001 respectively). On day 14 there is a trend in the same
direction (W = 153. p = 0.09). Although there is no significant difference between the
day 0 and day 28 control values, the latter tend to be lower ( W = 147. p < 0.08). and
thus w hen comparing the treated with the day 28 controls, a trend tow ards fewer mitotic
figures is seen only on day 21 (W = 134. p < 0.1) and day 28 (W = 256. p = 0.025).
conclusions not altered by including or excluding the regressing day 28 control
tumours. If all the treated and control tumours are respectively combined, there are
significantly fewer mitotic figures in the treated tumours ( W = 1330. p < 0.005). with
a highly significant downward trend over time for the mitotic index in the treated
tumours ( z = -4.47. p < 0.0001).
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Figure 3.2.2. Mitotic index in tamoxifen treated and control ZR-75-1 xenografts
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As the apoptotic/mitotic ratio is log-normally distributed, the two sample-t test is used
for statistical considerations. As can be seen in figure 3.2.3. the ratio is generally
higher in the treated tumours, as compared with the day 0 controls, although this is only
statistically significant on days 2 ( p = 0.05). and day 7 ( p < 0.005). in contrast none
of the values in the treated tumours are statistically significantly different from those in
the day 28 untreated tumours. Although there is no significant difference between the
values in the day 0 and day 28 controls, the ratios tend to be higher in the latter group,
and if the regressing day 28 tumours are excluded, there is a trend tow ards a significant
difference between the day 7 treated tumours and the day 28 controls (p = 0.1).
Combining the results of the treated tumours from days 2 & 7. and the untreated
tumours from days 0 & 28. there is a statistically significant difference ( p < 0.05).
which increases when the regressing day 28 control tumours are excluded ( p < 0.02).
Furthermore, over the 28 days of the experiment there is no significant trend for the
apoptotic/mitotic ratio (z = -0.88542, p > 0.25). whereas there is over the first 7 days
only ( z = 2.98. p < 0.005); indeed between days 7 and 28 there is an equally
statistically significant trend in the opposite direction ( z = -3.22. p < 0.002).
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Figure 3.2.3. Apoptotic:Mitotic ratio ill tamoxifen treated and control ZR-75-1 xenografts
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3.3. MIB-1, bcl-2, p53 & c-erb-B2 expression
MIB-1 :
Figure 3.3.1 illustrates the data on the proportion of tumour cells expressing MIB-1. It
can be seen that the mean value falls significantly with time in the tamoxifen treated
tumours ( z = -3.73232. p< 0.0002). At individual time points, as compared with the
day 0 untreated tumours, the values are significantly different only on days 21 (W =
160. p < 0.05) and 28 (W = 300. p < 0.01). Furthermore there is no significant
difference between the day 0 and day 28 control tumours.
mean treated tumours
mean control tumours
0 J t , 1 I
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time (days oftamoxifen treatment)
Figure 3.3.1. MIB-1 expression in tamoxifen treated and control ZR-75-1 xenografts
Bcl-2:
All ZR-75-1 tumour cells expressed bcl-2. There was no difference in intensity of
staining at any time points between treated and untreated tumours.
p53 & c-erb-B2:
All ZR-75-1 tumour cells, irrespectiv e of time points and treatment were consistently
negative for both p53 and c-erb-B2.
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3.4. Necrosis
The average proportion of each tumour section that was morphologically necrotic is
shown in figure 3.4.1. and it can be seen that there is significantly less necrosis in the
control tumours on day 28 as compared with day 0 ( W = 150. p < 0.05). This is
however no longer the case of the regressing control tumours are excluded.
Furthermore, in the treated tumours, there are no differences as compared with the day
0 control tumours on days 2 & 7. but thereafter the necrotic proportion is statistically
significantly less on days 14 ( W = 160 p < 0.05). 21 ( W = 186. p = 0.0001) and 28
(W = 335. p = 0.0001). This is confirmed by the trend test, which show a highly
significant downwards trend oy er the 28 day s ( z = -5.90141, p < 0.00001).
lime (days oftamoxifen)
Figure 3.4.1. Necrotic proportion of tamoxifen treated and control ZR-75-1 xenografts
3.5. Vascular density
Some tumours from each passage w ere too small to be cut in half prior to fixation in
paraformaldehyde. Thus the numbers available for cryostating are given in table 3.5 1.
w here it can be seen that the majority of the untreated tumours as well as most of the
treated tumours from days 2 & 7 were available.
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dav 0 dav 2 day 7 dav 14 dav 21 & 28 control dav 28
6/11 11/12 9/12 5/11 0/38 6/10
Table 3.5.1 Numbers of ZR-75-1 xenografts with sufficient residual frozen
material for crvostat sectioning.
The data on the vascular proportion of the tumours are shown in figure 3.5.1. where :t
can be seen that there appears to be less vasculature in the treated tumours. This is
significant, as compared with either of the groups of untreated tumours, on days 2 ( W
= 76. p < 0.05) and 7 (W = 69. p < 0.02) but not on day 14. There is no difference
between the day 0 and 28 control tumours, and there is no overall downwards trend
between days 0 & 14 ( z = -1.13051. p > 0.2). However it should be recalled that only
5/11 tumours excised on day 14 had sufficient residual tumour to permit cryostat
sectioning, and they may therefore not be representative of the group as a w hole.
Combining all the treated tumours and comparing them with all the untreated tumours,
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Figure 3.5.1 Vascular proportion of tamoxifen treated and control ZR-75-1 xenografts
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3.6. Fine Needle Aspirates
Fine Needle aspirates were taken from all tumours, just prior to their excision. The
intention was to determine whether or not FNAs could be used to detect the changes in
tumour biology that were under consideration in this study. The samples were analysed
on a flow cytometer. and therefore comparisons have been made betw een this data and
those obtained by histological methods. However some FNAs were of insufficient
qualm for the cell cycle analysis programme to analyse. The following table
summarises the available data :
treated tumours control
day 2 7 14 21 28 0 28
apoptosis 12 11 5 0 18 7 6
cell-cvcle 12 10 4 0 11 6 1
No. of tumours 12 12 11 11 27 12 10
Table 3.6.1 Numbers of tumours w ith material available for analysis on the flow
cytometer.
The data on the flow cytometric analysis of the proportion of cells in the different
phases of the cell cycle together with the fraction that are apoptotic will be presented.
3.6.1. Apoptosis
The available data for the flow cytometric analysis of apoptosis in the ZR-75-1
xenografts is shown in figure 3.6.1. and it suggests that the only difference between the
treated and control values is on day 14. although there are no significant differences,
nor any significant trend oxer the 28 days. It should be noted that the proportion of
cells measured to be apoptotic by the flow cytometric method is very much higher than
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Figure 3.6.1 FAC S estimated apoptosis in tamoxifen treated and control ZR-75- 1 xenografts
3.6.2 Cell-cycle analysis
The data from the FACS analysis of the proportions of cells in the different parts of the
cell cycle are shown in figure 3.6.2, where the trend can be seen for both S-phase and
G2/M to fall with tamoxifen treatment. For G2/M this is significant on day 7 (W =
114.5. p = 0.05). with a trend on day 28 (W = 135.5. p = 0.09). and a significant overall
trend with time ( z = -1.961. p < 0.05). In contrast for S-phase fraction, this is only
significant on day 28 ( W = 143, p = 0.03). but nonetheless the overall trend is
significantly downwards ( z = -2.864. p < 0.005). There are no differences between the
control tumours on day 0 and the two untreated tumours available for analysis from day
28. Data on the proportions of cells in G1 are not shown, as the figures are derived by
subtracting from 100% the combined figures for G2/M and S-phase.
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Figure 3.6.2 Cell-cycle analysis in tamoxifen treated and control ZR-75 xenografts
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3.7. Correlations
The observations on altered growth, apoptosts. mitosis. MIB-1 expression, necrosis and
vascular density are unlikely to have occurred in isolation from each other. However it
is more difficult to be certain of how these changes are related. One can propose
hypotheses that may on testing reveal direct correlations, but the association does not
necessarily imply cause and effect. On the other hand there are 55 possible bi-variate
correlations that can be tested which is further compounded by the treatment/no-
treatment variable and the possibility of multiple regression.
Therefore in order to reduce the possibility of a false positive significant association, the
relationships to be tested need to be stated in advance, and caution exercised w hen
interpreting relationships that are only significant at the 5% level.
The first set of correlations to be tested relate to the different methods of assessing
proliferation : MIB-1 expression, the mitotic index, and the percentage of cells in the
G0/G1. S & G2/M phases of the cell cycle. These are summarised in table 3 .7.1. where
it can be seen that in general the different measures of proliferation are in v ery good
agreement with one another, although there is no correlation betw een the mitotic index
and the proportion of cells in G2/M as measured by flow cytometry.
Proliferation MIB-1 MI G0/G1 S-phase G2/M
MIB-1 0.652 -0.508 0.54 0.415
<0 0001 <0.001 <0.001 <0.01
MI 0.656 -0.374 0.395 0.296
<0.0001 <0.01 <0.01 ns
G0/G1 -0.45 -0.393 -0.970 -0.913
<0.01 <0.02 <0.0001 <0.0001
S-phase 0.504 0.43 -0.98 0.793
<0.001 <0.01 <0.0001 <0.0001
G2/M 0.342 0.298 -0.893 0.73 <0.001
<0.05 ns <0.0001
Table 3.7.1 Correlations between different measure of proliferation for ZR-75-1
xenografts, w ith the values for the treated tumours given in the lower left part of
the table, and the values for all the tumours in the upper right section.
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It should be recalled that flow cytometric data were not available for all tumours, and if
the analysis is confined to the subset for whom all measures of proliferation are
available, the previously noted correlations remain statistically significant, with the
exception of the flow cytometric data and the mitotic index for all tumours ( although
the relations remain significant for the treated tumours).
For the control tumours, the only significant correlations are for MIB-1 expression and
the mitotic index, (r =0.527. p < 0.02). and between the three FACS-derived cell-cy cle
parameters ( all p <0.001). For the non-regressing control tumours. MIB-1 expression
also correlates with G0/G1 (r = -0.854. p <0.01). S-phase (r = 0.869, p < 0.01) and
G2/M ( r = 0.764. p < 0.02). These results suggest that the measures of proliferation
are all. as expected, related. The notable exception is the lack of any correlation
between the Mitotic index and the percentages of cells in G2/ M. This could be due to
the fact that the flow cvtometer cannot distinguish between cells in G2 and M on the
basis of their DNA content, and therefore the mitotic index is not measuring the same
group of cells as the flow cytometer. The weaker correlations within the control tumours
could be a reflection of the smaller numbers. Multiple regression analy sis can be done 5
ways, but consistently one finds that the GO/G1 variable drops out. which is not
surprising as it is calculated from two others being considered (G2/M and S-phase
fraction). Omitting this variable then, for the MI, only the MIB-1 coefficient is
significant ( R2 = 0.26, t = 3.29, p < 0.01); for MIB-1 both S-phase fraction & MI are
significant (R: = 0.40. respectively t = 2.67 & t = 3.29 ; both p < 0.01). For S-phase
fraction and G2/M. perhaps not surprisingly it is the only other cell-cycle measure
which is significant (R2 = 0.64. t = 7.05. p < 0.001). Thus although the different
measures of proliferation are related, they tend to fall into two groups ; FACS measures
and histological measures, each ofw hich have tighter correlation within the group than
with the other group ; the notable exception is the percentage of cells positive for MIB-
1, w hich is consistent with the property of the MIB-1 antibody to detect proliferating
cells in Gl, S-phase & G2/M (Cattoretti et al( 1992); McCormick et al( 1993)).
Furthermore these data are consistent with studies in clinical breast cancer w hich report
significant correlations between the lev el ofKi-67 expression (to which MIB-1 is a
highly specific monoclonal antibody (Cattoretti et al( 1992))) and both S-phase fraction
(Gaspanm et al(1994a); Keshgegian et al( 1995)) and mitotic index (Weidner et
al( 1994)).
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Similarly the correlations between the measures of cell-death are shown in tabic 3.7.2.
Perhaps surprisingly it appears that the histological measures of apoptosis and necrosis
are correlated, whereas the flow cytometric measure of apoptosis does not correlate with
either histological assessment. If the analysis is restricted to those tumours for which
all three measures are available, then the only significant correlation is between the
apoptotic index and necrosis in the treated tumours.








Table 3.7.2 Correlations betw een measures of cell death in ZR-75-1 xenografts,
with the treated tumours represented by the lower, left part of the table, and all
tumours in the upper right section.
There is also a significant correlation between the apoptotic index and necrosis in
untreated tumours, but in the opposite direction ( r = -0.45. p < 0.05). However
multiple regression analysis reveals no significant correlation for the apoptotic index :




necrosis 1.4 n s. R2 = 5 %
As far as the FACS measure of apoptosis is concerned, the multiple regression analysis
suggests that it is only significantly related to the amount of necrotic tissue (as it w ill
tend to make a larger contribution in the following equation). and not the proportion of
cells that are apoptotic morphologically :
FACS-TUNEL = 4.67 +150 * Apoptotic index + 15.2 * necrotic proportion
Predictor t-ratio
Constant 2.54
apoptotic index 0.74 n.s.
necrosis 2.08 p < 0.05 R2 = 8 %
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However the small R value suggests that even including the necrotic proportion onh
predicts a small part of the FACS measure of apoptosis.
Finally, there are possible relationships between cell proliferation and cell death, as well
as with the vascular supply. Rather than consider all measures of proliferation, the
FACS-measures will be discounted, except when also considering another FACS-
measure.
Necrosis MIB-1 M.L M.L vasculature
(univariate) (multivariate)
all tumours 0.528 0.582 t = 4.1 ns
<0.001 <0.001 <0.001
treated 0.481 0.53 t = 3.1 ns
tumours <0.001 <0.01 <0.01
control 0.55 0.46 t = 2.4 ns
tumours <0.05 ns < 0.05
Table 3.7.3. Correlations between necrotic proportion of the tumour and measures
of proliferation and vascular supply.
Table 3.7.3 demonstrates that the necrotic proportion of the tumour is strongly
correlated with proliferation, and not with the vascular supply. The observation that
this relationship holds in the untreated as w ell as the treated tumours gives further
credence to the observation that necrosis in these xenografts is not affected directly b>
tamoxifen treatment. A positive relationship between the rates of apoptosis and mitosis
are suggested by table 3.7.4. with further confirmation that proliferation and apoptosis
are linked by the correlation with MIB-1 expression. The lack of significance in the
control tumours could be due to the smaller numbers.
Apoptosis MIB-1 MIB-1 M.L vasculature
(univariate) (multivariate)
all tumours 0.362 t = 3.1 0.344 ns
<0.01 <0.01 <0.001
treated 0.486 t = 4.1 0.424 ns
tumours <0.001 <0.001 <0.001
control ns ns ns ns
tumours
Table 3.7.4. Correlations between the apoptotic index of the tumour and measures
of proliferation and vascular supply.
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Table 3.7.5 suggests that the flow cytometric measure of apoptosis has similar
correlations to the histological measures of cell death, although weaker, as suggested by
the lower p-values and the lack of a significant association with the mitotic index.
FACS- MIB-1 MIB-1 M.L S-phase G2/M vasculature
TUNEL (univariate) (multivariate)
all 0.324 t = 3.3 ns ns ns ns
tumours <0.01 <0.01
treated 0.425 t = 3.9 ns 0.395 ns ns
tumours <0.01 <0.001 <0.02
control ns ns ns ns ns ns
tumours
Table 3.7.5. Correlations between the flow cytometric measure of apoptosis of the
tumour and measures of proliferation and vascular supply.
Table 3.7.6. together with tables 3.7.3 - 3.7.5. demonstrates that the vascular proportion
of the tumour is not in general directly related to any of the other measures in the
treated tumours. In contrast, in the small group of untreated tumours, there are
apparently contradictory7 associations with proliferation ; positive with the flow






all tumours ns ns ns ns ns
treated ns ns ns ns ns
tumours
control ns -0.629 t = -2.4 0.763 0.727
tumours <0.05 <0.05 <0.05 <0.05




It is helpful therefore to summarise the trends noted in the preceding paragraphs, as in
table 3.8.1. where comments in parentheses refer to data that are not statistically
significant at the 5% level, but could still be meaningful as suggested by other
corroborative evidence.
control tumours treated tumours
growth increasing regression
apoptosis no change transient increase
mitosis no change (? decrease) decreased
apoptotic/mitotic ratio no change (° increase) increase (?sustained)
MIB-1 expression no change (? decrease) decreased
necrosis no change decreased
vasculature no change decrease (? sustained)
FACS G2/M no change decrease
FACS S-phase fraction no change decrease
FACS-TUNEL no change no change
Table 3.8.1. Summary of changes seen in tamoxifen treated and control ZR-75-1
xenografts over a 28 day period.
For the control tumours the only significant change over time is an increase in the
tumour size, although there is a suggestion that the proliferative fraction (as assessed by
the mitotic index and MIB-1 expression) falls. Consistent with this is the suggestion of
an increase in the apoptotic/mitotic ratio. These changes appear to be largely confined
to the 4/10 of the control tumours removed on day 28 that regressed towards the end of
the experiment. Thus figures 3.2.1 - 3.5.1 also show the values for the non-regressing
control tumours removed on day 28 w here, although they appear to differ from the
values for the group as a whole, in no case w ere the differences statistically significant.
Hence it may be concluded that the growth rate of all the control tumours w as not
consistent over time, but this does not appear to be as a consequence of changes in
vascular supply (as there were no changes in necrosis or vasculature).
Figure 3.1.1 demonstrates that tamoxifen causes regression of the oestrogen-receptor
positive ZR-75-1 breast cancer xenografts, and therefore the differences between the
treated and control tumours can be considered to occur at least in association with such
regression. As figure 3.2.1 show s, within two days of tamoxifen therapy there was a
significant increase in apoptosis. with the mean level rising from 0.7% to 1.05%, which
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translates to a 50% increase in cell loss, the same value as that calculated by Brunner
for tamoxifen treated MCF-7 xenografts (Brunner et al( 1989)). On day 7 the average
value is almost identical, but the range is wider, which may account for the lack of
statistical significance w hen comparing with either group of control tumours. How ever
when combining the day 2 & 7 values and/or the control values, the rise in apoptosis
becomes significant. (These data are consistent with most (but not all (Kristensen et
al( 1995b); Szende et al(1990))) prior data on the effect of oestrogen deprivation or
antagonism (Frankfurt. (1995); Kyprianou et al(1991b); Perry et al(1995a); Szende et
al( 1989); Szende et al(1990); Warri et al( 1993); Warri et al( 1993))). Thereafter the
value appears to fall, to around the same value as in the untreated tumours, and this is
also consistent with similar studies conducted on the effect of hormone-deprivation of
prostate cancer cells (Kvpnanou et al( 1990); Martikainen et al(1990)). as well as
oestrogen-deprivation of hormone-sensitiv e MCF-7 breast cancer xenografts (Kypnanou
et al(1991b)). The specificity of these changes in apoptosis to tamoxifen remains
uncertain, as there were no control tumours at these early time points. The v alues in
the day 28 control tumours are similar to the day 0 values, but a proportion of the
former regressed towards the end of the experiment.
In contrast to the pattern observed with apoptosis, figure 3.2.2 confirms previous
observations that tamoxifen induces a sustained decrease in proliferation (Brunner et
al( 1989); Butler et al(1988); Danova et al( 1993); Kute et al( 1985); Osborne et al(1983);
Osborne et al( 1985); Sarkaria et al( 1993); Sutherland et al( 1987)). and the fall in M3B-
1 expression (figure 3.3.1) corroborates this. Section 3.6 confirms that the methods
used to assess proliferation (mitotic index. MIB-1 expression and the proportions of
cells in G2/M and S-phase) are in general in agreement with one another. Figures 3 2 2
and 3.6.2 suggest that MIB-1 is less sensitive to the earliest changes in proliferation as
there are no significant differences in this marker until day 21 of treatment, although
there is a consistent trend for less proliferation with increased duration of tamoxifen
therapy. There is also the suggestion that the proliferative fraction may fall with time
in the control tumours, although this is to a large extent confined to the regressing
tumours.
The apoptotic:mitotic ratio serv es as a measure of the relative balance between
proliferation and cell loss. Figure 3 .2.3 demonstrates that this rises significantly ov er
the first 7 days of tamoxifen therapy, and then falls, but not to its original level.
However the control tumours also have an apparent but non-significant rise in the ratio
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over the same period, explained only in part by the regressing tumours Hence
tamoxifen appears to alter the relative balance between cell proliferation and apoptosis.
Table 3.7.4 confirms that there is a positive relation between the levels of apoptosis and
proliferation in these tumours. The lack of a significant relationship in the control
tumours could be due to the suggestion that the apoptotic:mitotic ratio is higher in the
regressing day 28 controls. There are no previous reports of the effect of tamoxifen
upon this ratio in xenografts.
The above changes in apoptosis occur without any detectable change in the level of
expression of either bcl-2 or p53. The latter is not particularly surprising, as p53 is
implicated in the induction of apoptosis in response to genetic damage, w hereas the
expectation is that tamoxifen acts by inhibiting growth, and is therefore likely to act in a
p53-independent manner. What is a little more surprising is the lack of any change in
the expression of bcl-2. The technique employ ed, namely immunohistochemistry. may
be partly responsible, as it may be insensitive to small, transient changes, particularly if
those changes only occur in cells just prior and dunng apoptosis. as the condensation of
the cytoplasm that occurs during apoptosis could conceivably be sufficient to mask any
reduction in concentration induced by tamoxifen. However it is more likely that if
tamoxifen induces apoptosis by inhibiting bcl-2 expression, it would do so in many (or
all) sensitive cells, and thus be visible across the section. Equally it is possible that it is
altered expression of another member of the bcl-2 family (Krajevvski et al( 1995 ), Oltav i
et al( 1993): Sumantran et al( 1995); Teixeira et al( 1995); Wang et al( 1995); Yang et
al(1995)) that increases the propensity for apoptosis. but the lack of reliable monoclonal
antibodies has prevented the testing of this hypothesis.
There is a clear fall in the proportion of each ZR-75-1 tumour that is necrotic dunng
tamoxifen therapy (see figure 3.4.1). In the control tumours there is also the suggestion
of a fall, but this mostly due to the low er values in the regressing day 28 control
tumours. Section 7 will confirm confirms that the proportion of each treated tumour
that is necrotic is highly significantly correlated with all measures of v olume or
response, consistent with its progressive Ml on treatment. Such a relation could
therefore explain the apparent fall in the regressing day 28 tumours; if they are
regressing because of oestrogen deprivation, then the data from the tamoxifen treated
tumours suggests that they too might manifest less necrosis. These data are however in
contradiction with a report of the effect of MCF-7 xenografts treated with a higher dose
of tamoxifen (Haran et al(1994)), w here the necrotic portion was measured non-
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invasive!) by MRI scanning. Unpublished observation from our own laboratory (Dr J
Keen) suggest that higher doses of tamoxifen are associated with more necrosis, w hich
could therefore be a non-specific effect of the drug. The data in the present stud)
however do not support the notion that any of the increased cell-loss occurring as a
result of tamoxifen therapy is due to necrosis.
Figure 3.5.1 shows that tamoxifen therapy is associated with a fall in the vascular
proportion of the tumour. This is consistent with previous reports of tamoxifen having
an anti-angiogenic action (Gagliardi et al(1993)). It is interesting that there are no
correlations between the level of vasculature and the amount of necrosis (see table
3 .7.3) - a prec ious stud) has suggested that there were changes in the vasculature as
well as increased necrosis in tamoxifen treated xenografts (Haran et al( 1994)). In the
control tumours the data suggest that the more vascular tumours have a higher
proliferativ e fraction, as assessed flow cytometrically. but not with MIB-1 (see table
3.7.6). It should be recalled that only 13/21 control tumours were available for
assessment of vasculature and this could result in a false negative correlation. What is
more difficult to explain is the inverse relation with mitotic index. Section 3.7 pointed
out that the correlations between proliferative markers were weaker in the control
tumours, and in particular the mitotic indices were not associated w ith any flow
cytometric parameters in this group of cells. Furthermore the control group of tumours
include three differing groups : day 0 untreated tumours, day 28 untreated non-
regressing and day 28 regressing tumours. As has already been discussed, there is a
trend for the regressing tumours to hav e less proliferation, and only one of these
tumours w as available for assessment of vasculature, as opposed to 5/6 non-regressing
tumours. In contrast FNAs were only available for two of the day 28 control tumours (
one regressing and one non-regressing) so that the correlation betw een cell cycle




MDA-MB-231 human breast cancer xenografts were, as explained in the methods,
derived from two separate passages ( N'os 2 & 7). There were, with one exception,
only minor differences between the results for the tumours from these different
passages, but none that alter the overall conclusions : therefore all the results have been
combined to simplifv the data presented The exception was that the proliferation in the
tumours from the later passage, as assessed bv the mitotic inde.v was consistently and
significantly higher than in those from the earlier passage (W = 140. p < 0.005). see
figure 4.1. This phenomenon has been previously noted (Steel et al( 1971)). and
although significant between these two passages, does not alter the overall conclusions
for this section. As in section 3. the data presented hav e been grouped according to
treatment status and the time point w hen the tumour was remov ed Results and the
correlation with tumour growth for individual tumours will be covered subsequently in
section 7 for clarity.
0.025




Passage 2 tumours Passage 7 tumours
Figure 4.1 Mitotic indices in the MDA-MB-231 tanours from passages 2 & 7
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4.1. Growth
The growth curves for the combined data set arc shown in figure 4 1.1. where it needs
to be pointed out that the data for the day 28 volumes onlv come from passage 2. and
there is a highly significant difference in the volumes of the day 21 control tumours (all
front passage 7) as compared with the day 28 control tumours (all front passage 2) ( \V
= 10. p < 0.025). This is due to a different growth curv e ov erall for the day 28 control
tumours, as shown in figure 4 1.2. Further examination of the growth curv es of the
tumours from the two passages shows that the treated tumours from the later passage
also grew faster, as figure 4.1.3 illustrates. There are however no statistically
significant differences between the treated and control tumour volumes at comparable
time-points.
0.001 4 i
-30 -20 -10 0 10 20 30
days (oftamoxifen >
Figure 4.1.1 Growth data for tamoxifen treated and control MDAMB-231 xenografts
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10 - mean day 28 control tumours
mean all control tumours
1 mean day 21 control tumours
0.001 t
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days (of tamoxifen)
Figure 4.1.2. Grow th data for control MDA-MB-231 xenografts
0.001 T i
-30 -20 -10 10 20
days (of tamoxifen)
Figure 4.1.3 Growth data for tamoxifen treated MDA-MB-231 xenografts according to passage
number
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4.2 Apoptosis (& necrosis)
All tumours were examined for mitosis and apoptosis as described in the methods In
general the incidence of apoptotic figures was similar to that found in the ZR-75-1
xenografts. The results are shown in figure 4.2.1. where it can be seen that there is no
evidence of a change in apoptosis w ith tamoxifen treatment, nor. as evidenced by the
control tumours, with time. The majority of the MDA-MB-231 tumours had a large
central necrotic core, and thus the tissue studied w as on the periphery of the tumour
Furthermore the size and consistency of the necrotic core was such that during
sectioning and fixation, necrotic material exuded from the core, so that no accurate
determination of the relative necrotic proportion of the tumour could be made. Hence no
comparative study on the effect of time and/or tamoxifen treatment could be conducted
on the MDA-MB-231 tumours.
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days (of tamoxifen)
Figure 4.2.1 Apoptotic indices in tamoxifen treated and control MDA-MB-231 xenografts
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4.3. Mitosis
Figure 4.3.1 illustrates the mitotic index in the treated and untreated MDA-MB-2? 1
tumours. There is an increase in mitotic index in the treated tumours over time, which
is statistically significant (z = 4.339. p < 0.00005 ). This is in part due to the higher
proliferation rates seen in the later passage, but not entirely, as comparing all day 0
controls with the day 21 & 28 controls combined there remains a significant difference
between them (W = 83. p < 0.015). However tamoxifen treatment does not alter the
mitotic index, as seen there was no statistical significant difference between the \alues
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Figure 4.3.1 Mitotic indices in tamoxifen treated and contori MDA-MB-231 xenografts
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4.4 Apoptotic:Mitotic ratio
The changes in apoptotic:mitotic ratio with time are shown in figure 4.4.1. There are no
significant differences between the time points, except for the tumours removed on day s
21 & 28. which as previously noted are from different passages with different rates of
proliferation. The observed difference in apoptotic:mitotic ratio is statistically
significant both for the treated tumours (p < 0.005 by t-test) as well as the control
tumours (p = 0.016 by t-test). Similarly when all treated tumours are compared
between the two passages the later passage again has a lower ratio (p < 0.005 by t-test).
These results are consistent with the previously observed higher proliferation in the
later passage. Howev er at any one time point there are no significant differences
between the v alues for the treated and untreated tumours, confirming that tamoxifen
does not alter the ratio in the MDA-MB-231 tumours.
0 5 10 15 20 25 30
days (of tamoxifen)
Figure 4.4.1 Apoptotic/mitodc ratio in tamoxifen treated and control MDA-MB-231 xenografts
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4.5 Vascular density
As with the ZR-75-1 xenografts (see section 3.5). some MDA-MB-231 tumours were
too small to be bisected prior to fixation in paraformaldehyde, or in the case of some of
the tumours from the later time points had large necrotic cores and thus were difficult to
bisect. Thus table 4.5.1 gi\es the numbers of tumours available for cryostat sections
w here it can be seen that there were representative samples from most time points, the
notable exception being the day 28 untreated tumours from passage 2.




3/11 4/6 7/10 3/8 2/16 2/4 2/5 0/4
Table 4.5.1 Numbers of MDA-MB-231 xenografts with residual frozen material
for cry ostat sectioning
The mean vascular proportion of the tumours is shown in figure 4.5.1. where it can be
seen that there is no difference in vasculature at different time points, and that
tamoxifen treatment had no effect on the vascular proportion of the MDA-MB-231
tumours.
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Figure 4.5.1 Vascular proportion in tamoxifen treated and control MDA-MB-231 xenografts
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4.6 FACS data
As for the ZR-75-1 tumours, fine needle aspirates were taken to correlate FACScan
analysis of apoptosis and proliferation with histological assessments Not all the FNAs
taken were of sufficient quality to permit analysis and table 4.6.1 summarises the
available data, in which it can be seen that data are available from all time points.
day 0 dav 2 day 7 day 14 day 21 day 21 day 28 dav 28
treated treated treated treated control treated control
cell evele 5 5 7 7 11 5 3 2
apoptosis 6 5 9 8 11 5 4 4
No. of 11 6 10 10 16 5 4 4
tumours
Table 4.6.1 Numbers of tumours w ith available data for FACS analysis of
apoptosis and cell cycle.
The data for FACS measures of apoptosis are seen in figure 4.6.1, and those for cell
cycle analysis are shown together in figure 4.6.2. with the proportion of cells in G1 not
included as this figure is derived from the other two parts of the cell cycle. There are
no differences between the values of FACS apoptosis. G2/M or S-phase fraction for
treated and control tumours at any time-point. However, when considering the
combined treated and control tumours from the final time-point (i.e. day 21 for passage
7 against day 28 for passage 2). significant differences were found in all measures (W =
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Figurew 4.6.1 Percentage of cells in Apoptosis as estimated by FACS for tamoxifen treated and
control MDA-MB-231 xenografts
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Similar analyses as were undertaken in section 3.7 for the ZR-75-1 xenografts, looking
at possible correlations between measures of proliferation and cell death can be
undertaken for the MDA-MB-231 tumours. However they are perhaps surprisingly
almost all negative. The exceptions to this is that for tumours from passage 2 there is a
significant correlation between the mitotic index and the S-phase fraction (r = 0.784. p
< 0.02). It should be recalled that there was a significant difference in the proliferation
rates for the tw o passages, and overall a smaller number of tumours in this experiment
as compared to the ZR-75-1 experiment. It is possible therefore that false negative
results are seen because of this, but in particular the lack of any correlation between the
histological and flow cytometric measures of apoptosis should be noted.
4.8 Discussion
The data presented for the MDA-MB-231 xenografts show that tamoxifen treatment has
had no significant effect on tumour growth, proliferation or apoptosis. The
apoptotic:mitotic ratio, a measure of the overall balance between cell proliferation and
death also remains unaltered by tamoxifen therapy. Finally the vascular proportion of
the tumour does not change over time, or with tamoxifen treatment. The data presented
however do suffer from two potential problems. The first, is that no control tumours
were excised at the intermediate time points, and as with the ZR-75-1 xenografts, the
values for apoptosis & mitosis in the control tumours excised at the end of the
experiment are not unequivocally the same as those for the control tumours from day 0.
This may be due to the control tumours w hich were left to grow unperturbed dunng the
experiment grew at very different rates according to their passage number (see figure
4.1.2) and had significantly different proliferation rates and apoptotic:mitotic ratios.
This difference in proliferation rate and growth was a feature of all the tumours. Thus
the conclusion that tamoxifen does not alter growth, tumour vasculature, proliferation
or apoptosis in these tumours still holds.
It is pertinent to comment on the lack of any pro-apoptotic effect of tamoxifen in these
oestrogen-receptor negative xenografts. The data would initially appear to be at odds
with a study in which MDA-MB-231 breast cancer cells were cultured and treated in
vitro with tamoxifen (Kang et al( 1996)) It was reported that a luM concentration of
139
tamoxifen increased c-myc transcription and apoptosis, as detected by inter-nucleosomal
DNA cleavage. Furthermore these effects were antagonised by a c-myc antisense
oligomer. However over the 72 hours that these changes occurred there was a five-fold
reduction in cell number, and sufficient cytotoxicity for DNA laddering to be detectable,
whereas it had not been in the control tumours The current study confirms the
existence of apoptotic cells in untreated xenografts, and suggests therefore that the level
of apoptosis observed by Perry el al (Kang et ah 19%)) in response to the induction of c-
myc was several-fold higher, bey ond those reported here in xenografts or that likely to
occur in clinical tumours. It has been previously reported that c-myc overe.xpression
induces significant apoptosis in the presence of growth-factor deprivation (Arends et
al( 1993)). Hence, whatever the mechanism for the c-myc induction on exposure to
tamoxifen (in an unspecified solvent), the changes seen are consistent w ith the know n
effects of c-myc. rather than that of tamoxifen. Furthermore lOpM tamoxifen in that
study was associated with reduced c-my c expression, whereas other studies from the
same group (Perry et al(1995a)) and others (Bardon et al(1987)) have suggested that
higher levels of tamoxifen induce apoptosis. Finally, a study (using similar techniques)
of the effect of oestrogen-withdraw al or treatment with the pure anti-oestrogenic
compound ICI 182,780 on the hormone-sensitive cell MCF-7 cell line (Wilson et
al( 1995)) observed decreased cell-number and the presence ofDNA fragments, but
little evidence for increased apoptosis as assessed by morphology.
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5 Mice bearing synchronously grown MDA-MB-231 and ZR-75-1
xenografts
In view of the lack of control tumour material that was removed at the time points w hen
the first changes in apoptosis and mitosis were seen in the ZR-75-1 xenografts, a further
experiment was conducted, in which mice bore one ZR-75-1 xenograft and one MDA-
MB-231 xenograft, and both treated and untreated tumours were excised on days 2 & 7
(see table 3).
5.1. Growth data
The growth curves of the ZR-75-1 tumours are show n in figure 5.1.1 and those for the
MDA-MB-231 tumours in figure 5.1.2. The volumes of tumours excised at each time
point are not significantly different between the treated and control groups for both
tumour types, although the day 7 ZR-75-1 tumours are significantly smaller than those












-25 -20 -15 -10 -5 0 5 10
days (of tamoxifen)






-25 -20 -15 -10 -50 5 10
days (of tamoxifen)
Figure 5.1.2 Growth of tamoxifen treated and control MDA-MB-231 lenografts
There were no significant differences in growth for any group of tumours, w ith no
evidence for tamoxifen induced regression of either ZR-75-1 or MDA-MB-231
xenografts. This is consistent with the data from the previous studies ( see sections 3.1
& 4.1). with no significant change in the volume of the tamoxifen treated ZR-75-1
tumour occurring before day 14, beyond the period studied in this experiment.
5.2. Apoptosis, mitosis and the Apoptotic:Mitotic ratio
Apoptosis. mitosis and the ratio of the apoptotic : mitotic indices were determined as
previously. The data for Apoptosis and Mitosis is shown graphically in figures 5.2.1 -
5.2.4.. where there appears to be a rise in apoptosis in the treated ZR-75-1 but not the
treated MDA-MB-231 xenografts, nor in the untreated xenografts of either ZR-75-1 or
MDA-MB-231 cells. However statistically there is only a trend towards significance in
the ZR-75-1 xenografts on day 2 ( W = 18. p = 0.06). In contrast the mitotic index
appears to fall in the treated ZR-75-1 xenografts, but not the untreated controls. This is
statistically significant on day 2, where the control tumours have higher mitotic rates
than the 2 treated tumours (W = 38. p = 0.04). The apparent falls in mitotic index in the
MDA-MB-231 tumours are not statistically significant. The same pattern as was
apparent in the earlier experiments is seen - no difference between treated and control




treated ZR-75-1 tumours Considering the hypothesis that there should be no
differences in the control tumours irrespective of the da> of remov al, one can compare
the treated and untreated tumours by combining the results from days 2 & 7; this
increases the number of tumours for the statistical comparisons and thus reduces the
possibility of a type II error ( a false negativ e). If this is done, then there is a highly
sigmficant difference in apoptosis between the treated and control ZR-75-1 tumours ( W
= 61. p < 0.005). as well as mitosis ( W =111. p < 0.05). In contrast there are no such
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Figure 5.2.1 Apoptotic index in tamoxifen treated and control ZR-75-1 xenografts
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Figure 5.23 .Mitotic index in tamoxifen treated and control ZR-75-1 xenografts
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Figure 5.2.4 Mitotic index in tamoxifen treated and control MDA-MB-231 xenografts
When the natural logarithm of the apoptotic: mitotic ratio is considered significant
differences are found. For the MDA-MB-231 tumours, there are no statistically
significant differences between treated and untreated tumours (see figure 5.2.6). but for
the ZR-75-1. the ratio is significantly higher on day 2 ( p < 0.05, t-test). although not on
day 7 (see figure 5.2.5). However the graph suggests that the ratio continues to increase
on day 7. with a trend tow ards significance (p = 0.08). in contrast to the untreated ZR-
75-1 and treated MDA-MB-231 tumours ( p > 0.4 in both cases). Furthermore when
considering the combined treated and control tumours from days 2 & 7. the
apoptotic:mitotic ratio is significantly higher for the ZR-75-1 tumours ( p = 0.02) but











0 1 2 3 4 5 6
days (oftamoxifen)
Figure 5.2.5 Apoptotk:Mitotic ratio in tamoxifen treated and control ZR-75-1 xenografts
days (of tamoxifen)
Figure 5.2.6 Apoptotic:.Mitotic ratio in tamoxifen treated and control V1DA-MB-231 xenografts
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5.3 Discussion
This experiment was conducted to confirm that the changes in apoptosis. mitosis and
their ratio, observed in the tamoxifen treated ZR-75-1 xenografts, were specifically
caused by tamoxifen, the prior experiment being limited by the non-availability of
untreated tumour material removed on the days when the changes were maximal,
namely after 2 and 7 days' therapy. The pattern seen in this repeat experiment is
entirely consistent with the conclusion of the earlier work, namely that tamoxifen
induces an increase in apoptosis and a fall in the mitosis, which results in an increase in
the apoptotic:mitotic ratio, and that these effects are seen within the first week of
therapy only in the oestrogen-sensitive ZR-75-1 breast cancer xenografts. The lack of
significant differences at all the individual time points do not detract from these
conclusions, as there are no significant changes with time in the untreated tumours, and
combining the data from the treated tumours excised on days 2 and 7 confirms that
tamoxifen therapy induces a significant increase in apoptosis and reduction in mitosis.
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6. Sequential Fine Needle Aspirates of ZR-75-1 and MDA-MB-231
Xenografts
The final experiment involved sequential aspiration of both treated and untreated
tumours, in order to determine more precisely the timing of changes in proliferation and
apoptosis. The tumours used were ZR-75-1 and MDA-MB-231 xenografts grown from
the same passage as the last experiment, with 12 mice bearing a single tumour of each
type ( a total of 24 ammals). FNAs were taken and analysed as described as in the
methods, w ith the exception that the tumours were only removed on day 21.
FNAs were performed on all tumours starting on day 0. before the insertion of the
tamoxifen pellets in the treated animals, and again on days 2.5.7.9.12.14. & 21.
Howev er one animal died on day 5 (bearing a tamoxifen treated MDA-MB-231
tumour).
6.1 Growth
The growth curv es for the ZR-75-1 and MDA-MB-231 tumours are shown in figure
6.1.1 & 6.1.2 respectively. It can be seen that the only tumours to regress are the
treated ZR-75-1 tumours, consistent with prior results, although the volumes are only
significantly different from the control ZR-75-1 tumours on days 16 (p < 0.05). 19 & 21
(p < 0.01). There are no significant differences betw een the volumes of the treated and
untreated MDA-MB-231 tumours at any time point
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6.2 FACS data
The design of this experiment was intended :o identify the time points at which
significant differences in apoptosis and proliferation w ere to be found between treated
and control ZR-75-1 tumours. However not all the FNAs were of sufficient qualm to be
assessable, and in the case of the treated tumours the proportion of tumour cells in the
aspirates fell, such that at day 9 and beyond. few were lnlerpretable. both with regards
to the cell cycle soft-ware w hich has to distinguish between the cells of mouse and
human origins, as well as the fluoro-TUNEL technique. The numbers that were
available are detailed in table 6.2.1. where it can be seen that the majority of FNAs were
of sufficient quality to giv e dependable data, particularly at the early time points.
Control T reated
ZR-75-1 MDA-MB-231 ZR-75-1 MDA-MB-231
dav Cell FACS Cell FACS Cell FACS Cell FACS
cvcle TUNEL cvcle TUNEL cvcle TUNEL cycle TUNEL
0 6 6 6 6 5 5 4 4
2 6 6 6 6 6 6 5 5
5 6 6 6 6 5 5 5 5
7 5 5 6 6 5 5 4 4
9 5 5 6 6 3 3 3 3
12 6 5 6 6 4 3 4 4
14 4 4 6 6 3 3 4 4
21 6 5 6 6 2 1 4 4
Table 6.1.1 Numbers of FNAs from ZR-~5-l and MDA-MB-231 xenografts that
were assessable for cell cycle parameters and apoptosis using the FACScan
(maximum no. available at any time point was 6).
6.2.1 S-phase & G2/M
There were differences between treated and control ZR-75-1 tumours in the proportions
of cells in S-phase and G2/M after day 0. as can be seen in figure 6.2.1. For the treated
tumours, the percentage of cells in G2/M was significantly low er on days 2 and 5 ( p <
0.02). and 7 ( p < 0.01). On days 9 and 12 there were only 3 treated tumours
assessable, with a trend towards significantly ( p < 0.1) lower v alues. Beyond that time
point there were no significant differences, possibly due to the even smaller number of
tumours available for assessment.
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mean treated tumours
0 5 10 15 20 25
days of tamoxifen
Figure 6.2.1 C2/M in sequential FNAs from tamoxifen treated and control ZR-75-1 xenografts
For the S-phase fraction there is a similar trend towards a lower percentage of cells in
S-phase in the treated ZR-75-1 tumours, as shown in figure 6.2.2. However this is only
significant on days 7.9. and 12 ( p < 0.05). with an apparent rise on days 14 and 21.
Although this could be due to the smaller number of available FNAs at these later time
points, there is a non-significant rise in the proportion for these same tumours as
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Figure 6.2.2 S-phase in sequential FNAs from tamoxifen treated and control ZR "5-1 xenografts
In contrast there were no differences over time for the S-phase fraction or G2/M
population in the MDA-MB-231 tumours, irrespective of whether or not they had been


































6.2.2 Apoptosis and Apoptosis:G2/M ratio
Figure 6.2.5 illustrates the proportions of cells in apoptosis for the treated and control
ZR-75-1 xenografts, as measured by FACS-TUXEL. However it can be seen that there
is an initial anomaly - the day 0 values for FAC S-TUNEL are larger in the treated
tumours as compared with the control ( W = 25. p=0.06). at a time just before any
tamoxifen has been administered. Therefore the graph includes the two series of
tumours with and without all the day 0 values combmed. Although there are no
significant differences between the values at am indiv idual time-point, if the v alues on
days 2 and 5 (and or 7) are combined then the treated values are higher ( W = 105. p <
0.02) than the control v alues. If all the day 0 tumours are combined there are still no
significant differences between the treated and day 0 v alues, but the control v alues are
significantly less on days 5 (W = 32. p < 0.05) and 12 (W = 21. p < 0.02).
mean treated tumours
0 2 4 6 8 10 12 14
days of tamoxifen treatment
Figure 6.2.5 Apoptosis in sequential FNAs from tamoxifen treated and control ZR-75-1
xenografts
.As mentioned in the methods (see page 26). one possible way around the potential
problem of identifying DNA fragments in necrotic cells in the aspirates (and thus
counting them as apoptotic) is to pre-treat the samples with DNAase. This was
performed for the ZR-75-1 tumours with sufficient remaining material (5 treated and 4
control tumours) after a further period of storage w hich therefore introduced a freeze-
thaw cy cle which could reduce the viability of the samples. The data are shown in
figure 6.2.6, where it can be seen that the initial difference between the day 0 samples
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has been reduced but so apparently have the subsequent differences between the control
and treated samples. Visualh there is the suggestion of a rise in the treated samples,
and using the non-parametric trend test for samples up to day 14 ( as there is only one
da\ 21 treated sample), this approaches significance ( z = 1.92. p < 0.06). whereas for
the control samples, there is no such trend ( z = 0.84. p > 0.4).
mean treated tumours
0 5 10 15 20 25
days of tamoxifen treatment
Figure 6.2.6 Apoptosis (using DNAase) in sequential FNAs from tamoxifen treated and control
ZR-75-1 xenografts
Furthermore, as shown in table 6.2 1. there are excellent correlations between this
method of assessing apoptosis and the original method w hich omits the DNAase step
all tumours control tumours treated tumours
r, = 0.712 ( p < 0.0001) 0.901 (p<0.0001) 0.498 ( p < 0.01)
Table 6.2.1 Correlations between the percentage of cells in apoptosis as measured
on the FACScan, when analysed with and w ithout pre-treatment with DNAase.
The Apoptotic:G;/M ratio (calculated as the ratio between the proportion of cells in
apoptosis and G2/M) for tamoxifen treated and control ZR-75-1 xenografts is shown in
figure 6.2.7. The values for the treated ZR-75-1 tumours are significantly higher than
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Figure 6.2.7 Apoptotic:G2/M ratio in sequential FNAs from tamoxifen treated and control 7.R-75-
1 xenografts
In contrast there appears to be a fall in the level of apoptosis (as detected by FACS-
TUNEL) in the MDA-MB-231 tumours, irrespective of w hether or not they had been
treated with tamoxifen, as can be seen in figure 6.2.8. However this apparent trend is
not significant, and indeed there are no significant differences between the treated and
control tumours at any time point, confirming that tamoxifen does not have any effect
upon the rate of apoptosis in MDA-MB-231 tumours.
days of tamoxifen treatment
Figure 6.2.8 Apoptosis in sequential FNAs from tamoxifen treated and control MDA-MB-231
xenografts
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Similarly, when considering the apoptotic:mitotic ratio in the treated and control MDA-
MB-231 xenografts, figure 6 2 0 confirms that there are no differences between the
\alues in the treated and control tumours. Consistent with the apparent fall in apoptosis
in the treated tumours, a similar trend is seen for the Apoptotic:mitotic ratio, but it is
not significant
0 5 10 15 20 25
days of tamoxifen treatment
Figure 6.2.9 Apoptotic:G2/M ratio in sequential FN'As from tamoxifen treated and control MDA-
MB-231 xenografts
The more important question is however whether the sequence of values for an
individual tumour can identify it as a treated (and thus responding) or a control ZR-75-
1 tumour. Clearly one approach w ould be to consider the regression lines of the
log(Apoptotic:G;/M ratio): how ev er for none of the treated tumours are these
significantly different from horizontal, even if they do in most cases rise. In contrast the
control tumours have horizontal or down-sloping lines, although again none are
significantly different from the horizontal. Examples of the results for indiv idual treated
and control tumours are to be seen respectively in figures 6.2.10 and 6.2.11 (although
note the different y -axis scales), where it can be seen that the variation in values for one
tumour is too great to be able to distinguish treated from control tumours. Equiv alent




Figure 6.2.10 Apoptotic:G2/\l ratio in individual tamoxifen treated ZR-75-1 xenografts
subjected to sequential FNAs
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The data obtained by subjecting individual tumours to sequential fine needle aspiration
do not appear to clarify the timing of the previously noted changes in apoptosis and
mitosis consequent upon tamoxifen treatment of the ZR-75-1 xenografts. It had been th
hope that this experiment would indicate that either changes in proliferation, apoptosis
or their ratio would serve as a marker sufficiently sensitis e to be able to identify an
individual tumour as responding to tamoxifen. Furthermore by taking samples at vanoi
time points it was anticipated that the group analysis would indicate more precisely the
duration of the changes in apoptosis and mitosis. Howev er the data remain entirely
consistent with the results seen in sections 3 and 4 where data from separate tumours ar
pooled and compared.
Firstly figures 6.1.1 and 6.1.2, when taken into consideration with figures 3.1.1 and
4.1.1. strongly suggest that taking sequential FNAs in individual tumours does not
profoundly affect their growth curves, nor the ability of tamoxifen to induce regression i
the sensitive ZR-75-1 breast cancer cell line. Furthermore figures 6.2.1 and 6.2.2
confirm that tamoxifen has an anti-proliferative effect in these same tumours, and indee
when compared with figure 3.6.2. the difference between the treated and control tumoui
is more definite in this current experiment. Similarly for the changes in apoptosis. the
treated tumours as a group do not appear to manifest a rise as compared to the initial da
0 value, but when comparing the values seen on days 2-7 with those in the control
tumours, then there is a significant difference, which was not apparent in the prior
experiment (see figure 3.6.1). Furthermore there are no differences between the treated
and control MDA-MB-231 tumours, confirming the data in section 4 (see figures 4.6.1,
4.6.2). Thus the changes induced by tamoxifen in the proportions of cells in the various
stages of the cell cy cle and/or apoptosis would appear to be better detected by the use of
sequential FNAs than single FNAs in different tumours. However the pattern seen
within one tumour shows too much v ariation to permit identification of the tumour as
one that is responding to tamoxifen, as figures 6.2.10 & 6.2.11 demonstrate.
Consideration of figure 6.2.5 suggests that the rise in apoptosis induced by tamoxifen is
not sustained beyond day 7. as was also seen in figure 3.2.1, whereas the anti¬
proliferative effect appears to be prolonged.
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7. Analysis of individual ZR-75-1 and MDA-MB-231
Xenografts
The data presented from the xenografts in sections 3 - 6 have concentrated on the
results of analysing the tumours in groups, usually on the basis of the time that the
tumour was excised ( or subjected to an FNA). and whether or not it had been treated
with tamoxifen. However, as has already been noted not all tumours of the same cell
line behaved in an identical manner. For example. 4/10 of the ZR-75-1 xenografts that
were untreated and excised on day 28 actually regressed between days 21 & 28. in
contrast to their prior growth and the behaviour of the other 6. Equally the MDA-MB-
231 tumours from passage 2 that had been left untreated and excised on day 28. had
smaller volumes, and statistically different mitotic indices and apoptotic:mitotic ratios
as compared with their untreated counterparts removed on day 21 at the end of passage
7. Further evidence for considerable intra-tumour v ariation in proliferation and
apoptosis comes is seen in figures 6.2.10 and 6.2.11. where the changes in the
apoptotic:mitotic ratio within a single xenograft are such that the trend over time
cannot be used to distinguish clearly a tamoxifen treated from an untreated tumour.
Hence it is appropriate to consider the individual behaviour of all these xenografts, both
in terms of their growth and its relation to measurements made such as the apoptotic
and mitotic indices, necrosis and flow cytometric data.
This section will therefore examine individual tumour growth; how it can be modelled
and/or predicted by the Gompertz function, and the conclusions that can be drawn from
analy sing data pertaining to individual tumours.
7.1 Grow th of ZR-75-1 xenografts
Although tamoxifen treated tumours as a group clearly regressed from day 14 onwards
(see figure 3.1.1), individual tumours regressed at varying time points, as illustrated in
table 7.1.1 where it can be seen that ev en after 28 days' tamoxifen. 2 treated tumours
had not regressed. In particular, on day 14 w hen the volumes as a group were
significantly less than for the untreated tumours, more than half the excised tumours
(and upon w hich the histological and flow cytometric data were recorded) were still
larger than they had been at the time tamoxifen therapy was commenced. The
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equivalent data for the day 28 control tumours is shown in table 7.1.2, which confirms
that a proportion of the day 28 tumours had started to regress before the end of the
experiment.
dav 2 7 14 21 28
all treated 64/64 39/62 16/50 5/39 2/28
excised 12/12 6/12 5/11 2/11 2/28
Table 7.1.1 Numbers of tamoxifen treated ZR-75-1 xenografts that were still
larger than they had been on day 0.
dav 2 7 14 21 28
day 28 control
(n = 10)
10 10 10 9 6
Table 7.1.2 Numbers of untreated ZR-75-1 xenografts that were still larger than
they had been at the previous time point
This point is further illustrated by figure 7.1.1, where it can be seen that the volumes of
the tumours actually excised at each time point are not necessarily representative of
those of the tumours that remain on treatment; the volumes of the excised tumours are
significantly larger than the remaining treated tumours on day 2 ( p < 0.02), with trends
on days 0 ( p = 0.1) and day 7 (p = 0.08).
-30 -20 -10 0 10 20 30
time (days oftamoxifen treatment)
Figure 7.1.1. Grow th of control and tamoxifen treated ZR-75-1 xenografts
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With these differences in growth in mind tumour volumes from individual xenografts
were fitted to a Gompertz function. Assessment of goodness-of-fit can be done in
different ways, since there are inevitable errors in the tumour measurements from which
the volumes are calculated. Residuals (the terminology is taken from linear regression
analysis) refer to the difference between the actual measured volume, and that predicted
by the model function. Thus one method of assessing the goodness-of-fit of
Gompertzian growth is to use the residuals to compare actual with predicted growth, but
this can only be done for the untreated tumours. Table 7.1.3 gives the average residual
for the day 28 control tumours, where it can be seen that the data suggest that the
prediction up to day 14 is good but thereafter becomes less accurate. Figures 7.1.2 and
7.1.3 respectiv ely illustrate a tumour with excellent and poor prediction of growth, but
it needs to be recalled that 4/10 of the these control tumours regressed betw een days 21
& 28. and one indeed started to regress between day 14 & 21. Furthermore, tumour
DAC051 had no growth between day 21 & 28. so it is perhaps less surprising that of the
non-regressing controls, the growth curve based on the v olumes up to day 0 appears to
fit least well for this tumour. The cause of the regression seen in some of these control
tumours is not apparent, but it is therefore no great surprise that the Gompertz function
becomes a less accurate predictor of growth beyond day 14, suggesting that there w as a
fundamental change in the control tumour growth tow ards the end of the experiment
volumes
used
Average residual for predicted
volumes
up to day 0 up to day 0 up to day up to day all volumes
(predicting (predicting 14 21
up to day 28) only to day 14
DAC050 0.24 0.11 0.016 0.041 0.0056
DAC051 2.63 0.74 0.013 0.023 0.0093
DAC053 0.042 0.0090 0.046 0.049 0.0055
DAC056 inadequate data 0.15 0.00042 0.013
DAC058 inadequate data
DAC059 0.32 0.42 0.31 0.14 0.030
Regressing tumours
DAC052 2.35 0.46 0.76 j 1.14 0.11 1
DAC087 1.9 2.2 2.2 1.2 0.14 |
DAC082 0.40 0.26 0.44 0.42 0.036 1
DAC096 0.36 0.14 0.57 0.42 0.066
Table 7.1.3. Average residuals for day 28 control ZR-75-1 xenograft tumours,
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Figure 7.1.3 DAC'052 - a control ZR-75-1 tumour with poorly predicted growth curves
There is another way to assess the ability of the Gompertz growth function to model
subsequent tumour growth, again comparing actual and predicted growth. Since the
tumour volumes are all log-normally distributed, one can use the student t-test to
consider the null hypothesis that there are no differences between the actual and
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predicted volumes of control tumours. Table 7 1 4 shows the results of these tests, and






actual vs predicted on
day 0 dav 7 day 14 day 21 dav 28
dav 0 n.s. n s n.s. n.s. n.s
dav 7 n.s n.s. n.s. n.s.
day 14 n s. n.s. n.s
dav 21 n.s. n.s.
dav 28 n.s.
Table 7.1.4. Student t-test comparisons betw een actual and predicted growth
curses for untreated ZR-75-1 xenografts.
The same methodology can be used to compare predicted and actual tumour volumes in
the tamoxifen treated tumours ; and as it is shown in table 7.1.5. significant differences
are detected at day 7 and beyond. It should be recalled from section 3.1 that comparing
the treated tumour volumes with the control volumes, no significant differences were
detected until day 14. Thus table 7.1.5 suggests that the use of a predicted growth curve
for an individual tumour might be a more sensitis e way to detect alterations in tumour
growth than a comparison with untreated growth in a different tumour, in which there




treated tumours excised on dav
0 2 7 14 21 28
dav 0 n.s. n.s. n.s. n.s. n.s. n.s.
dav 2 n.s. n.s. n.s. n.s. n.s.
day 7 p < o.oo: p<0.01 n.s. p< 0.001
dav 14 p < 0.002 p<0.01 p< 0.001
day 21 p < 0.002 p< 0.001
dav 28 p< 0.001
Table 7.1.5. Student t-test comparisons betw een actual and predicted growth
curses for tamoxifen treated ZR-75-1 xenografts, fitting a Gompertz curve to the
pre-treatment volumes.
Implicit in all the analysis of growth and regression is the assumption that there are no
differences in tumour behaviour dependent upon the particular flank of the animal into
163
which the initial fragment was inserted. Previous reports suggest that for Gompcrt/ian
a/5
growth the maximum tumour volume (e ) is animal (species) specific (Brunton et
al( 1978)). One would expect therefore that the parameters for the tumours would be
independent of the side of the animal into which they were implanted : this is in fact
the case for a. b. their ratio a/b and the "time from" parameter. Indeed only 10/37
pairs of tumours had any significant difference between the a/b ratios of the two
tumours.
7.2 Growth of MDA-MB-231 xenografts
The first analysis of individual tumour growth in the MDA-MB-231 xenografts is to
compare for each time point the v olumes of the excised tumours with the remaining
treated tumours. Figure 7.2.1 illustrates, that in contrast to the ZR-75-1 xenografts,
there are no significant differences for the MDA-MB-231 tumours. Similarly
individual growth comparisons betw een time points can be made ; there was 1
tamoxifen treated tumour that was smaller when excised (on day 14) than it had been
on day 0 (having regressed from day 2 onward), and 1 further treated tumour that
regressed between days 14 & 21. There was also one untreated tumour that regressed
between days 14 & 21. and another that was smaller w hen excised on day 28 than it had
been on day 0 ! Hence there was v ariation in individual tumour growth for the MDA-
MB-231 xenografts.
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Figure 7.2.1 Grow th data for tamoxifen treated and control NIDA-MB-231 lenografts
As for the ZR-75-1 xenografts, individual tumour growth was fitted to a Gompertz
function. Comparison of actual and predicted growth was assessed using the same tw o
methods as for the ZR-75-1 xenografts. Table 7.2.1 gives the average residual for the
control tumours, using the volumes only up to day 0. It can clearly be seen that in
general the Gompertz curve provides a much better fit over the duration of growth for
the control tumours than was seen in the ZR-75-1 tumours, particularly in the day 28
control tumours from passage 2.
volumes
used
Average residual for predicted volumes
up to day 0 beyond day 0 all volumes
Dav 21 controls
DAC243 0.0021 0.293 0.207
DAC247 0.005 0.061 0.043
DAC252 0.0034 0.279 0.211
DAC256 0.0077 0.651 0.460
DAC260 inadequate data
Day 28 controls
DAC201 0.00001 0.00012 0.00007
DAC205 <0.00001 0.00002 0.00001
DAC222 <0.00001 0.00046 0.00031
DAC223 <0.00001 0.00147 0.00084
Table 7.2.1. Average residuals for day 21 & day 28 control MDA-MB-231
xenograft tumours.
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As with the ZR-75-1 tumours, one can use the student-t test to consider the null
hypothesis that there are no statistrcally significant differences between the (logarithms
of) the actual and Gompertz-predicted tumour volumes, as seen for the control tumours,
in table 7.2.2. and the tamoxifen treated xenografts in table 7.2.3. In both cases there
are no overall significant differences, showing that not only does the Gompertz function
predict subsequent growth well, but confirming that tamoxifen treatment does not alter
the fundamental growth of the MDA-MB-231 tumours. The single significant
exception, the day 28 tumours on day 14. is probable a chance event as the same trend





control tumour volumes on
day 0 day 7 day 14 day 21 day 28
dav 0 n.s. n.s. n.s. n.s. n.s.
dav 7 n.s. n.s. n.s. n.s.
dav 14 n.s. n.s. n.s.
dav 21 n.s. n.s.
dav 28 n.s.
Table 7.2.3. Student t-test comparisons between actual and predicted growth
curves for untreated MDA-MB-231 xenografts.
166
treated tumours excised on dav
actual vs predicted
volumes on
0 2 7 14 21 28
dav 0 n.s. n.s. n.s. n s. n.s. n.s
dav 2 n.s. n.s. n.s. n.s. n.s
dav 7 n.s. n s. n.s. n.s
dav 14 n.s. n.s. p <0.1)1
dav 21 n.s. n.s
dav 28 n.s
Table 7.2.4. Student t-test comparisons between actual and predicted growth
curses for tamoxifen treated MDA-MB-231 xenografts.
Correlations between individual tumour growth and biology
The important associations in this studs are between tumour growth or regression, and
the changes in the tumour biology. Detailed relationships between the biological
parameters for groups of tumours hav e been reviewed in section 3.7, and thus this
section will concentrate on the relationships between the biology and relative tumour
size. Giv en that the majority of the ZR-75-1 tumours regressed w hen treated with
tamoxifen, one needs to consider different measures of this regression. The three that
will be considered are the actual tumour volume, the relative volume (as compared with
the v olume on day 0). and the response, defined as in the introduction (see page 40).
namely the proporuonal reduction from the predicted volume at the same time-point,
using a Gompertz growth curve fitted to the pre-treatment v olumes for that individual
tumour. In order to reduce the possibility of reporting false positive correlations, those
significant at the 5% lev el are excluded unless there is another significant result for a
similar variable. Table 7.3.1 reports the correlations between proliferative markers and
tumour volume/response, and it can be seen in general that although there are no
significant relationships for the untreated tumours, there is a significant association in
the treated tumours such that higher proliferativ e rates are seen in the larger tumours
(as ev idence by higher actual or relative v olumes), whereas negative correlations are
seen with response MIB-1 expression and S-phase fraction giv e consistent significant
correlations - the mitotic index does not correlate with the relative v olume and no
significant relationships are seen with the proportion of cells in G2/M.
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Cell growth
tumours MIB-1 MI S-phase G2/M
response treated -0.463 -0.477 -0.488 -0.304
< 0.001 <0.001 <0.01 ns
control ns ns ns ns
relative treated 0.65 ns 0.402 ns
volume <0.0001 <0.01
control ns ns ns ns
actual treated 0.565 0.505 0.408 ns
volume <0.0001 <0.0001 <0.01
control ns ns ns ns
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control ns ns ns ns
Table 7.3.2 Correlations between cell death and tumour growth/regression for ZR-
75-1 xenografts.
In contrast table 7.3.2 reveals that there are fewer significant relationships between
tumour volume/response and indicators of cell death. The apoptotic index correlates
with all three measures of tumour growth in treated tumours, as does the necrotic
proportion of the tumour. Again positive correlations are seen with volume and relative
volume, w hereas negative ones are seen with response. However given the previoush
noted positive associations between proliferation and both necrosis and apoptosis (see
section 3.7). these observations are no more than consistent with table 7.3.1. The flow
cytometric measure of apoptosis only correlates w ith the relative volume, and the
Apoptotic:Mitotic ratio correlates with none of the three. For the untreated tumours,
there are significant negative correlations between the relative volume and apoptosis as
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measured by histology and flow cytometry. Figure 7.3.1 illustrates the data for the
apoptotic index and highlights the regressing tumours. (It should be noted that the
relative volume is alway s 1 for the day 0 control tumours and therefore they are
excluded from any analysis of a relationship between the relative volume and other
data.) The data suggest that higher lev els of apoptosis are associated w ith a smaller
relative increase in v olume. as would be anticipated as apoptosis is one of the
mechanisms for cell loss during tumour growth It can be seen that the explanation for
this negative trend is not just that four of the tumours had started to regress, and it
should be recalled that the Gompertz growth curv es suggest that in general this group of
control tumours had undergone a change in ov erall growth behaviour before the end of
the experiment. Given that the oestrogen pellets, essential for the growth of these
xenografts, were nearing the end of their 60-day life, it is possible that the explanation
for the regression and the negative correlation between apoptosis and relative v olume
was due to effectiv e oestrogen withdraw al. The absence of a significant relationship
between the apoptotic index and the response could be due to the previously-
demonstrated divergent trend between Gompertz-predicted and actual tumour v olumes
bey ond day 14 : recalling that the response is defined using the Gompertz curve fitted
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Figure 7.3.1 Apoptotic index and relative volume in dav 28 control ZR-75-1 ienografts
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However, the aim of this study w as primarily to detect changes that are associated
with, and might therefore be predion e of. tamoxifen sensitivity. By volume
comparisons, tamoxifen only had significant growth effects by day 14. although
Gompertz growth curve deviation was significant for most tumours by day 7 (see
section 7.1). Therefore table 7.3.3 lists the significant relationships at these early
time points. It can be seen on day 7. when the group analy sis demonstrated that
apoptosis had risen and proliferation fallen in the treated tumours, there are
significant relationships such that the apoptotic:mitotic ratio, the apoptotic index
and MIB-1 expression all correlated with the response. It should be recalled that
day 7 is also the first day at w hich Gompertz growth curves could detect a
significant change in growth in these same tumours. Relative volume. a cruder
indicator of the change in v olume with treatment, also correlated with the
apoptotic:mitotic ratio and the proportion of cells expressing MIB-1 On day 14.
the relationships become weaker for response, although there are significant
correlations with the mitotic index. In the control tumours there are no
relationships with MIB-1 expression, but there are with apoptotic index (w hich has
already been previously commented upon for relative volume).
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Table 7.3.3 Correlations betw een markers of proliferation and apoptosis in
individual ZR-75-1 xenografts removed at different time points.
Figure 7.3.2 illustrates the correlation on day 7 between the apoptotic:mitotic ratio ar.
response. and that for MIB-1 expression is shown in figure 7.3 .3. It should be noted
that a negative value for response indicates that the tumour volume on day 7 is larger
than that predicted for by the Gompertz growth curve, and correspondingly v alues c:
response that are greater than zero reflect increasing degrees of tumour regression
Hence we see that the more a tumour has fallen away from its predicted Gompertz















Figure 7.3.2 Apoptotic : Mitotic ratio and tumour response in ZR-75-1 xenografts after 7 days'
tamoxifen treatment
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Tumour response
Figure 7.33 MIB-1 expression and tumour response in ZR-75-1 xenografts after 7 days'
tamoxifen
In contrast it should be noted that for the treated MDA-MB-231 xenografts there are no
significant relationships between on the one hand volume, response and relative volume
and on the other apoptosis, mitosis or their ratio.
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7.4 Synchronously borne ZR-75-1 and MDA-MB-231 tumours
Insufficient tumour measurements had been taken prior to the insertion of tamoxifen
pellets in this experiment, so that not all tumours had sufficient volume data to which a
Gompertz growth curse could be fitted. Table 7.4.1 reports the available data, and it
can be seen that on average only about half the tumours could be fitted with an
individualised growth curve.
control tumours treated tumours
MDA-MB-231 ZR-75-1 MDA-MB-231 ZR-75-1
dav 0 2/4 2/4
dav 2 4/5 2/5 4/5 5/5
dav 7 2/5 3/5 3/5 1/5
Table 7.4.1 Tumours w ith sufficient pre-treatment volumes for Gompertz growth
curse fitting.
The paucity of data makes it impossible to use the difference between actual and
predicted growth to determine whether, as was seen in sections 7.1 & 7.2, Compert/
curve analysis could detect tamoxifen-induced changes in the growth of the treated ZR-
75-1 but not MDA-MB-231 xenografts. Howes er the average residuals can still be
determined, and they are show n in table 7.4.2. They suggest that only the treated ZR-
75-1 and untreated MDA-MB-231 tumours dev iate substantially from the predicted
growth curves. However the latter comment is partly due to a single regressing control
MDA-MB-231 tumour, which interestingly was borne by the same animal as the only
regressing untreated ZR-75-1 tumour - and this may well therefore reflect a problem
with that particular mouse rather than the MDA-MB-231 tumours as a whole.




dav 2 0.011 0.0066 0.0013 0.0062




Table 7.4.2 Average residuals for MDA-MB-231 and ZR-75-1 xenografts.
One way around the lack of individual tumour volume data is to use the av erage










curve from them. Figures 7.4.1 - 7.4.4 illustrate that this can be done for the treated
and untreated tumours as a whole, for both ZR-75-1 and MDA-MB-231 xenografts,
with no discernible effect on growth being evident as a consequence of tamoxifen
therapy. Furthermore there are no statistically significant differences between the
actual and predicted volumes for any group of tumours.
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Figure 7.4.4 Predicted and actual growth curves for control MDA-MB-231 xenografts
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These "average" Gompert/ growth cunes can be looked at in slightly more detail by
considenng their growth parameters. Table 7.4.3 demonstrates that although the two
types of tumours appear to have begun growing at more or less identical times (as
evidence by the similarity of their "time from" parameters), consistent with their
identical implantation dates, they do not follow identical growth curves, with the MDA-
MB-231 tumours having smaller maximum v olumes. With a only small number of
tumours in this experiment it is not possible to say w hether or not this represents
fundamental differences in the growth determinants of these tumours
ZR-75-1 tumours MDA-MB-231 tumours
treated control dav 0 treated control dav 0
vT max 0.218 0.872 0.871 0.176 0.0881 0.289
alpha 0.2559 0.1786 0.3043 0.3536 0.2740 0.4882
beta 0.0475 0.0264 0.0450 0.0684 0.0612 0.0851
"time from" 4 45 5.31 3.33 4.29 5.2 1.3
Table 7.4.3 Growth parameters for Gompertz growth curves fitted to average
volumes for MDA-MB-231 and ZR-75-1 xenografts.
It has been previously noted that for the MDA tumours there were no correlations
between the apoptotic and mitotic indices and actual or predicted tumour volumes, and
similarly there was no relationship between the apoptotic:mitotic ratio and tumour
volumes. In contrast, relationships were found for the treated ZR-75-1 tumours ( see
section 7.3). with the apoptotic:mitotic ratio being correlated with the response on day s
7 & 14.
In this experiment there were inadequate data to fit individual growth curves.
Therefore a similar relationship between response or relativ e volume and the
apoptotic:mitotic index in indiv ldual tumours cannot be determined. However one
could use "av erage" Gompertzian growth cun es. fitted to the average of all ZR-75-1
tumour v olumes in this experiment, normalised to the day 0 volume of the individual
tumours. In this case, as figure 7.4.5 shows, the 4 tamoxifen-treated ZR-75-1 tumours
excised on day 7 closely fit the regression line deriv ed for the equivalent tumours in the
previous experiment (as described in section 3.7). Although visually these four tumours
appear to demonstrate a similar relationship betw een response and their
apoptotic:mitotic ratio, this does not approach statistical significance
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■ data from combined ZR MDA experiment
a data from first experiment
Regression line from first experiment
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tumour response
Figure 7.4.5 Apoptotic : Mitotic ratio and tumour response in all ZR-75-1 xenografts after 7
days' tamoxifen treatment
ZR-75-1 and MDA-MB-231 tumours subjected to sequential FNAs
For the tumours subjected to sequential FNAs. there were again insufficient data points
to undertake individual Gompertz growth curv e fitting. Therefore the average volumes
for the four groups of tumours were used, and the Gompertz growth curv e parameters
are shown in table 7.5.1. This confirms that the ZR-75-1 and MDA-MB-231 tumours
do grow differently, with as in the previous experiment, larger maximum volumes being
seen for the ZR-75-1 xenografts. It should be recalled that the tumours in both this
experiment and that immediately before were all established at the same passage. An
understandable similarity, particularly for the MDA-MB-231 tumours, then becomes
apparent between the figures in tables 7.5.1 and 7.4.3.
ZR-75-1 MDA-MB-231
treated control treated control
v
* 2.252 3.971 0.105 0.105
alpha 0.1967 0.1572 0.4823 0.4921
beta 0.02548 0.01897 0.1036 0.1057
Time from" 5.23 7.11 3.60 2.31
Table 7.5.1 Growth parameters for Gompertz growth curves Fitted to average
volumes for MDA-MB-231 and ZR-75-1 xenografts subjected to sequential FNAs.
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These average predicted growth curves are demonstrated in figures 7.5.1 and 7.5.2.
w here it can be seen that the only group of tumours to significantly dev iate from the
predicted growth curv e are the ZR-75-1 treated tumours, and that the predicted curv es
are very similar for the treated and untreated groups of tumours of each type.
mean treated tumour volumes
10 T
predicted treated tumour volumes
mean control tumour volumes
-25 -20 -15 -10 -5 0 5 10 15 20 25
days (of tamoxifen)
Figure 7.5.1 Predicted and actual mean volumes in ZR-75-1 xenografts subjected to sequential
FNAs
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mean control tumours volumes
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days (of tamoxifen)




However close examination of the curves suggests that the treated MDA-MB-231
tumours do not grow as fast as the control. There are in fact only five tumours under
consideration, and three regressed: one after day 9 and two from day 12. The growth
curves of these tumours is shown in figure 7.5.3 w here it is clear that the pattern of
growth regression is quite different from that seen in the ZR-75-1 tumours, in that it
appears to begin before the tamoxifen therapy was commenced!
non-regressing tumours
0.001 : r i ) t •
-25 -20 -15 -10 -5 0 5 10 15 20 25
days (of tamoxifen)
Figure 7.5J Growth curves for tamoxifen treated MDA-MB-231 tumours
These changes in growth are confirmed by the student-t test for the actual and predicted
volumes, as shown in table 7.5.1. which confirms not only that the tamoxifen treated
ZR-75-1 xenografts regressed, as assessed by the difference between the actual and




treated control treated control
up to day 0 n.s. n.s. n.s. n.s.
beyond day 0 <0.00001 n.s. <0.01 n.s.
all volumes < 0.0002 n.s. <0.01 n.s.
Table 7.5.1 Student t-test comparisons between actual and predicted volumes for
MDA-MB-231 and ZR-75-1 xenografts subjected to sequential FNAs.
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7.6 Discussion
There are few examples in the literature of the use of a function to fit and thus predict
the subsequent growth of xenografted human cancers. The first study to do this reported
no measures of goodness of fit. but pictorially showed that three early v olume
measurements could be sufficient to predict the subsequent (unperturbed) growth of a
rat carcinoma (Norton et al(1976)). The only other study, which included a serially
passaged human breast cancer, fitted curves to indiv idual xenografts, but with a
common, average, maximum tumour size, and thus reduced the growth variation
permitted to an individual tumour (Spang-Thomsen et al( 1980)). No goodness-of fit
data were therefore available.
The critical issue for modelling tumour growth is not the degree of fit of the chosen
function (Gompertz in this study), as when there are only three or four data points most
bounded non-linear growth functions can be made to fit, but w hether or not it is an
accurate predictor of subsequent growth, assuming that there are no fundamental
changes in the determinants of growth. Hence one cannot test the assumption that
growth is truly Gompertzian in the treated tumours, and as has already been noted,
there are problems with the ZR-75-1 control tumours removed on day 28. in that 4/10
regressed, including all three in the second passage (no. 29). Thus the accuracy of
growth curv e prediction will be assessed before day 28, and since the key changes in
apoptosis. mitosis and their correlation with response occurred between days 2 - 14 . it
is over the first two weeks' of therapy that the predictiv e ability of the model is
paramount.
There are two hypotheses that need to be tested. Firstly that any differences observed
between predicted and observ ed control volumes at a certain time point are no more
than would be expected by chance ; and secondly that any differences between predicted
and actual volumes will be significantly more in the treated ZR-75-1 tumours, as
compared with control tumours (confirming tamoxifen induced growth regression),
w hereas for the MDA-MB-231 tumours growth prediction should be as accurate in
control as treated tumours.
Section 7.1 confirms that although the Gompertz growth curv e does not predict the
precise v olumes of the untreated ZR-75-1 xenografts, there are no significant
differences between the actual and predicted v olumes for the control tumours at any
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point between day 0 and 28. using al! volumes up to any time points therein.
Furthermore, table 7.1.3 indicates that the prediction is accurate for up to 7 days beyond
the last time point, although thereafter the residuals rise, suggesting that the lack of a
statistical difference between the actual and predicted volumes could be due to the
relativ ely small number of control tumours.
For the MDA-MB-231 tumours no such changes were seen, and there is in general
much better growth prediction for the control tumours as w ell as the treated tumours
(see section 7.2); which further confirms the observation that tamoxifen had no effect
on the growth of these tumours. As commented upon there is only one time-point (day
14 ) where one group of treated tumours (those excised on day 28) had actual v olumes
that were significantly different from those predicted by the Gompertz function. This
could have occurred by chance, although the low er confidence limit of 1% w as used to
reduce the possibility of such a type I error. There is indeed no other obvious
explanation for this, as all the volumes measured on day 14 were not significantly
different from those predicted by the individual growth curves.
The next group of tumours that had their growth modelled were from the experiment
w here different xenografts were grown in the opposite flanks of the same animal. As
has already been commented upon (see section 7.4). there were fewer tumours and
measurements of tumour volume available than had been intended No differences were
seen betw een the predicted and actual v olumes for any group of tumours, but the small
numbers prohibit any useful conclusion being draw n from this data. However they are
consistent with the observations from the larger, earlier experiments. This experiment
also afforded the possibility of examining the effect of growing different tumours in the
same animal ; and for the few animals w here this w as possible, there were no
differences in the Vmas. a. or b for the two different tumours. This is consistent with the
data of Brunton (Brunton et al(1978)) who noted that the Gompertz growth parameters
were species, not tumour specific. However when considering the "av erage"" Gompertz
growth curves, as in tables 7.4.3 & 7.5.1. there is a suggestion that Vmai is tumour-
dependent. being smaller for the MDA-MB-231 tumours than the ZR-75-1 xenografts.
The growth of the tumours that were subjected to sequential FNAs needs to be
considered. It is clear from section 7.5 that in the control tumours of both types, there
was no evidence that sequential FNAs had any impact upon tumour growth. The
treated ZR-75-1 tumours had a significant change in growth, confirmed by comparisons
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of the treated volumes w ith both those seen in the untreated ZR-75-1 tumours, as well
as those predicted by the growth curves However the treated MDA-MB-231 tumours,
as a group, appear to have less growth than w as predicted, even if their volumes are not
significantly different from the control MDA-MB-231 tumours at any time point.
Figure 7.5.3 suggests how ever that the regression that occurred in three of the five
tumours that sunived beyond day 5. could be due to a change in growth that
commenced before the tamoxifen treatment No definite explanation can therefore be
given, and the notion that these tumours responded to tamoxifen is inconsistent with all
the prior data. However the data are equally inconsistent with the possibility of the
sequential FNAs inducing significant alterations in growth, and thus the data on
apoptosis & proliferation during this experiment can be considered as a reflection of the
effects of time and/or tamoxifen in these tumours.
In conclusion therefore, the tumour volumes do appear to be w ell-modelled by the
Gompertz function. The growth curves of the untreated tumours of both types can be
predicted bv the volumes measured up to day 0 ; however the confidence of the fit
recedes with time, especially for the ZR-75-1 tumours. The volumes of the treated ZR-
75-1 tumours are only different from the predicted volumes at day 7 and bey ond ;
w hereas those of the treated MDA-MB-231 are not different for the duration of the
experiment. The data indeed suggest that the use of a Gompertz curve to predict growth
provides a more sensitive measure of differences in growth than a comparison of the
volumes of treated and untreated tumours.
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Discussion
Tamoxifen treatment of breast cancer is clearly associated with considerable clinical benefit, w hether
used to treat macroscopic, or as in the adjuvant setting, microscopic disease. A considerable bocy of
data already exist as to the biological consequences of tamoxifen treatment of breast cancer, and the
data presented here confirm some of these prior findings. In particular the anti-proliferative action
of tamoxifen has been confirmed in both clinical tumours and xenografts. Although no reduction m
mitotic activity was observed in the ER-negative MDA-MB-231 tumours, the data from the clinical
breast cancers do not suggest that this anti-proliferative action is synonymous with clinical efficacy..
in that it was observed in both responding and non-responding tumours, consistent with prior reports
(Clarke et al(1993)). Furthermore tamoxifen treatment clearly increased the level of apoptosis in the
sensitive ER-positive ZR-75-1. but not the insensitive MDA-MB-231 xenografts. Although the
precise pattern of this change over time remains unclear, the analysis of both the histological
sections and the FNAs strongly suggest that this increase is temporary , abating within two weeks
therapy. In contrast the clinical breast cancers when re-examined after three months' treatment
showed no overall change in the incidence of apoptosis, w hich further implies that any increase m
apoptosis induced by tamoxifen is transient, in contrast to the permanent reduction observed in
proliferation.
The exact relationship between apoptosis and bcl-2 remains unclear for breast cancer. Undoubtedly
the bcl-2 expressing clinical tumours have lower rates of apoptosis. but as already discussed the rate
of apoptosis also correlates with the rate of proliferation, and higher proliferative fractions are in
general seen in ER and/or bcl-2 negativ e tumours Such a direct relation between bcl-2 expression
and lower proliferation was how ev er not confirmed in the current series of ER-positive tumours. The
av ailable data do therefore suggest that bcl-2 expression may play at least some role in inhibiting
apoptosis in clinical breast cancer. The effect of three months' tamoxifen was to reduce bcl-2
expression in the majority of tumours, and indeed the analy sis in section 2.7 suggests that the
tumours w hich respond to tamoxifen in the clinical sense of volume reduction, also do so
biologically in that the fall in bcl-2 expression is accompanied by a rise in apoptosis at three months.
However in the xenografts, those that respond clinically manifest no change in bcl-2 expression over
the four weeks of the study, but a clear and probably transient rise in apoptosis occurs. Hence
changes in apoptosis at least in the short term do not seem to necessitate alterations in bcl-2 protein
lev els, but longer-term reduction in bcl-2 can be associated with higher rates of apoptosis.
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Although the results suggest some concordance between the data obtained from the analyses of the
clinical breast tumours and the xenografts, there were in fact important differences in experimental
design between these two studies. In particular, the timing of the acquisition of the on-treatment
tumour samples w as very different for the clinical and xenografted breast cancers. Tumour material
was only available from the patients after three months" tamoxifen, whereas in the xenograft
experiments all samples were taken within 28 days' treatment with the most significant changes
occurring in the first week. Nonetheless both studies show that there was a correlation between
tumour response and respectively the change in the ratio and the absolute value of apoptotic:mitotic
ratio. Furthermore the definitions of response were different - in the patients a comparison could
only be made with the pre-treatment v olume, whereas in the xenografts the use of a Gompertz growth
curve allowed accurate prediction of how the tumours would have grown if left untreated, and thus
the on-treatment v olume could be contrasted with the predicted v olume for the same time point.
Howev er table 7.3.3 confirms that there was also a significant correlation between the relativ e
v olume and the apoptotic:mitotic ratio, w hich corresponds more closely with the definition of
response for the clinical tumours. These observations suggest that measuring the relative balance
betw een tumour cell growth and death during tamoxifen treatment may allow identification of
tamoxifen sensitivity. In the clinical breast cancers the relationship was in fact stronger between
response and the pre-treatment level of ER expression and/or the change in ER expression. However
in only two tumours did the level not fall with treatment, and all tumours were ER positive, so that
the specificity of these changes to tamoxifen sensitivity remains unclear. The level of significance of
the correlations between response to tamoxifen and the pre-treatment level of bcl-2 expression as well
as the change in bcl-2 expression were similar to that found for the change in apoptotic:mitotic ratio.
But the use of a sample taken after three months' treatment with which to compare the pre-treatment
biology is potentially a less-specific measure of drug efficacy. as the subsequent behaviour of the
individual tumour is more uncertain. In contrast, the identification of changes in apoptosis and
proliferation during the first week of tamoxifen therapy in the xenografts, together with the observ ed




The use of the cellular DNA content to estimate, using the flow-cytometer. the percentage of cells in
different parts of the cell-cycle is a tried and tested technique. Given that the source material
however is not from cell culture, but rather from FNAs. some thought needs to be given on the
methodology, and its correlation w ith histopathologic^ markers of proliferation There is only one
published study reporting proliferation in control and tamoxifen-treated breast cancer MCF-7
xenografts (Brunner et al( 1989)). in w hich no significant changes in the percentages of cells in G:. S
or GVM were seen during 21 days' therapy. However in that same study, the volume reduction in the
treated tumours was less than 50% after 21 days, considerably less than that presented here, but
consistent with our own experience with xenografts of this cell line.
The data presented in section 3.7 suggests that in general the flow-cytometric and histopathological
measures of proliferation are tightly correlated, with the exception of the percentage of cells in G2/M
and the mitotic index. This at first consideration appears unexpected, but the difference between
these two v ariables is that the former contains cells in G2 Given that an FNA from an untreated ZR-
75-1 xenograft has on average 6% of its cells in this phase of the cell-cy cle, w hereas the av erage
mitotic index in the same tumours is just under 0.1%. it is immediately clear that any small changes
in the proportion of cells in mitosis will not be seen unless the percentage of cells in G; falls by the
same degree. Furthermore it is now recognised that cells can undergo apoptosis at any point in the
cell cy cle (Kroemer et al( 1995)). and therefore there may be varying numbers of cells in G2
(identified as such by flow cytometer) w hich w ould subsequently be undergoing apoptosis and not
mitosis.
The use of the fluoro-TUNEL technique was designed to give a reproducible measure of apoptosis in
fine needle aspirates. However, as has already been commented upon in the introduction. DNA
fragment detection sy stems cannot per se identify whether the DNA fragments are from (in) an
apoptotic cell or a necrotic cell (Collins et al(1992); Gold et al( 1994): Grasl-Kraupp et aft 1995):
Lizard et aft 1995): Wijsman et aft 1996)). When employed immunohistochemically, light
microscopy can be used to aid the distinction (Wijsman et aft 1996)). but this requires the use of at
least some of the same criteria as used in a morphological assessment, and therefore does not totally
avoid the problem of subjectivity. With the flow cytometer. no such visual assessments are practical.
A small study w as therefore done, with a cell sorter being used to separate the cells in the apoptotic
and non-apoptotic regions. These groups of cells w ere then smeared onto a slide and examined
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under fluorescent light. Morphologically apoptotic cells, identified by fluorescent, condensed blebbed
chromatin were seen only in the cells from the apoptotic region (data not shown). This does not
however confirm that all the apoptotic cells were in this region, nor that necrotic cells were not
included. Hence the correlation between the histological and flow cytometric measures of cell death
need to be critically examined. It has already been noted that whereas there is overall a correlation
between the amount of apoptosis and necrosis, no such relationship exists between the FACS-
measure of apoptosis and either measure of cell death alone However although multivariate analysis
did suggest that FACS-apoptosis was related to both, the only statistically significant factor was
necrosis, with a low R" v alue. Hence one must interpret the results of this technique with a certain
degree of caution.
Removal of necrotic (and late stage apoptotic) cells from the sample with a pre-treatment. such as
that using DNAase (Darzynkiewicz et al(1984)). is possible The data reported in section 6.2.2
confirm that the results correlate well with the fluoro-TUNEL method without pre-treatment.
However it was not possible to re-examine all the FNAs using this technique, because there is the
considerable risk that a further freeze-thaw cycle might increase the permeability of the cell
membranes, w hich is the property of dead cells upon which the method relies to identify necrotic
(and late stage apoptotic) cells.
Hence although the data from the flow cytometric analy ses remain consistent with those obtained by
histological examination of the sections, they are in general less sensitive to the changes observed
with tamoxifen therapy. It remains unclear as to exactly why this is. but suggests that the use of
FNAs of xenografts does not necessarily offer a solution to the difficulty of repeat biological
examination from individual xenografts and possibly clinical tumours.
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Conclusion
This study has focused upon changes that are consequent upon the tamoxifen treatment of breast
cancer. The clinical data suggest that, as previously reported, the level of expression of ER and bcl-2
predict for tamoxifen-sensitivity. However the changes occurring after three months" therapy suggest
that reduced expression of bcl-2 is only associated with a response w hen apoptosis is increased, yet
the pre-treatment lev el of apoptosis does not predict for sensitivity. There are tentativ e data to
suggest that tumours with a low initial apoptotic: mitotic ratio, and/or tumours w hose ratio increase
during therapy are more likely to be responders, and that these changes do not appear to be as closely
related to alterations in bcl-2 expression as might at first be expected.
The model system considered xenografts of two well-established breast cancer cell lines, one
hormone-sensitive (ZR-75-1) and the other hormone-insensmve (MDA-MB-231). Despite the
variations in tumour growth, and in particular that of the untreated tumours, there are clear data
confirming that only the former tumour is hormone-sensitiv e Furthermore histological assessment
confirms that tamoxifen sensitivity is associated with an increase in apoptosis and a fall in
proliferation, best evidenced by the apoptotic:mitotic ratio. Using Gompertzian growth curves, fitted
to individual tumours, one can identity tamoxifen-induced changes in the growth of the ZR-75-1
xenografts after only 7 days' therapy, at which point there is an extremely tight correlation with the
apoptotic:mitotic ratio, suggesting that the relative balance between proliferation and apoptosis is the
prime determinant of the change in growth in these tumours. In contrast, the other mechanism of cell
loss, necrosis, would appear to have no part to play in tamoxifen induced tumour regression, at least
in this model system. Furthermore tamoxifen treatment of the sensitive ZR-75-1 xenografts, but not
the insensitive MDA-MB-231 tumours, clearly reduced the extent of tumour v asculature. Howev er
these changes coincided with the increase in apoptosis. and therefore it remains unclear as to which
of these two processes is the prime determinant of regression, although the existence of a significant
correlation between the degree of regression (response) and the apoptotic: mitotic ratio but not the
vascular portion of the tumour favour the hypothesis that the change in v asculature is the
consequence of rather than the cause of the tumour regression.
Attempts to circumv ent the need for a repeat biopsy to establish the presence of these early changes
in clinical tissue by the use of flow cytometry was not totally successful, in part because of the
difficulty with the methodology for assessing apoptosis. However when several sequential samples
w ere taken from the same tumour, the assay was more sensitiv e to tamoxifen-induced changes, but
not sufficiently to predict whether or not the individual tumour would respond to therapy .
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Clearly further work is required to validate the specificity of these changes as predicting for
tamoxifen sensitivity - both in this model sy stem, by using other cell lines, such as paired cell lines in
which tamoxifen resistance has been induced in an initially sensitive line ( such as ZR-75-1 and its
resistant counterpart ZR-75/LCC3 (Knstensen et al( 1995a))). and in the clinic. For the latter, further
clinical studies need to be performed, using tumour material made available after 7-14 days'
tamoxifen therapy. Such protocols are underway in the Edinburgh Breast Unit, with the intention of
assessing changes in proliferation, apoptosis. angiogenesis as well as the neo-angiogenic growth
factors such as VEGF (Ferrer et al( 1989)) and basic FGF w ith w hich it may act in sy nergy (Goto et
al( 1993); Pepper et al(1992)). The relative timing of these changes and the specificity of their
relationship to clinical tamoxifen sensitivity will then be determined.
However more fundamental questions are raised by this study. The exact mechanism by which
tamoxifen induces apoptosis remain to be elucidated. No changes in bcl-2 or p53 were observed in
the model sy stem, but this does not exclude the possibility that the techniques used were insensitive
to any change that might have occurred, nor does it exclude the involvement of other members of the
bcl-2 family . Equally in the clinical study, the changes in bcl-2 expression and apoptosis confirm an
inverse relationship in responding tumours, but w hether they are causally linked or independent
effects of a more fundamental change in tumour biology remains unclear.
Finally , one must consider briefly the implications of the correlation between proliferation and
apoptosis. Tamoxifen clearly acts as an anti-proliferative agent, and in general the relation between
apoptosis and proliferation is preserv ed, even if altered, during tamoxifen therapy. Hence if
continuous tamoxifen exposure reduces the proliferative fraction of a tumour, with a concomitant
reduction in apoptosis. this potentially undermines some of the initial cytotoxicity of the drug. It
begs the question as to whether or not continuous or intermittent therapy might have a more
significant anti-tumour action, as has been partially addressed by studies comparing sequential
tamoxifen and progestogen therapy with continuous tamoxifen (Crawford et al( 1992)).
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